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Abstract
Purpose: Patients’ decisions about whether or not to adhere to their prescribed regimens
are shaped not only by their knowledge and beliefs about their condition and its treatment
options, but also by what they value in these domains. This study represents an
integration of theory and methods from nursing/public health, psychology and economics
to explore the additive effects of knowledge, beliefs and preferences on adherence to
preventer medication in a sample of patients with asthma. It was hypothesized that
knowledge, beliefs and preferences pertaining to long term outcomes would
independently predict improved adherence. Method: 140 patients with asthma were
asked to complete a series of surveys assessing their knowledge and beliefs about asthma
and its treatments as well as a discrete-choice task (DCE) in which they selected which
hypothetical medication they would choose from among eight choice sets that varied
along seven attributes (Long Term Efficacy, Short Term Efficacy, Immediate Relief,
Number of Inhalers, Steroid Dose, Administration Time, and Side Effects). Adherence
was measured using the self-report Medication Adherence Report Scale one month after
their clinic visit. Results: A latent cluster analysis of the DCE data suggested four
distinct groups of patients, namely, those whose choices were guided by (1) long term
benefits, (2) medication side effects, (3) the trade-off between side effects and efficacy
and (4) all attributes equally. Multiple regression analyses indicated that pathophysiology
knowledge, the belief that preventer medication is necessary and membership in the
group valuing long term outcomes each uniquely predicted reported adherence, together
explaining 39% of the variance. Preferences for long term outcomes predicted an
additional 10% of the variance above and beyond that accounted for knowledge about
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asthma pathophysiology and treatment beliefs alone. Conclusion: These findings suggest
that to improve patient adherence to asthma preventer medications, patients should be
helped to understand why they require medications. Once the long term effects of asthma
are understood, believed and valued, patients will be more likely to adhere. Via DCE
methodology, we have also demonstrated a novel approach to elucidating patient
variations in treatment-related values.

Key Words: Asthma, Adherence, Illness Beliefs, Treatment Beliefs, Knowledge, Discrete
Choice Experiments
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Introduction
Decision making is a fundamental part of the health care provision process. From
patients’ initial decision to seek treatment, to the treatment option(s) offered by the health
care provider, to whether patients choose to adhere to the regimen – all are decisions that
affect the course of an illness. There is increasing recognition of the importance of
including patients in the health care decision making process (Little et al., 2001).
Systematic reviews have shown that involving patients in treatment planning results in
better quality of care, higher patient satisfaction and self-esteem (Crawford et al., 2002;
Kinnersley et al., 2007), improved physical outcomes (Michie, Miles, & Weinman, 2003)
and better self-management by patients (Heisler, Bourknight, Hayward, Smith, & Kerr,
2002; Mead & Bower, 2002). Thus, collaborative decision making is increasingly being
recognized as the key to effective control of chronic diseases (Leventhal, Weinman,
Leventhal, & Phillips, 2008).
According to the World Health Organization (2003), in the developed world,
roughly half of those with chronic diseases fail to use their medications- often a central
component of self-management plans- as recommended. Suboptimal patient adherence to
chronic disease management programs poses a serious health threat. Therefore, although
governments and health organizations invest considerable effort and expense developing
and improving efficacious treatments, these resources are wasted if the programs are not
reliably adopted by patients.
In an effort to combat non-adherence, practitioners and researchers, largely drawn
from the fields of public health, medicine and nursing have developed and implemented
educational programs aimed at enhancing patients’ knowledge about their conditions and
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associated treatments. In contrast, the psychological literature has tended to focus on
patients’ beliefs about their conditions and treatment options. However, as the ensuing
literature review will indicate, targeting what people know and believe is not sufficient to
influence adherence.
Health care decision making is a complex process which involves the weighing
of risks and benefits as well as personal values (Schapira, Gilligan, McAuliffe, &
Nattinger, 2004). The central tenet of this thesis is that to understand and subsequently
improve adherence, one also has to know what matters to people, that is, their values and
preferences. Values and preferences, while not a focus in the adherence literature, have
been of interest to health economists invested in gauging health care consumer’s
“willingness to pay” for services and treatments. To do so, they have developed a range
of innovative approaches to assess patient preferences, one of which- the Discrete Choice
Experiment- will be used in this study.
To date, research on patient knowledge, beliefs, and preferences has been
conducted largely in different professional ‘silos’ (nursing/policy, psychology and
economics, respectively).Yet, knowledge, beliefs and preferences likely work additively
on adherence and should be examined in tandem. For example, patients may know that an
inhaled corticosteroid is designed to prevent subsequent asthma attacks, but this does not
necessarily mean that they believe it will help control their asthma symptoms. Similarly,
patients may know that a preventer medication is designed to improve their asthma in the
long-term (but not relieve their symptoms in the short-term) and believe that it will work.
However, they may be seeking treatment for immediate symptom relief and are,
therefore, disinclined to use a medication that will prevent long-term effects. In essence,
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although correct knowledge and treatment-compatible beliefs may steer patients towards
making the proper health care decisions, without the necessary motivation, patients will
not engage in the behaviour. As noted by the World Health Organization (WHO, 2003, p.
44), “Patients’ knowledge [italics added] and beliefs [italics added] about their illness,
motivation [italics added] to manage it, confidence in their ability to engage in illness
management behaviours and expectations… interact in ways not yet fully understood to
influence behaviours”.
Accordingly, this research project represents an integration of theory and/or
methods from three disciplinary literatures- nursing/public health, psychology and
economics- to explore the additive effects of knowledge, beliefs, and preferences on
preventer medication adherence in a sample of patients with asthma. In the sections that
follow, the relevant literatures in these three spheres are reviewed with an eye towards
showing how current efforts to increase adherence in the domain of asthma selfmanagement have been hindered by not taking into account all three elements.
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Chapter I: Literature Review
Adherence: An Ongoing Challenge
Given that the benefit of medical advice is contingent on whether or not patients
choose to follow it, adherence has been deemed the “key” mediator between medical
practice and patient outcomes (Kravitz & Melnikow, 2004). The consequences of nonadherence are troubling. They include poor medical outcomes, higher health care costs,
as well as increased frequency of emergency room visits (Phillips, 2008). In general,
adherence rates tend to be lower for chronic than acute conditions (WHO, 2003).
Anywhere from 20-50 percent of patients with chronic conditions do not adhere to their
prescribed medication regimen (Kripalani, Yao, & Haynes, 2007) and more than 70
percent do not adhere to their diet or exercise programs (Their et al., 2008). Pulmonary
diseases, diabetes and sleep disorders are chronic conditions with the lowest adherence
rates (DiMatteo, 2004).
Accordingly, although there has been widespread improvements in our
understanding of the pathophysiology of many conditions and consequently treatment
efficacy (Sweeny, Edwards, Stead, & Halpin, 2001), treatment effectiveness has not kept
pace with these developments. Thier et al. (2008) conducted a retrospective analysis of
claims from a national insurer and found that, although physicians, on average, tended to
follow evidence-based practice guidelines 59 percent of the time, patients followed their
physician’s advice only between 11 and 42 percent of the time.
Research on the gap between physician’s recommendations and their patients’
behaviours has shown that treatment characteristics, such as medication side effects
(Catz, Kelly, Bogart, Genosch, & McAuliffe, 2000) and treatment complexity (Ley,
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1997) negatively correlate with adherence. In contrast, contextual factors such as social
support (Tanner & Feldman, 1997) and the quality of the patient-physician relationship
(Ciechanowski, Katon, Russo, & Walker, 2001) positively correlate with adherence.
Other predictive factors include, but are not limited to, poor instruction by the health care
provider, poor patient memory and cost of treatments (Haynes, Ackloo, Sahota,
McDonald, & Yao, 2008).
Adherence Interventions: Is Education Enough?
Poor adherence rates have catalyzed practitioners and researchers to develop
interventions to improve adherence in a broad range of populations and across a large
number of treatments. Educational interventions to improve adherence have been applied
to a range of patient populations, including individuals with asthma (e.g., Lemiere et al.,
2003), chronic heart failure (Clark et al., 2009), hypertension (Devine & Reifschneider,
1995; Schroeder, Fahey, & Ebrahim, 2004), hyperlipidemia (Schedlbauer, Schroeder,
Peters & Fahey, 2004), diabetes (Lutoto et al., 2011), HIV (Khachani, et al., 2011) and
chronic obstructive pulmonary disease (Simone et al., 2011). Unfortunately, although
some successful interventions exist, at least half fail to produce meaningful changes in
adherence (van Dumlen et al., 2007). Moreover, many interventions are time consuming
and complicated and result in only modest behaviour changes (Awad, 2004; Simpson,
2006).
After conducting a systematic review of 38 reviews of the literature on adherence
in the health care domain across a wide range of conditions, Van Dumlen et al. (2007)
concluded that technical (e.g., reducing the complexity of treatment) and behavioural
interventions (e.g., memory aids, reminder calls, etc.) were most effective. However,
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education, defined as “any intervention given with the intent of improving the person’s
ability to manage his or her disease” (p. 9), though effective in the short term, was less
effective over time. For example, an educational program for those with diabetes yielded
strong immediate (post-intervention) effects (d = 1.05) on adherence, but smaller effects
at four week follow-up (d = .46; Devine & Reifschneider, 1995).
Haynes et al. (2008) conducted a review of the efficacy of a broad range of
adherence interventions that involved instruction and counseling about a disease in
conjunction with other approaches (e.g., family and/or couple intervention,
psychotherapy, group meetings, providing reminder aids, or a combination thereof). They
found that less than half (45%) yielded statistically significant improvements in
adherence. Moreover, those that were most effective in the long term were quite labour
intensive, thereby reducing their cost-effectiveness and clinical utility.
Van Dumlen et al. (2007), commenting on the stagnancy of adherence rates over
the prior decade despite research proliferation, suggest it might be due to the lack of
guidance by suitable theoretical frameworks. Moreover, most interventions do not take
patients’ perspectives into account. Rather, they give patients information and
erroneously assume that they will then “think the right way” and behave accordingly.
However, helping physicians recognize that their patients’ views of their condition may
not match their own has been shown to improve physical and mental functioning
(Berkanovic, Hurwicz & Lachenbruch, 1995) and to decrease poor medical appointment
attendance (Chesney, Brown, Poe, & Gary, 1983). Therefore, for adherence intervention
research to move forward, we need to better understand how patients’ health beliefs and
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perspectives lead them to follow (or not) health care recommendations. This literature is
reviewed in the upcoming section.
Psychological Theories of Health: Do Beliefs Have a Role to Play In Medical
Decisions?
Health psychologists have long been interested in how individuals perceive their
health and what guides health behaviours. Early models, such as the Health Belief Model
(Janz & Becker, 1984), the Theory of Reasoned Action (Ajzen & Fishbein, 1980) and the
Subjective Expected Utility Theory (Sutton, 1982) emphasize the role of perceived health
risks in predicting health protective behaviours. However, these models rely on the
assumption that people use information in a linear fashion when deciding how to behave
(Brannon & Feist, 2004). The more recently proposed Transtheoretical Model (Prochaska
& DiClemente, 1983; Prochaska, Redding, & Evers, 2002) better accounts for the
complexity of health care decisions, in that it suggests that people move through a
sequence of defined, qualitatively different stages (i.e., precontemplation, contemplation,
preparation, action, maintenance) and takes into consideration how people initially
consider a problem as well as how they decide to act and maintain health actions.
However, this model has not been adequately supported by the literature as there is little
evidence for sequential movement across stages (Little & Girvin, 2002). Furthermore, the
model has not proved to be particularly predictive in longitudinal studies (Wilson &
Schlam, 2004).
To date, perhaps the most comprehensive model of patient health-protective
behaviour is Leventhal and colleagues’ (1984) Common Sense Model of Illness (CSM).
The CSM is predicated on a recursive, parallel processing system which is proposed to
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explain both the development and maintenance of health behaviours (Leventhal, Nerenz,
& Steele, 1984; Stuifbergen, Phillips, Voelmeck, & Browder, 2006). According to the
CSM, the noticing of symptoms or the receipt of a diagnosis activates schematic and
organizational frameworks, referred to as cognitive and emotional illness representations.
Cognitive and emotional representations work in parallel, but are proposed to have
reciprocal influences (Wearden & Peters, 2008). They prompt coping behaviours, the
consequences of which are appraised by the individual for effectiveness and changed
based on the information gleaned during the appraisal phase (Hagger & Orbell, 2003;
Leventhal, Brissette, & Leventhal, 2003; Scharloo & Kaptein, 1997).
Research over the past few decades (Hagger & Orbell, 2003; Moss-Morris et al.,
2002; Rutter & Rutter, 2007) has shown that cognitive representations can be grouped
into five distinct but correlated domains including: (1) individual beliefs about the
diagnostic label and associated symptoms (identity), (2) beliefs about the cause, (3)
beliefs about the course of the illness (timeline), (4) views about the consequences of the
illness and (5) beliefs about the controllability of the disease. More recently, illness
coherence, or the extent to which individuals feel they understand their illness, has been
added as a domain (Moss-Morris et al., 2002).
The construct and discriminant validity of these five cognitive components have
been studied extensively (Hagger & Orbell, 2003; Heijmans & de Ridder, 1998;
Frostholm et al., 2007; Moss-Morris et al., 2002; Petrie, Jugo, & Devcich, 2007; Rutter &
Rutter, 2007). Evidence for the distinctness of the categories has been found in studies of
patients with chronic illnesses (Leventhal et al., 1984), acute illnesses (Lau, Bernard, &
Hartman, 1989) as well as among undergraduates assessing hypothetical illness (Bishop,
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Briede, Cavazos, Grotzinger, & McMahon, 1987). A meta-analysis of 45 empirical
studies suggests strong support for a consistent five factor structure and provides
evidence of conceptual distinctions among the domains (Hagger & Orbell, 2003).
Moreover, to-be-expected relationships among the domains are observed, with high
positive correlations between the identity, chronicity and consequences domains and
strong negative correlations among the identity and cure dimensions. That is, patients
who attribute more symptoms to their condition construe it as having a larger impact on
their daily functioning and see it as more chronic.
Empirical studies have supported the hypothesis that illness representations are
associated with health outcomes. For example, illness representations have been shown to
predict return to work (Lacroix, Martin, Avendano, & Goldstein, 1991), success in
coping with chronic illness (Hampson, Galsgow, & Toobert, 1990) and functional
outcomes (Petrie, Jago, & Devcich, 2007; Scharloo et al., 1998). A considerable amount
of literature also exists on the illness representations of patients with cardiac disease
(Cooper, Lloyd, Weinman, & Jackson, 1999; Lau-Walker, 2006), type II diabetes
(Hampson et al., 1990), psoriasis (Fortune, Richards, Main, & Griffiths, 2000), kidney
disease (Fowler & Baas, 2006), cancer (Hagger & Orbell, 2006; Scharloo, Baatenburg de
Jong, Langeveld, van Velzen-Verkaik, Doorn-op den Akker, & Kaptein, 2005),
rheumatoid arthritis (Murphy, Dickens, Creed, & Bernstein, 1999; Scharloo et al., 1998),
Addison’s disease (Heijmans & de Ridder, 1998) and epilepsy (Kemp, Morley, &
Anderson, 1999). The importance of each dimension varies among the conditions. In the
context of various illnesses, cognitive illness representations have been shown to be
related to the decision to seek health care (Leventhal, Diefenbach, & Leventhal, 1992)
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and satisfaction with medical consultations (Frostholm et al., 2005). Additionally illness
representations have been associated with quality of life at a six month follow-up
(French, Lewin, Watson, & Thompson, 2005).
Thus, there is good evidence that patients’ subjective interpretations of their
physical ailments, or the “psychology” of physical symptoms has implications for health
outcomes. Moreover, certain dimensions of the illness model are differentially associated
with outcomes. For example, the perception of a strong illness identity, serious
consequences and chronic timeline are negatively associated with psychological and
physical well-being, whereas those with greater perceived control of their illness do
better psychologically and socially (Hagger & Orbell, 2003). It should be noted that the
majority of studies in this arena are cross-sectional, which makes it difficult to discern
whether these illness representations caused maladjustment or were its consequence.
Beliefs and Adherence
Leventhal et al. (2003) postulate that the process of constructing a representation
is symmetrical in that there is pressure to connect both abstract (disease labels and the
meaning of illness) with concrete physical symptoms. That is, once patients are given a
diagnosis, this hierarchical processing system compels them to search for symptoms that
confirm the diagnosis. Similarly, experiencing symptoms motivates individuals to seek
out a diagnosis. The interpretation of both sources of information leads to the formation
of distinct thematic dimensions that comprise a cognitive illness representation and have
important implications for treatment adherence. For example, in an actively treated
sample of patients with hypertension, Meyer (1981, as cited in Leventhal, Nerenez &
Steele, 1984) noted that the majority of the group used vacillations in a symptom to
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monitor changes in their condition. Of the patients who believed that the treatment was
acutely and directly affecting their symptoms, 70% were compliant with their medication.
In contrast, only 31% of patients who felt the medications were not affecting their
symptoms adhered to the treatment regimen, suggesting that perceived symptom
reduction is an essential component of medication adherence. These findings
demonstrate the difficulty in promoting adherence to occult conditions that do not
provide feedback in the form of symptom relief.
Horne and Weinman (2002) have argued that the CSM be extended to include
beliefs about the necessity of a treatment and concern for the adverse effects of
medications, because just as people have thoughts and beliefs about their illnesses, they
have thoughts and beliefs about the treatments being offered (Horne, 1996). In a study of
patients with several chronic disorders (i.e., asthma, diabetes, cardiac disease, and
cancer), Horne and Weinman (1999) found that self- reported non-adherence was
correlated with doubts about the necessity of the medication and concerns about potential
adverse effects. Thus, treatment beliefs are now frequently assessed alongside illness
beliefs, particularly when adherence is the outcome of interest. Beliefs, both about
illnesses and their treatments, have been shown to predict adherence to, among others,
HIV HAART treatment (Gellaitry et al., 2005), coronary treatments (Sud et al., 2005),
asthma preventer medication adherence (Horne & Weinman, 2002), Type II diabetes
treatments (Farmer, Kinmonth, & Sutton, 2006) and follow-up attendance at a lipid clinic
(Avishay, Lishner, & Melamed, 2011). Moreover, a narrative systematic review of both
patient and pharmacy level studies identified patients’ concerns for their treatment as well
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as their perception that medication was not necessary as the primary reasons they did not
fill their prescriptions (McHorney & Gadkari, 2010).
While beliefs account for a considerable amount of variance in adherence
(approximately a quarter of the variance as per Horne and Weinman, 2002), they do not
tell the whole story. As Kuhl (2000) notes, cognitive representations and subsequent
coping strategies cannot energize behaviour unless they have personal meaning. In other
words, behavior may be influenced by factors beyond clinical efficacy, including how
patients weigh the costs (e.g., side effects, inconvenience, and price) and benefits (e.g.,
immediate and long term symptom relief) of treatments, as well as how important these
costs and benefits are to them. As has been argued (Chapman & Sonnenberg, 2000)
patients choose whether or not to adhere, and so a better understanding of what drives the
decision would be helpful.
Decision Theory: What Really Matters to Patients?
Decisions, ubiquitous to daily life, are important in so far as they direct
behaviours. Ultimately, it is values and preferences that drive decisions and choices (an
overt expression of what is important to people) and their associated behaviours. In
addition, the value one places on the outcome motivates behaviours (Borders,
Earleywine, & Huey, 2004). To make a decision, one has to consider the range of
available options, each of which vary along a range of attributes. Each attribute, in turn,
is differentially valued. Thus, decision making can be a cognitively demanding task,
made even more difficult when stakes are high, as is the case with one’s health.
Notably, decisions are easy when one outcome is clearly valued over another. For
example, some individuals may value being medication free. But, these same individuals
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may place more value on their eyesight than being medication free. Consequently, when
faced with the decision as to whether to take their medication for glaucoma or risk
becoming blind, they opt for the medication. Decisions become considerably more
complicated when valued outcomes are equally preferred. In fact, often it is not until
values come into conflict that individuals realize that they have competing values
(Schwartz, 1996). For example, patients with asthma may not want to take a medication
containing steroids but also want to improve their symptoms in the long term. When this
occurs, people are required to make “trade-offs” between different attributes to ultimately
make their choice and act upon it.
Cognitively engaging in the trade-off process can be difficult and stressful
(Tetlock, Peterson, & Lerner, 1996). First, individuals may be hesitant to make these
types of decisions because the more important the value, the greater the potential for
anticipatory regret over the sacrificed value (e.g., getting rid of a pet because one is
allergic to it and the allergies exacerbate one’s asthma). Second, these types of decisions
involve difficult cognitive comparisons, as it is often the case that options are not
evaluated along the same metric. For example, how does one weigh the love of pet
against one’s long term health?
The Value Pluralism Model (VPM; Tetlock 1986) was proposed to explain the
cognitive strategies people use when it is necessary to make the kinds of trade-offs
described above. The theory suggests that individuals use increasingly complicated
coping strategies as trade-offs become increasingly difficult. If the value conflict is weak
(i.e., if one value is clearly stronger than another) individuals will downplay the weaker
value and focus on the stronger value (termed denial and bolstering). As the value

14

conflict increases, individuals begin to engage in lexicographic strategies in which they
use the most important value as a criterion to rank order their options and select the
highest ones. The most intense conflicts involve the comparison of interdimensional
values and at this stage individuals will use explicit trade-off reasoning, deciding how
much of one value they are willing to give up for the other (Tetlock, Peterson, & Lerner,
1996).
Trade-offs are inherent in decisions about whether or not to adhere to a prescribed
treatment regimen. As Horne et al. (2007) note, “In real life, patients make choices
between different attributes of the disease and its treatment, trading off one aspect for
another (p. 11)”. Given that real life decisions involve trade-offs, health economists have
developed techniques to quantify patients’ decisional “trade-offs” (Lanscar et al., 2007;
Lanscar & Louviere, 2008). Economic models, however, assume that preferences are
stable, consistent and rational (Phillips and Abramson, 1992). Because of the assumption
that preferences remain stable, health economists have been less concerned with how
preferences emerge. Moreover, classic economic theory has had difficulty explaining
inconsistent choices (Phillips, Johnson, & Maddala, 2002), though it should be noted that
the sub-field of behavioural economics, spawned by Kahneman and Tversky’s (1979)
Nobel winning work on cognitive heuristics, has made some significant inroads in this
domain.
Measuring preferences.
Measuring patient preferences for health care interventions and medications,
however, has proven to be a significant challenge for health care researchers (Phillips et
al., 2002). Many rely on attitude surveys in which individuals are asked to indicate the
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extent to which they favour or disfavour a particular entity (Eagly & Chaiken, 1996).
However, attitudes (i.e., judgments about the degree of like or dislike for something) are
not the same as preferences. Preferences, by definition, involve the relative weighing of
one option against another. For example, one may have a strong negative view/attitude of
medication side effects. However, when given the choice between taking a medication
with known side effects and taking no medication, people might choose medication
because alleviating symptoms is more highly preferred than experiencing side effects.
The theoretical differences between attitudes and preferences have
methodological implications. The social psychology literature on attitude measurement is
vast and the most widely used instruments tend to involve ranking or rating scales.
However, ranking or rating scales do not allow for the assessment of trade-offs so
relevant to daily life. Methodologies used in the field of economics more accurately
assesses preferences and trade-offs. In particular, recent studies have employed a type of
conjoint analysis, known as discrete choice experiments (DCEs).
In DCE’s, individuals’ preferences are revealed through their pattern of choices
when presented with multiple pairs of hypothetical scenarios. The technique assumes that
a product or program (or for the current purposes, treatment) can be described by a range
of characteristics or attributes (Lanscar et al., 2007). Each scenario contains a series of
these attributes, varying along different levels. The combinations of the levels of each
attribute vary across the scenarios such that when respondents make decisions about the
gestalt of the scenarios, they are, in essence, making “trade-offs” between the attributes.
By analyzing their pattern of choices, it is possible to glean the extent to which people
value each attribute (McTaggart-Cowan et al., 2008).
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The application of DCE methodology to discern patient/health care consumer
preferences is relatively new. However, research suggests that it provides different
information than attitude surveys. For example, Phillips et al. (2002) compared the
preferences gleaned from an attitude survey and a conjoint analysis tasks. Their
participants observed that they had to think ‘harder’ while doing the conjoint analysis
task than attitude survey. And, while the approaches yielded some consistent results,
there were halo effects in the attitude survey wherein respondents used evaluations of one
attribute as a marker for other attributes. Consequently, an attribute that was ranked
highly on the rating task turned out to be the least significant predictor of choice when
participants were forced to make trade-offs in the conjoint analysis task.
Given that DCEs allow for the consideration of the mix of outcome (e.g.,
improved health in 10 years) and process (e.g., treatment regimen characteristics)
variables, DCEs serve as an ecologically valid measure of patient preferences and are
useful to address policy relevant issues and patient preferences for medical treatments
(Kellet, West, and Finlay, 2006). DCEs have also demonstrated good levels of both
internal and convergent validity and have been shown to be relatively insensitive to the
ordering and levels of attributes (Ryan, Bate, Eastmond, & Ludbrook, 2001). As such,
DCE’s may help us better to understand the role that complex tradeoffs play in patients’
decision making about medical treatments, such as the one required for asthma. For
example, an individual with asthma may believe (correctly) that using a corticosteroid
inhaler on a daily basis will prevent subsequent attacks, and also believe (correctly) that
corticosteroid use is associated with a slight risk of long term effects, such as bone loss.
However, the extent to which this patient uses his/her steroid inhaler on a daily basis (as
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prescribed) may be driven in part by the relative ‘weight’ he/she places on these two
factors, as well as on other treatment features (e.g., number of inhalers, immediate versus
delayed symptom relief, frequency of dosing, etc.).
Notably, DCE research tends to be descriptive rather than predictive in nature.
That is, studies employing this technique have sought to describe group characteristics of
patients. This has limited the use of this methodology in psychology, which primarily is
concerned with processes and with predicting behaviour at the level of the individual
rather than group. Data at the group level and individual level both have their limitations.
Whereas aggregate data may over-generalize preferences, individual data may paint a
mosaic of preference that cannot easily be used by policy makers to help guide the
development of cost effective interventions. There is, therefore, a potential benefit of an
intermediate approach, whereby one captures the heterogeneity of preferences within a
large group by identifying subgroups with specific preference profiles. To date, only a
couple of studies have extracted subgroup data from a conjoint analysis. Namely, Singh,
Cuttler, Shin, Silvers and Neuhauser (1998) found five preference patterns among
patients considering growth hormone therapy and Cunningham et al. (2008) identified
subgroups of parents based on their preferences for children’s mental health care.
However, both studies are descriptive in nature in that the predictive value of these
preference patterns was not examined.
This study will apply this methodology within a predictive model, by examining
the extent to which subgroup differences in preferences about various asthma-related
states and treatment characteristics predict adherence to preventer medication.
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Asthma: A Case in Point for Studying Knowledge, Beliefs and Preferences
Asthma is a serious illness, resulting from both chronic inflammation and
intermittent constriction of the airways (Holgate, Price, & Valovirta, 2006), the latter
producing the rapid onset of respiratory symptoms (i.e., asthma attack) such as
breathlessness, coughing and wheezing. In contrast, while inflammation does not directly
cause acute symptoms, it does so indirectly by increasing the frequency of
bronchoconstrictive episodes. Thus, given the phasic (bronchoconstrictive) and tonic
(inflammatory) nature of its underlying pathophysiological processes, asthma treatment
guidelines stipulate the overall goals of asthma control should include both day to day
symptom control as well as minimizing future risk (O’Bryne, 2010).
Accordingly, optimal management of asthma involves the use of both
corticosteroids as a preventive medication to decrease the chronic inflammation, as well
as the use of rescue/reliever medications to alleviate the constriction of the airways and
associated symptoms of an acute attack (Ohm & Aaronson, 2006). Rescue medications,
which reduce broncoconstriction, produce an immediate improvement in symptoms. As
such, they are inherently negatively reinforcing, which likely means patients do not need
convincing or reminding to use their rescue inhalers. In contrast, preventer medications,
typically prescribed for daily use, target the underlying pathophysiology (airway
inflammation) and do not provide immediate symptom relief (i.e., are not negatively
reinforcing). Recently, a new class of “combination inhalers”, which combine preventer
and rescue medications in one inhaled dose, was introduced. This regimen requires
patients to take a prescribed dose regularly for the subsequent rescue puffs to be effective
(C. Licskai, personal communication, October 2008).
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The incidence of asthma has increased substantially over the past 20 years and the
increased health care costs, missed days of work and lost productivity pose a heavy
economic burden (WHO, 2003). Non-adherence to preventer medications is widespread,
and adherence to asthma medications is the poorest of that for all other chronic medical
conditions (Claxton, Cramer, & Pierce, 2001; DiMatteo, 2004). Despite physicians’ best
efforts to prescribe according to empirically supported treatment guidelines (in fact, the
highest for any disorder), patient non-adherence rates to preventer medications were 37
percent and 42 percent for adults and children, respectively (Bender, Milgrom, & Rand,
1997; Thier et al., 2008). In other words, there is a large gap between the efficacy of
treatments and their use in controlling the disorder (Hancox et al., 2010).
As such, most individuals with asthma experience an inadequate level of control,
which leads to unnecessarily high morbidity, mortality, and health care burden (Anis et
al., 2001; Horne, 2006). These increases are unwarranted because asthma is a disease that
can be effectively controlled through self-management.
Factors Affecting Asthma Adherence
According to the World Health Organization (2003), non-adherence to inhaled
corticosteroids results from a number of factors, broadly classified into five categories:
(1) Socioeconomic factors (poverty, family dysfunction, fear of health system, cultural
and lay beliefs about illness), (2) Health care factors (health care providers’ inadequate
knowledge and lack of training in behaviour change principles), (3) Condition- related
factors (inadequate understanding of the disease), (4) Therapy related factors (complexity
of treatment, duration of therapy, adverse effects of treatment), and (5) Patient related
factors (forgetfulness, misunderstanding, drug abuse). In addition, patient personality
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factors, such as having a high external locus of control, being highly extroverted, as well
as scoring low on social desirability measures, have been demonstrated to be associated
with poor adherence to asthma medications and monitoring (Halimi et al., 2010).
The WHO goes on to suggest that guidelines for the management of asthma
should consider these factors and argues that the majority of factors (2 -5) can be
remedied by asthma education programs. Consequently, policy makers and government
officials have tried to narrow the efficacy-effectiveness gap for asthma treatments by
advocating and implementing educational programs to enhance patients’ knowledge
about asthma and its treatment (Allen & Jones, 1998; Schaffer & Yarandi, 2007).
Current Asthma Adherence Intervention Programs
While recent reviews have suggested that interventions need to be multifaceted
and incorporate behavioural and educational components (Haynes et al., 2008; Roter et
al., 1998; van Dulmen et al., 2008), the majority of asthma adherence interventions are
solely focused on education. At the recommendation of the National Asthma Education
Prevention Program (Bethesda, 1997), standard content areas in asthma education
programs include basic information about (1) the pathophysiology of the disease, (2) the
different roles of preventer versus relief medications, (3) the proper techniques for using
inhalers, (4) self-monitoring approaches, and (5) ways to reduce environmental triggers
(Janson, Hardie, Fahy, & Boushey, 2001). However, evidence for the effectiveness of
knowledge-focused interventions is mixed, at best. As has previously been argued, this is
likely due to the fact that, to date, these interventions have addressed neither beliefs nor
preferences. In examining these interventions, it is essential to differentiate those that
involve purely educational interventions (knowledge interventions) and those that target
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self-management (i.e., behaviours), as they can be expected to produce different
outcomes (Leventhal & Cameron, 1987).
Knowledge interventions.
Evidence for the effectiveness of knowledge- based interventions on preventer
medication adherence is mixed. In a meta-analysis of the effectiveness of asthma
education programs, Bender, Milgrom and Apter (2003) cited nine studies demonstrating
significant enhancement of asthma control. Yet, Ho and colleagues (2003) found no
relationship between knowledge and adherence to an asthma treatment regimen.
Moreover, Bailey et al. (1999) found that patients receiving educational materials and one
hour of individualized education sessions were no different from a standard care group in
terms of functional status at follow-up. A similar null finding recently was observed in a
sample of adults above the age of 65 (Baptist, Talreja, Clark, 2011). Furthermore, several
studies have shown improvements in knowledge following an educational intervention
yet no changes in asthma control or adherence (Cote et al., 1997; Garrett et al., 1994;
Lopez-Vina & Castillo-Arevalo 2000).
Notably, the shortcomings associated with knowledge measures may obfuscate
the ability to interpret the effect of knowledge based interventions. For example, Allen
and Jones (1998) developed a general knowledge of asthma questionnaire, which served
as the primary outcome measure in an effectiveness trial of an asthma education program.
The survey, however, did not differentially assess knowledge about preventer versus
rescue medications nor did it assess knowledge about how these two classes of
medications target the pathophysiology of asthma. A more recently developed asthma
questionnaire (Schaffer & Yarandi, 2007) rectified some of the problems associated with

22

earlier surveys, but continues to have a number of limitations including the failure to
address knowledge about asthma pathophysiology as well as the absence of items about
combination inhalers, which have properties of both preventer and rescue medications.
The failure to assess patients’ knowledge of asthma pathophysiology is
problematic, in that it’s crucial to understanding why preventer medications are needed.
Taylor and Bower (2004), for example, demonstrated that giving people an explanation
as to why they should follow instructions enhances compliance. Thus, an intellectual
understanding of the “why” may be particularly important for adherence to medications
that, like asthma preventer medications, do not immediately yield symptom
improvement.
Self-management interventions.
According to the World Health Organization (2003), self-management programs
have been shown to be cost-effective, reducing both direct (hospitalizations) and indirect
(loss of productivity) costs. However, individual studies seem to suggest otherwise. For
example, Bailey et al. (1999) randomly assigned 236 asthmatic patients to receive either
(1) usual care, (2) an asthma self-management skill-oriented program consisting of a
minimum of two group sessions in which they focused on a workbook about asthma
triggers and care services as well as how to use a peak flow meter in addition to followup reminder phone calls at one, two and four weeks, or (3) a shorter version of the
workbook and a 15 minute session with a nurse educator. Despite the investment of time,
neither intervention group improved more than the standard care group.
Similar null findings were observed by Morice and Wrench (2001) who
randomized 80 patients with acute asthma admitted to hospital into two groups: (1)
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control group who received standard care, and (2) an intervention group who received a
minimum of two one-on-one 30 minute sessions with a nurse educator with the goal of
developing an individualized self-management plan. Hospital re-admission rate, their
primary outcome variable, was the same for both groups four months post-discharge.
However, as the authors acknowledge, the study may have been insufficiently powered to
adequately assess group differences. Levy et al. (2000) delivered a similarly complex and
controlled nurse educator delivered intervention. The intervention improved self-reported
adherence as well as symptoms at six month follow-up amongst the severe asthmatic
patients in their sample, but not in those with mild asthma.
Conclusion: Knowledge is not enough.
Despite these mixed findings, experts rightly note that correct knowledge is a
prerequisite for self-management (Gibson & Boulett, 2001; Gibson, Ram, & Powell,
2003). However, studies that have demonstrated that educational interventions focusing
on these content areas improve asthma control (e.g. Bonne et al., 2002; Couturaud et al.,
2002) all have entailed time consuming educational programs that take place over a series
of weeks or even months. Indeed, coverage of all content areas dictated by educational
guidelines would require a significant amount of clinician and patient time, making the
cost-effectiveness and even patient attendance of the educational program themselves
potential concerns.
What has become clear is that educational interventions alone are not sufficient.
Accordingly, recent adherence intervention programs have begun to incorporate clientspecific risk factors to improve adherence (Jinhee et al., 2010). Moreover, Elliot (2006)
suggests that knowledge based interventions, while providing patients with correct
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factual information fail to address patients’ misguided beliefs about asthma, thereby
limiting their effectiveness. The psychological literature on lay illness beliefs and models
helps one to understand why, despite increased knowledge following education programs,
a patient’s behaviour may remain unchanged.
Beliefs about Asthma
The proper use of asthma medications requires patients to understand both the
chronic (tonic) nature of the disease as well as the episodic (phasic) exacerbation of the
symptoms associated with the disorder. Most patients, however, view asthma as a series
of discrete acute illnesses, separated by what appear to be (given that they are
asymptomatic) normal, disease-free time frames (Insel, Meek & Leventhal, 2005). Halm,
Mora, and Leventhal (2006) found that 53% of asthmatic patients believed that their
asthma was episodic because they had symptoms only occasionally. In essence, patients
subscribed to the view that when they have no symptoms, they do not have asthma. This
poses a significant problem for medication adherence, as patients with asthma who hold
this belief adhere less to their preventative treatment regimens (Halm et al., 2006; Horne
& Weinman, 2002). As a case in point, Jessop and Rutter (2003) explored the role of
illness beliefs on asthma medication adherence and found that those who believed their
asthma could be controlled were more likely to adhere to their preventer medications,
whereas those who attributed their asthma symptoms to external causes (e.g.,
environmental pathogens) were less likely to adhere.
Asthma specific treatment beliefs that drive adherence to corticosteroid inhalers
may be particularly instructive. As noted earlier, corticosteroids, prescribed as
‘preventer’ medications for asthma, offer no immediate symptom relief. Rather, they
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afford only long-term benefits (Hand & Bradley, 1996), decreasing the number of future
asthma attacks by improving lung functioning and presumably preventing structural
airway changes (Bender et al., 1997). Also as noted earlier, given that preventer
medications are not negatively reinforcing (i.e., they do not immediately remove
symptoms), their sustained use would, arguably, need to be guided and driven by internal
working models (Jessop & Rutter, 2003).
Research within the CSM framework has shown that beliefs about the necessity of
a treatment and concerns about the risks associated with it correlate with adherence to
asthma preventer medications. Namely, Horne and Weinman (2002) found that treatment
beliefs partially mediated the relationship between illness representations and adherence
to asthma preventer medications. Moreover, they demonstrated that non-adherence was
associated with greater doubts about the necessity of the medications, concerns about its
potential side effects and perceived negative consequences of the illness.
In a recent position paper, Horne et al. (2007) argue that “…it may be possible for
healthcare professionals to improve asthma control [i.e., consistent use of inhaled
corticosteroids] by achieving a greater understanding of the patient’s perspective” (p. 9).
Certainly, exploring patients’ illness models would facilitate understanding and improve
current asthma education protocols. In fact, there have been efforts to target and alter
patients’ illness models to effect behavioural outcome. For example, Petrie, Cameron,
Ellis, Buick, and Weinman (2002) conducted a brief hospital intervention for patients
who had recently suffered a myocardial infarction (MI) that targeted individuals’
negative illness perceptions (as assessed by the Illness Perception Questionnaire) to
specifically alter beliefs about the timeline of recovery and consequences of having an

26

MI (e.g., that individuals would have to significantly reduce exercise activity over the
long term). They found that those receiving the intervention returned to work faster and
reported fewer symptoms at follow-up than those in the control group. Similarly, in a
prospective study, Moss-Morris et al. (2007) found that illness representations changed as
a function of a cognitive-behavioural intervention for pain, and that reductions in beliefs
about the negative consequences predicted improved physical functioning and reductions
in emotional representations and also found that an improved sense of coherence
predicted psychological functioning.
While statistically significant, the correlations between treatment beliefs and
adherence are quite modest, ranging from only .31 to .43 (Horne & Weinman, 2002).
Why might beliefs, in and of themselves, account for no more than 21 percent of the
variance in adherence? It may be because behavior is driven not only by patients’ beliefs
about the costs (e.g., side effects, inconvenience, and price) and benefits (e.g., immediate
and long term symptom relief) of treatments, but also how important each of the costs
and benefits are to them.
This weighing of risks and benefits may be especially important for asthma
preventer medications, which, while providing relief, also include a number of inhaled
corticosteroids that may result in side effects (McTaggart-Cowan et al., 2008) and daily
exposure to steroid medication. The decision to take preventer medications, therefore,
involves balancing the probability of a desirable outcome (e.g., future symptom
reduction) against that of an undesirable outcome (e.g., current and long term side
effects). The health economic and marketing literatures provide useful frameworks for
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examining the role that patient preferences may play in adherence to preventer
medication.
Assessing what Matters to Patients with Asthma
The use of preference-based models in health care is relatively new. However, a
few studies have applied a DCE paradigm to better understand the trade-offs patients
with asthma are willing to make both in terms of symptoms as well as treatment. For
example, McKenzie, Cairns, and Osman (2001) presented patients with moderate to
severe asthma with a series of pairs of scenarios characterized by different combinations
of symptoms, including cough, breathlessness, wheeze, chest tightness and sleep
disturbance. Analysis of respondents’ choices suggested that, as a group, participants saw
cough as the most important symptom to target and reduce. The authors suggest that
identifying patient preferences for symptom alleviation has important implications for
treatment development.
In terms of treatment attributes, Haughney et al. (2007) administered a DCE to
147 patients with asthma. Based on qualitative interviews, the six attributes deemed most
important for asthma self-management were: (1) symptom relief, (2) steroid dose, (3)
asthma action plan, (4) management of acute exacerbations, (5) number of inhalers, and
(6) response to deterioration. The overall relative importance of the attributes was
assessed. As a group, participants were willing to trade some symptom relief for a
simpler treatment regimen involving fewer inhalers and a lower dose of steroid.
Also using a DCE paradigm, McTaggart-Cowan and colleagues (2008) assessed
patient preferences for various forms of asthma treatment. Participants were provided
with scenarios which varied with respect to the degree of symptom free days, side effects
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(i.e., the number of tremors/palpitations per month and oral thrush episodes per year), out
of pocket costs, number of medications, and frequency of use per day. As did Haughney
et al. (2007), they found that patients, as a group, were willing to trade symptom free
days for a more convenient regimen with a decreased number of side effects.
With the introduction of the combination inhalers, however, new variables must
be considered. For instance, the Symbicort and Advair combination inhalers require
patients to carry only one inhaler (likely seen as an advantage by patients) yet it delivers a
larger dose of corticosteroids than most stand-alone preventer inhalers (which might be
seen as a disadvantage). In addition, for the “reliever” portion to work effectively,
patients must also take their medications at set times each day, rather than “as needed”, as
per standard reliever medications. Therefore, preferences for steroid dosing, frequency of
medication use and complexity (one versus two inhalers) must also be assessed.
Knowledge, Beliefs and Preferences for Asthma: Can We Study Them Together?
The Multiattribute Utility Model (MAU) is based on the premise that decisions
are complex and that different factors are hierarchically weighted to influence ultimate
behaviour (Chang, Chan, Chang, Yang, & Chen, 2008). This model provides a good
framework for examining non-adherence to asthma medications for two reasons. First, it
stipulates that many elements are incorporated into a decision. Second, it demonstrates
that the elements influencing a decision form a hierarchical structure such that some are
more important to the ultimate behaviour than others. For example, knowledge about
asthma medications may not be as important to the decision making process as patients’
preferences for treatment. The methodology adopted most typically by MAU researchers
requires patients to explicitly state the importance of each category in their decision
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making process. Given that patients could not be expected to have insight into the relative
importance of their knowledge, beliefs or preferences in their decision making process,
the methodology of MAU research is unsuitable for use in this study. The theory,
however, offers a rationale for exploring the individual roles and combined effects of
knowledge, illness and treatment beliefs and preference on adherence behaviour.
Study Rationale and Hypotheses
Although effective treatments for asthma have been developed and have been
shown to reduce asthma morbidity and mortality (WHO, 2003), their utility is highly
contingent on proper use by patients. That is, efficacy does not translate to effectiveness.
This is why an understanding of factors governing adherence is a crucial element of
health research. However, as Van Dulmen et al. (2007) have observed, adherence
research over the last decade has remained largely atheoretical or driven by theories that
are too circumscribed in scope.
As the previous review indicates, proper asthma preventer medication use may be
driven by a number of factors, including the degree of knowledge about proper inhaler
technique and asthma pathophysiology, beliefs about asthma and its treatment, and
preferences for various health states and treatment regimens. Efforts to enhance patient
adherence to preventer medication that take patient knowledge, beliefs, and preferences
into account are likely to be more successful than those that do not and research on how
these three elements work additively to produce adherence could be instructive.
Unfortunately, to date, these three components have been studied in relative isolation, in
the nursing, health psychology and health economics/medical decision making literature,
respectively.
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Accordingly, the proposed study will seek to integrate these three lines of
research and model their additive effects on adherence behaviours. Specifically, it is
predicted that:
Hypothesis 1: Increased knowledge about the pathophysiology of asthma will predict
adherence to preventer medication.
Hypothesis 2: Beliefs about the chronicity of the disease, amount of control, severity of
symptoms, sense of coherence and necessity of preventer medications will predict
increased treatment adherence.
Hypothesis 3: Patient preferences will predict adherence. In particular, those who value
long term outcomes will be more adherent to their preventer medications.
Hypothesis 4: Patient preferences for elements of their medication will predict adherence
above and beyond that predicted by knowledge of their disease and beliefs about the
disease and its treatment.
In addition, this study will extend the DCE methodology by generating preference
parameters at a subgroup (rather than overall group) level. To my knowledge, this will be
the second study in the adult health care domain (the first being Singh et al., 1998) to
attempt to extract subgroup data from a conjoint analysis technique, and the first to apply
the extracted data to predicting behavioural outcomes. Accordingly, an exploratory
analysis will be conducted to assess the degree of convergence between patients’
explicitly stated preferences (as measured by a standard 10 item rating scale) and their
implicit preferences, as indicated by the discrete choice preference parameters and their
differential effects on adherence.
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The study was conducted in four phases: (1) Knowledge questionnaire
modification, (2) Preference measure development, (3) In-field pilot study of
questionnaires and, (4) Main study.
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Chapter II: Methods and Results of Phases 1 - 3
Phase I: Knowledge Questionnaire Modification
This phase consisted of three stages: (1) Item modification and generation, (2)
Assessment of item relevance and clarity, (3) Assessment of content validity.
Stage 1: Item modification and generation.
Currently, the most comprehensive self-report measure of asthma knowledge is
the Asthma Knowledge Questionnaire developed by Schaffer and Yarandi (2007). The 24
item self-report, True-False measure taps the five content areas specified as necessary for
asthma self-management by the National Asthma Education and Prevention Program: (1)
Asthma pathophysiology, (2) Roles of medications, (3) Skills of inhaler use, (4)
Environmental Controls, and (5) Rescue Medication Information. The total scale
demonstrates a reasonable internal consistency of .69 (Schaffer and Yarandi, 2007).
In reviewing this measure with the consulting respirologist (C. Lisckai), however,
it was apparent that knowledge of asthma pathophysiology, arguably the most important
for understanding the rationale behind one’s prescribed self-management regimen, was
not adequately assessed in the original scale. Accordingly, four items pertaining to the
pathophysiology of asthma either were generated or taken from other sources: (1) Having
swollen airways does not increase the risk of having an asthma attack (F; New), (2)
During an asthma attack, the muscles around the airways tighten and the airways
become narrow (T; as per Allen & Jones, 1998), (3) Asthma is a disease that comes and
goes (F; New), and (4) If asthma attacks stop, it means that the asthma has gone away (F;
as per Grant et al., 1999).
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In addition, the questions on the original scale were worded in either personal
(i.e., “you”, “your”) or general (i.e., “people”) terms. We changed personal to general
wording to increase the likelihood that responses to the items would tap global
knowledge about asthma in general rather than reflecting the particulars of an
individual’s condition. Thus, items such as “Keeping your bedroom windows open at
night will help prevent asthma symptoms” were changed to “Keeping bedroom windows
open at night will help prevent asthma attacks”. Finally, two items were eliminated. The
first, “Getting rid of cockroaches in your house may help your asthma” was removed
because it applies to densely populated cities and was deemed irrelevant for our sample,
largely drawn from small to mid-sized urban and rural communities. The second, “To use
an asthma inhaler correctly, you need to breathe in as you press down on the inhaler”
was removed as our consulting physician deemed it inaccurate.
We also included an “Unsure” response option to discourage guessing,
particularly by those prescribed single inhalers who thus might not be expected to have
knowledge about combined inhalers.
The interim measure (Appendix A) consisted of 30 items that were then rated for
relevance and clarity by a group of clinician experts (Phase 2). Based on their feedback,
the scale was further altered and the 36 items of the revised scale were then rated by a
group of graduate students for content validity (Phase 3). These stages are outlined
below.

34

Stage 2: Assessment of item relevance and clarity.
Method.
Participants. A panel of approximately 35 respirologists, allergists, and/or
asthma nurse educators from clinics across Ontario and Quebec were recruited by C.
Lisckai, the consulting respirologist.
Procedure. Panelists, by means of an on-line survey, were presented with items
from 6 content areas, including pathophysiology, medications and their effects,
technique, symptoms, environmental triggers, and other asthma facts, purportedly
covered by the survey. They were asked to rate the relevance/clarity of each item (1 =
not relevant, 2 = confusing and cannot be assessed without revisions, 3 = relevant but
requires minor changes, or 4 = succinct and relevant to content area; as per Schaffer &
Yarandi, 2007). Space was also provided for written feedback.
Results.
Twenty-one of the thirty-five (a response rate of 60 percent) expert reviewers
responded. The results are presented in Appendix A. All items received a mean rating
above 3.32 (out of 4), suggesting that, on balance, they were deemed acceptable. Minor
semantic modifications were made and conceptual issues were readdressed with the
consulting physician (C. Lisckai). To enhance clarity, two items (#15 and #19) each
were subdivided into two questions and one item (#23) was deleted because it was
deemed inaccurate. Moreover, based on the panelists’ comments, it was clear that more
questions were needed to address knowledge about combination inhalers. As such, in
collaboration with the consulting physician, the following two questions were added, (1)
A combination medication includes two types of medication to control asthma (T), (2) A
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person with asthma can use a combination inhaler for quick relief, even if they do not use
it every day (F). In addition, the symptom and technique subscales were deemed to need
more items and so the following three questions were added: (1) Chest tightness is a
common symptom of asthma (T), (2) People with asthma get relief from their symptoms
at night (F), (3) Asthma attacks often come on suddenly without any warning (F).
The revised scale, consisting of 36 items, was then evaluated for content validity,
as described below.
Stage 3: Assessment of content validity.
Method.
Participants. Raters were 11 graduate students in psychology from the
University of Western Ontario and Concordia University, ten of whom had training in
survey design. The raters were not expected to have much previous knowledge about
asthma and indeed rated themselves as only slightly knowledgeable (i.e., mean rating =
4.36 on a 10 point Likert scale, where 0 = no knowledge and 10 = extremely
knowledgeable).
Procedure. The raters were presented with six content areas and descriptions of
each (See Table 1, column 2) and were asked to indicate which of the six constructs each
item was most consistent with. They were instructed to select “other” only if they were
really unsure which category the item should be placed.
Results.
For an item to be considered indicative of a given content area, at least seven of
the eleven raters had to place the item in its corresponding category. The items they rated
pertaining to each category are presented in Table 1. The amount of agreement indicated

Table 1
Knowledge Domain Descriptions and Questions
Domain

Description

Pathophysiology Physiology and functional changes
associated with asthma and its acute
exacerbations, and about the course
of the disease in general.

Allocated Questions after Graduate Student Ratings
1. People with asthma can have swollen and inflamed airways even
when they feel well. (T)
2. Asthma is a disease that does not last for a long time. (F)
3. It is possible for someone’s asthma to be worse without them noticing
a change in their breathing. (T)
4. Asthma can be cured. (F)
5. During an asthma attack, the muscles around the airways tighten and
the airways become narrow. (T)
6. Having swollen airways does not increase the risk of having an
asthma attack. (F)
7. When someone’s asthma attack is over, it means that the asthma has
gone away. (F)
8. Untreated asthma can cause death. (T)
9. If a person does not have asthma by age 40, they will never get it. (F)
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Domain

Description

Allocated Questions after Graduate Student Ratings

Medication and
Effects

Purpose and effects of asthma
medications. The three types of
asthma medication include: (1)
Inhaler steroid (controller)
medications- used to prevent asthma
attacks; (2) Quick relief medicationsused to relieve an asthma attack once
they begin; (3) Combination inhalerscombine control and relief
medications in one inhaler.

1. Quick relief medications should be taken every day, even if people
are feeling well. (F)
2. Inhaled steroids (controller medications) prevent asthma attacks. (T)
3. People with asthma should wait until their symptoms are really bad
before using a quick relief medication. (F)
4. A person with asthma can use a combination inhaler for quick relief,
even if they do not use it every day. (F)
5. Taking an antibiotic such as penicillin will help most bad asthma
attacks. (F)
6. People may not notice improvements in their breathing for 1-4 weeks
after they start using inhaled steroids. (T)
7. The purpose of steroid medication inhalers is to stop an asthma attack
when it happens. (F)
8. People with asthma can usually help control their symptoms by
taking the appropriate medications. (T)
9. It is okay to take inhaled steroids (controllers) only when people
notice their symptoms getting worse. (F)
10. Inhaled steroids will relieve an asthma attack within 20 minutes. (F)
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Domain

Description

Allocated Questions after Graduate Student Ratings
11. People with asthma do not need to take their daily inhaled steroids
(controller) if they feel well. (F)
12. A combination inhaler includes two types of medication to control
asthma. (T)

Technique

The way technical skills and
procedural information needed to
effectively use an asthma inhaler.

1. People with asthma should try to hold their breath for 8-10 seconds
after each puff of their inhaler. (T)
2. People with asthma should rinse and gargle after each use of their
inhaled (controller) steroid. (T)
3. People with asthma should wait about one minute between puffs of
their quick relief medication. (T)
4. People with asthma should breathe out partially, but not fully, just
before taking their medication. (F)

Environmental
Triggers

Environmental conditions (e.g.,
irritants, allergens) that can worsen
asthma symptoms.

1. Molds can trigger asthma symptoms for some people. (T)
2. Being around others who smoke does not bother a person’s asthma,
so long as they do not smoke themselves. (F)
3. Cold air can make asthma symptoms worse. (T)
4. People can usually help control their symptoms by avoiding things
(triggers) that make their asthma worse. (T)
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Domain

Description

Allocated Questions after Graduate Student Ratings
5. People with asthma should avoid exercise.(F)
6. Keeping bedroom windows open at night will help prevent asthma
attacks. (F)

Symptoms

Changes in the body or its function
experienced by the patient and
indicative of disease.

1. Frequent coughing can be a symptom of asthma. (T)
2. Asthma may cause wheezing during exercise. (T)
3. Chest tightness is a common symptom of asthma. (T)
4. People with asthma get relief from their symptoms at night. (F)
5. Asthma attacks often come on suddenly without any warning. (F)

Other

Information about asthma that does
not fit into any of the other five
categories.

None
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good content validity, and so the version rated by the students was not altered further.
Accordingly, the final scale (See Appendix B) consisted of 36 items, with nine in the
disease category, 12 in the medication category, 4 in the technique category, 6 in the
environment category, and 5 in the symptoms category.
Phase II: Development of the Preference Measures
Method.
Discrete choice scenarios.
McKenzie, Cairns and Osman (2001) stipulate that the process of creating discrete
choice scenarios involves a series of steps. These steps include: (1) Identifying the
attributes important to the population in question, (2) Reducing the scenarios to a
manageable number of combinations, and (3) Deciding how to establish preferences
based on the selected scenarios. As per previously conducted DCEs in health care
(Lanscar et al., 2007), the attributes and their levels adopted for this study reflected
common variations in asthma treatments and their outcomes, informed by consultations
with two respiratory specialists (C. Lisckai and N. Patterson), a thorough literature
review and perusal of asthma treatment guidelines. The factors were then culled to the
seven pertaining most directly to the study’s main questions. All (binary) attribute levels
were plausible and clinically relevant. The attributes and their levels were as follows:
1. Long-term outcomes (Asthma will be the same in 10 years versus worse in 10
years)
2. Short-term consequences (Fewer asthma attacks over next six months versus
the same number of attacks over the next six months)
3. Immediate effects (Relief within 5 minutes versus Relief within 30 minutes)
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4. Side-effects (Major/ Long-term versus Minor/Short-term)
5. Fixed dosing (Every day at set times and more if I need it versus Only when
needed)
6. Number of Inhalers (1 versus 2)
7. Dose of Steroid (High versus Low)
Given that DCEs applied to consumers’ health care decision-making have involved as
many as 12 factors (Lanscar & Louviere, 2008), the cognitive load for participants
imposed by a seven-factor manipulation was deemed reasonable.
The most common DCE design involves factors each having only two levels, thus
referred to as a ‘binary attribute design’. To keep the design and resultant data analysis
reasonable, the binary approach was used here as well. Although a limitation of the
binary attribute design is that it cannot generate non-linear effects, it can estimate main
factor effects, thereby capable of providing meaningful information (Street & Burgess,
2007). The present study is unique in that unlike previous DCE studies applied to asthma
or its treatment, these scenarios captured treatment features (complexity and frequency)
that differentiate combination therapy from regular asthma treatments.
Rating scale development.
To date, the standard approach to eliciting patient preferences is for participants to
rate individual attributes with respect to their importance (Phillips, Johnson, & Maddala,
2002; Ryan et al., 2001; Singh et al., 1998). To compare information derived from these
rating scales with those from DCEs, we generated items that captured the attributes of
interest and wrote instructions designed to encourage participants to think about the
“trade-offs” involved in making a decision about taking a medication. The intent was for
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these rating scales to explicitly gauge the variables assessed more implicitly in the
discrete choice experiments. The instructions read: “There are different things people
have to weigh when deciding whether or not to use an inhaler. For example, while some
people with asthma may worry about a medication’s side effects, they feel that the
benefits from the medication are worth the risk. Others are not so sure. We are interested
in what kinds of things you consider when deciding whether or not to use an inhaler.
Trying to keep the list of things below in mind, for each item, please circle on the scale
the number that best describes the importance of each of the following.” The scale was
designed such that 1 = Least important and 10 = Most important. Items included: (1) The
number of inhalers I need to take, (2) Having to take an inhaler every day, (3) Being able
to take an inhaler only when I need it, (4) Possible short-term side effects of the inhaler,
(5) Possible long-term side effects of the inhaler, (6) Risk of addiction from the inhaler,
(7) The inhaler can take my symptoms away within minutes, (8) The inhaler can help
keep my asthma from getting worse over the next 10 years, (9) The inhaler can reduce
how often I get asthma attacks over the next 6 months, (10) The cost of the inhaler. The
scale is presented in Appendix C.
Results.
The scenarios were developed for a partial factorial design. Seven attributes each
with two levels (i.e., 27) yielded 128 permutations. By means of SPSS ORTHOPLAN
and Addelman’s formula (1962), the scenarios were culled into 8 orthogonal scenarios.
Using the “shifted-set” method (Chrzan & Orme, 2000), another 8 scenarios were
generated and paired to create the choice sets. The sets met the three criteria for
generating a DCE (McTaggart-Cowan et al., 2007), namely: (1) orthogonality, to ensure
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a minimum amount of overlap between the attributes, (2) level balance, so that all levels
occurred with equal frequency, and (3) minimum overlap, such that no attribute appeared
twice within the same choice set. Moreover, care was taken to ensure that all level
combinations were plausible treatment options.
The choice sets and instructions are presented in Appendix D.
Phase III: In-Field Feasibility Study
Method.
To ensure that the DCE task and self-report measures were comprehensible to the
target population, a pilot study was conducted. All procedures were approved by the
University of Western Ontario Health Sciences Review Board (Protocol # 16500E,
Appendix E).
Participants.
All consecutive patients over the age of 18 attending the asthma clinic reporting
that they could understand written English were invited to participate. Of the roughly 70
individuals approached, 56 (for a response rate of 80%) individuals consented to
participate.
Measures.
Asthma Knowledge Questionnaire.
This self-report measure developed in Phase I (See Appendix B) consisted of 36
items assessing participants’ knowledge across five domains: (1) Pathophysiology of the
disease, (2) Knowledge of Medication, (3) Technique, (4) Environmental Triggers, and
(5) Asthma symptoms. Participants were asked to record the extent to which they
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believed each item was true or false. There was an “unsure” option to discourage
guessing.
Discrete Choice Experiment (DCE) measure.
Participants were presented with the same eight discrete choice sets (16 scenarios)
developed in Phase II (Appendix D) which varied along the seven factors relevant to the
study hypotheses.
Rating scales.
Participants were presented with the 10 item rating scale developed in Phase II
(Appendix C) with the preamble described above. To ensure that overt ratings did not
influence more implicit ratings associated with the DCE, half the participants were given
the rating scales before completing the DCE and half were given the rating scale after
completing the DCE.
Demographic and health history information.
Self-reported demographic and health history information was collected on
gender, age, years of education, years with asthma and the frequency of asthma-related
medical visits over the past year.
Procedure.
Once participants arrived at the asthma clinic they were asked by the receptionist
if they would be willing to hear about a research study. If they agreed, a research assistant
approached patients in the waiting area and went through the informed consent
procedure. Those who consented were asked to complete the knowledge questionnaire,
discrete choice scenarios, demographics page and rating scales while waiting to see their
physician. This took approximately 10 minutes.
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Results.
Demographic information.
Participants’ demographic information is presented in Table 2. The average age
was 46 years and 65% were female. Over 50% reported some college or university
education. This was the first asthma clinic visit for 30% of the sample. They had carried
their asthma diagnosis for an average of 21.64 (sd = 14.82, range = 1 – 57) years and
reported having visited an emergency room an average of 1.3 times over the previous
year for asthma-related concerns.
Knowledge questionnaire.
Participants’ knowledge of the pathophysiology of asthma, asthma medications
and inhaler technique were all normally distributed. The normality statistics for the
subscales are presented in Table 3. Knowledge with regards to both environmental
triggers as well as asthma symptoms was significantly negatively skewed. Total scores
were normally distributed, suggesting that participants had a range of knowledge about
asthma and its management. The percentage of participants responding correctly is
presented in Appendix F. One item, Asthma attacks often come on suddenly without any
warning symptoms, was responded to incorrectly by 80% of the participants. In
consultation with clinic staff, it was decided that the wording of the question was
ambiguous and the item was removed from the scale.
The total scale was not internally consistent (α = .40), nor were the subscales (all
α’s < .52; See Table 3). However, one would not necessarily expect pockets of
information to hang together. Accordingly, the knowledge subscales were retained.
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Table 2
Demographic Information of Participants in Pilot Study
Observed
N (%)

M (SD)
Range

Demographics
Age

52

46 (16.80)

18 - 85

Years of education

55

4 (1.26) †

1-6

Years with asthma diagnosis

44

21.64 (14.82)

1 - 57

Health Care Use Variables
Attendance at Clinic

56

First Visit

18 (30)

-

-

Second Visit

7 (11.7)

-

-

Third Visit

5 (8.3)

-

-

26 (42.3)

-

-

56

2.52 (3.04)

0-12

56

1.30 (2.16)

0 - 10

Greater than 3 visits
Family doctor visits in past year
for asthma related concerns
ER visits in last year for asthma
related concerns

† 1 = Completed grade 8, 2 = Some high school, 3= Completed high school, 4 = Part
college/University, 5 = Completed college or university, 6 = Graduate school

Table 3
Descriptive Data for Knowledge Subscales from Pilot Study Sample
N of Items

Ma

SD

Cronbach’s α

Skew

Kurtosis

Pathophysiology

9

2.74

.22

.31

-.72

-.42

Medication

12

2.39

.27

.45

-.37

-.78

Technique

4

2.64

.32

.12

-.47

-.65

Symptom

4

2.87

.24

.52

-2.17

4.84

Environment

6

2.84

.20

.14

-1.05

.08

Total Scale

35

2.61

.16

.40

-.70

.57

Scale

Note. N = 56.
a

1 = Incorrect, 2 = Unsure, 3 = Correct.
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Discrete choice experiments.
Participants reported that they understood what they generally were being asked
to do for the DCE and their behaviour during the task seemed to bear this out. However,
participants were confused by the long-term outcome option, in which they were asked to
decide whether or not they would choose their asthma to be the same or worse in 10
years, not knowing whether to term referred to pathophysiology (as intended) or
symptoms. Accordingly, in the final version of the task, the term asthma was replaced
with airways.
Rating scales.
Participants stated to the research assistant that they understood the explicit rating
task. Given that we were asking participants to rate their preferences both implicitly
(through the use of DCEs) and explicitly (through the rating scale) we wanted to ensure
that one rating was not affecting the other. Accordingly, MANOVA analyses were
conducted on the rating scale items to assess whether those participants who completed
the DCEs before the ratings had significantly different ratings on the scales than those
who completed the DCEs after the ratings. The analysis was non-significant, F(10,43) =
6.99, ns, indicating that there were no group differences on the rating items whether the
DCEs were given before or afterwards. Similarly, a MANOVA on the implicit (i.e.,
DCE) scores revealed no order effect, F(7,48) = 1.95, ns.
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Chapter III: Method for Main Study
Participants
One hundred and forty individuals between the ages of 19 and 82 (M = 45.29,
SD= 15.97) with a diagnosis or possible diagnosis of asthma were recruited from the
Asthma Centre at St. Joseph’s Hospital in London, Ontario. The Centre is a tertiary care
facility serving adults outpatients. It receives approximately 30-40 % of its referrals from
the local emergency department, approximately 40 % from general practitioners, and the
remainder from various specialists’ offices. As such, it treats individuals with varying
levels of asthma severity. As standard practice, patients are seen by either a respirologist
or an allergist during their first visit and are seen by the other specialty during their
second visit. Patients found to have a primary diagnosis of another respiratory condition
are referred to the appropriate clinic (e.g., venom and allergy, the chronic obstructive
pulmonary disease clinic, etc.).
All patients over 18 years of age, who had sufficient comprehension of written
English and were prescribed a preventer medication, were approached to participate.
Patients with significant other lung diseases (e.g., Chronic Obstructive Pulmonary
Disease, emphysema, lung cancer, vocal cord dysfunction) were excluded from the study.
The study was approved by the University of Western Ontario Health Sciences
Review Board (Protocol # 16869E, Appendix G). Participants read a letter of
information, signed an informed consent form (Appendices H and I, respectively) and
received a total of $50.00 for their participation, paid in intervals based on study
completion. Funding was provided by the Canadian Institutes of Health Research (CIHRCGD Fellowship 87781: Awarded to N. Gryfe).
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Measures
Asthma Knowledge Questionnaire.
The self-report measure used in this study was a modified version of the recently
developed Asthma Self-Management Questionnaire (Schaffer & Yarandi, 2007). The
current 35 item self-report scale was based on the expert panel ratings as well as the
content validity ratings, as described earlier. Participants were asked to indicate whether
they believed each item was true or false. An “unsure” option was also given.
Beliefs about illness.
The most widely used quantitative measure of illness cognitions is the Illness
Perception Questionnaire- Revised (IPQ-R; Moss-Morris et al., 2002), which has three
sections: The first section, an ‘identity’ subscale, consists of 14 common symptoms (e.g.,
pain, nausea, upset stomach, breathlessness). Respondents are asked both to indicate the
extent to which they are bothered by each symptom and to indicate whether they think
each of the symptoms they have endorsed are related to the illness in question (asthma).
The instructions for this scale were modified slightly to increase clarity for the reader.
The second section is comprised of 50 items rated by the respondent on 5 point
Likert-type scales (1 = strongly disagree 5 = strongly agree). Items include statements
about the consequences of asthma for patients (e.g., My illness has major consequences
on my life), the extent to which it makes sense to them (e.g., My condition is a mystery to
me) and causes them emotional distress (e.g. When I think about my condition I get
upset). Moreover, they are asked about the perceived timeline (e.g., My condition will last
a long time), personal controllability (e.g., There is a lot which I can do to control my
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illness) and treatability (e.g., My treatment will be effective in curing my condition) of
their asthma.
The third section, an 18 item cause subscale, includes common causes of illnesses
(e.g., germ or virus, heredity, my own behaviour). The authors encourage a tailoring of
the measure to the illness in question (Moss-Morris et al., 2003) and, as such, two
asthma-specific causes were included: 1. A physical problem with my breathing airways,
2. My sensitivity to physical changes in my breathing airways.
Prior research (Moss-Morris et al., 2002) has shown the subscales to have good
internal reliability with Cronbach's alphas ranging from .79 for the cyclical timeline
dimension to .89 for the timeline chronicity. Previous data collected in our lab indicate
similarly high internal consistencies with asthma patients, the one exception being the
treatment control subscale (α = .33). One possible explanation for this low score is that
the treatment control subscale was designed as a broad based measure to gauge
perceived efficacy of a variety of medications and thus is not sufficiently nuanced to
distinguish between perceptions of different classes (i.e., preventer versus recue) of
asthma medications. Given our specific interest in perceptions of preventer medication,
the necessity scale of the beliefs about treatment scale (see below) was taken as the index
of perceived preventer medication efficacy.
Beliefs about treatment.
The Beliefs about Medicines Questionnaire- Asthma Specific (BMQ) is a 14 item
self-report Likert-type scale (1 = strongly disagree to 5 = strongly agree) that taps
patients’ concerns about the potential adverse effects of preventer medications as well as
their doubts about the necessity of taking the medication (Horne, Weinman, & Hankin,
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1999). Ten of the fourteen items assess beliefs that can apply to a range of chronic
illnesses, and four items specific to asthma medication were later added by Horne and
Weinman (2002). Sample items include: “This inhaler is the most important part of my
asthma treatment” (necessity) and “People who use these inhalers should stop their
treatment every now and again” (concern). The treatment concern and necessity
subscales have adequate internal consistency (α’s =.71 and .82, respectively). Scoring is
such that higher values on the treatment concern subscale indicate more concern about
adverse effects and higher scores on the treatment necessity scale indicate stronger beliefs
about the importance of the medication for their management. Participants completed this
measure not only with reference to their preventer medication but also with reference to
rescue inhalers, as we reasoned that beliefs about the necessity for and concerns about
this class of medication might also influence the use of preventers. The presentation of
these measures was counterbalanced.
Preference tasks.
Discrete Choice Experiments (DCE).
Discrete choice scenarios were designed specifically for this study. Participants
were presented with 8 choice sets (16 scenarios) that varied along 7 dimensions, each
with two levels (See Appendix D). The pilot study (Phase III) confirmed that the
cognitive load for participants was not too large, consistent with work in the area which
suggests that 8 or 9 choice sets can be effectively processed (Street & Bourgess, 2007).
Rating scales.
Respondents were asked to rate 10 items (created specifically for this study)
pertaining to asthma treatment (e.g. side-effects, cost, long-term effects, etc.) on a scale
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of 1 (least important) to 10 (most important). The instructions encouraged participants
think about the “trade-offs” involved in making a decision about taking a medication. The
rating scales are presented in Appendix C.
Medication adherence.
Medication Adherence Report Scale (MARS).
Measurement of adherence is controversial and fraught with methodological
limitations. For example, electronic monitoring as well as biochemical data can be
prohibitively costly and pharmacy data is logistically difficult to obtain (Rau, 2005). In
addition, while self-report measures tend to be the most widely-used measures in
research, they have been found to underestimate non-adherence by approximately 20
percent (Horne & Weinman, 1999), probably because patients are loathe to admit (to
themselves and others) that they do not follow their health care providers’ prescriptions.
Self-report measures, however, are easily implemented and allow for the examination of
behavioural and psychological processes that underlie adherence behaviour (Mora et al.,
2011; Wroe, 2002).
The Medication Adherence Report Scale (MARS) is a self-report measure of
adherence designed to measure respondents’ tendencies that impede the regular use of
prescribed medications (Cochrane et al., 1999). Different versions of the MARS for
asthma have been studied, but research suggests that behaviours as assessed by both the
full (10 item) and short (5 item) version of the scale to be significantly correlated with
more objective measures of adherence such as electronic monitoring (Cohen et al., 2008;
Ohm & Aaronson, 2006) and pill counting (Menckeberg et al., 2008).
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In this study, a nine-item self-report measure, using a five point (ranging from 1 =
always to 5 = never) Likert-type scale was administered to assess adherence (Horne &
Weinman, 2002). The 9 items scale was selected as it has been validated for use in other
studies measuring illness beliefs along with adherence (Horne & Weinman, 2002). The
scale demonstrated good internal validity (α = .85 and a single factor principal
component analysis accounting for 88.7% of the variance) and good criterion validity
when compared to electronic monitoring, and strong construct validity (Cohen et al.,
2008). In addition, Cohen et al. (2008) found that patients who claimed to use inhaled
corticosteroids even when they were not symptomatic were more likely to classified as
adherers by the MARS for asthma as were those who responded that their inhaled
corticosteroid medication was a controller medication.
Following the suggestion of Rand and Wise (1994), the MARS was administered
with the following preamble, aimed at promoting a non-defensive mindset: “Many people
find a way to use their inhaler preventer medicine which suits them. This may differ from
the instructions on the label or from what their doctor had in mind. Here are some ways
in which people have said they use their medicines. For each statement, circle the
number which best applies to you”. By focusing on non-adherence, rather than
compliance with practitioner instruction, the preamble purportedly makes it easier for
respondents to report acts that interfere with the ‘proper’ use of their preventer
medications.
To further minimize social desirability, many of the items are worded to refer to
non-adherent behaviour (e.g., “I alter the dose”), rather than adherent behaviours (e.g. I
take the dose as prescribed) (Cohen et al., 2008) because reports of non-adherence tend
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to be more accurate than reports of adherence (Haynes et al., 1980). Horne and Weinman
(2002) reported that 73.2% of asthma patients reported that they sometimes, often or
always, engaged in one of the eleven non-adherent behaviours assessed by the MARS.
These levels of non-adherence are similar to levels of non-adherence to asthma
medications found in other studies that have used more “objective” measures of
adherence such as tablet count and drug serum assays (e.g. Bosley, Fosbury, & Cochrane,
1995; Horne & Weinman, 2002).
To ensure participants were thinking about their preventer (and not rescue)
medications while answering the questions, they were instructed to write down the name
of their preventer medication at the top of the questionnaire. Scores for each item were
summed to give a total score ranging from 9 – 45, with higher scores indicating greater
adherence.
Medication diaries.
To assess the frequency with which patients used their rescue and preventer
medication, participants completed a daily medication log. A sample of the medication
diary is presented in Appendix J. Although Oldenmenger et al. (2007) demonstrated
patients’ ability to complete medication diaries each day for 28 days, so as to encourage
full study participation patients were asked to complete these logs only for the first week
following their appointment and for a full week four weeks later. Participants prescribed
combination inhalers (which contain both preventer and rescue medication) were
instructed to record any additional puffs that they took for relief purposes in the rescue
medication space provided.
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Dose counter.
Many preventer medications are equipped with a mechanism that counts down
the remaining inhaler doses. While this does not indicate whether patients are taking their
medications when they are supposed to, it theoretically provides an inexpensive and
objective measurement of the number of doses taken. Accordingly, participants were
asked to record the “number on their inhaler” at the end of each week’s treatment diary.
Unfortunately, even though this procedure was clearly explained to participants and we
encouraged participants to ask questions, the data obtained from this measure ultimately
were unusable. This is both because some participants confused the dose counter with the
dosage accompanying the brand of medication (e.g., Advair 500mg, Symbicort 200mg)
and because the dose counters on the combination inhalers do not record each
administration of the medication, but rather, demarcate blocks of 10 or 20 doses.
Individual difference variables.
Demographic information.
Participants provided information about their gender, age, annual household
income, years of education, relationship status, years with asthma and the frequency of
asthma related medical visits over the past year (Appendix K).
Patient enablement.
Patient enablement was gauged by the Modified Patient Enablement Instrument
for asthma patients (Haugney et al., 2007). The scale is a 6 item Likert-type self-report
measure in which patients rate (from 0 = Same, less or not applicable to 3 = Much better)
their perceived ability to cope with and participate in their own care as a consequence of
a medical encounter. For the purposes of this study, the rating scale was changed to a 5
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point scale (where 0 = Not applicable, 1 = Less, 2 = Same, 3 = Better, 4 = Much Better).
Sample items include “Able to cope with life” and “Confident about your health”. The
measure is highly internally consistent (α = .92).
Patient satisfaction.
The Satisfaction Questionnaire (Jackson, Kincey, Fiddler, Creed, & Tomenson,
2004) is a 15 item self-report measure that assesses how satisfied patients are along four
dimensions: (1) patient-provider interaction, (2) information given to them by their
provider, (3) their health (4) the health care environment. The satisfaction with the
environment subscale was omitted for the purpose of this study. All subscales have been
validated and the summed scores demonstrate excellent levels of internal consistency (α
= .94).
Quality of life.
The Asthma Quality of Life Scale- Mini Version (Juniper, Guyatt, Cox, Ferrie, &
King, 1999) is a disease-specific instrument comprised of 15 items, grouped into four
domains: (1) asthma symptoms, (2) responses to environmental stimuli, (3) limitations in
activities, and (4) emotional dysfunction. Respondents are presented with a 7 point
Likert-type scale on which they are asked to rate their degree of impairment (1 = Greatest
impairment to 7 = Least impairment). The AQLQ-mini has been demonstrated to be
reliable (ICC = .83) and is a valid measure of asthma quality of life.
Panic-Fear.
The Panic-Fear Subscale of the Asthma Symptom Checklist (Ritz, Bobb,
Edwards, & Steptoe, 2001) is a 7 item, Likert-type (where 0 = Never and 4= Always)
scale assessing patients’ emotional responses (being frightened, afraid, or worried) during
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an asthma attack. The scale demonstrates excellent internal consistency (Cronbach’s α =
.94).
Positive and Negative Affect Schedule (PANAS).
The PANAS (Watson, Clarke, & Tellegan, 1988) is a 20-item self-report
questionnaire in which participants rate, on a five-point Likert-type scale (where 1 = very
slightly or not at all and 5 = extremely) the extent to which a range of emotional
adjectives such as “enthusiastic”, “excited”, “distressed” and “nervous” describe them in
general. The PANAS generates two subscale scores: Negative Affect and Positive Affect.
Each subscale demonstrates good internal consistency and test-retest reliability.
Procedure
For ease of presentation, the following elements of the protocol will be presented
chronologically: (1) Recruitment, (2) Pre-clinical encounter, (3) Post-clinical encounter,
and (4) Follow-up.
Recruitment.
Upon arrival at the clinic, those patients who met the eligibility criteria were
asked by the receptionist if they would mind being approached about a research study
under way at the clinic. Two hundred and fifty four patients (119 new clinic patients and
135 patients returning for follow-up visits) were approached to participate, given a verbal
overview of the study and asked to read over a letter of information. Figure 1 illustrates
the recruitment procedure and consent rates for the study participants. One hundred and
seventy four patients (68%) consented. The primary reasons cited by those who declined
to learn more about the study were time constraints (n = 33), disinterest (n = 22) and
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Figure 1
Flow of Participants Through Study

Patients
Approached
(n = 254)

Reasons for Declining
Time Constraints
(n = 33)

Reasons for Exclusion

Agreed to Learn
More About the
Study (n=174)

Were Disinclined
to Participate
(n=80)

Unsure About
Ability to Follow
Through
(n = 25)

Other
Respiratory
Condition
(n = 12)
No Preventer
Medication
Prescribed
(n = 9)
Excluded for
Other Reasons
(n = 13)

Disinterest
(n = 22)

Provided Consent and Completed First
Package at Clinic
(n=140)

Usable One Week Follow-Up Packages
(n=129)

Usable One Month Packages
(n=120)
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concerns that they would not follow through (n = 25). Of the 174 who consented, 34
subsequently did not meet eligibility requirements, leaving 140 participants, 11 of whom
did not complete the one-week post-appointment questionnaires. An additional nine did
not submit the one-month post appointment measure. Accordingly, complete data were
available for 120 participants.
Pre-clinical Encounter.
Once eligibility criteria were established and patients consented to the study,
while waiting for their pulmonary function test, participants were asked to complete a
booklet containing the demographics information questionnaire, the Asthma Quality of
Life Measure (AQLQ), the Positive-Negative Affect Scale (PANAS), the Panic-Fear
Scale, and the Medication Adherence Report Scale (MARS). Those who did not have
time to complete these measures before the pulmonary function test finished them
afterwards while waiting to see their physician or nurse.
Post-clinical Encounter.
Following the clinical visit, patients were asked to complete the Discrete Choice
Experiment Task (DCE), the Illness Perception Questionnaire (IPQ-R), the Beliefs about
Medicines Questionnaire (BMQ), the Asthma Knowledge Questionnaire and the
preference rating scales. To mitigate against respondent fatigue, participants were given
the patient satisfaction and enablement scales to complete at home along with the first
seven day treatment diary. The diary also included a space for them to indicate the dose
count from their inhaler (though, as noted earlier, these data were not included in the
analyses).
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Patients had the option of completing the satisfaction and enablement measures as
well as the treatment diary online, and, if so inclined, were instructed on how to do so.
Those choosing to complete hard copies of these measures were given a return-addressed
postage paid envelope. The researcher ensured that participants understood the
instructions for all take-home measures. They were reimbursed $10 for their time and
additional parking expenses.
Follow-Up.
The 61 participants who completed the follow-up portion of the study by mail
were contacted three weeks following their appointment by telephone to remind them that
a medication diary, a copy of the MARS, and an AQLQ would arrive shortly by mail.
Included in the package was a return-addressed postage-paid envelope as well as
instructions to start completing the MARS and AQLQ and diaries the evening they
received the package.
The 79 participants completing the follow-up portion of the study online were
sent an email one month after their appointment to ensure they were prompted at the
same time as those who chose the mailing option. The email included links to the AQLQ
and MARS as well as the daily records. Participants were instructed to complete the
AQLQ and MARS on the evening that they began the records.
Participants were compensated for the portion of the follow-up study they had
completed ($20.00 for each of the two-week records) once their final packet was
received.
Once all data were collected, participants’ prescription regimens were extracted
from their clinical records by an administrative clerk employed by the hospital.
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Moreover, a nurse educator affiliated with the asthma clinic reviewed patients’ clinical
files to confirm that they did indeed have asthma, which they all did.
Statistical Analyses
Statistical analyses were carried out using PSAW 18 and LatentGold 4.5 software
packages.
Relationships between the predictor and outcome variables were examined using
Pearson and Spearman correlation coefficients, as appropriate. Preference data were
explored through latent class analysis.
The contributions of knowledge, beliefs and preferences individually on
adherence were evaluated using simple linear regressions. The relative contribution of
each of these variables as predictors of adherence was assessed using a hierarchical linear
multiple regression analysis, with reported MARS scores as well as diary reports as the
dependent variables and predictors entered in the following order: 1. Knowledge of the
pathophysiology of asthma; 2. Illness beliefs and Treatment Beliefs and 3. Treatment
preferences. All study analyses were repeated to determine whether there was a main
effect of gender or previous experience at the clinic (i.e., number of prior clinic visits)
and whether inclusion of these variables as co-variates altered the findings. No such
effects were observed.
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Chapter IV: Results
Sample Demographics
The demographic and asthma-related characteristics of the sample are presented
in Table 4. The majority of the sample (69%) was female. On average, participants had
been diagnosed with asthma at age 24 (SD = 18.71). The majority (74%) had visited their
family doctor for respiratory related issues at least once in the previous year, with the
mean number of visits close to three. Fifty-three percent had visited the emergency room
for respiratory related symptoms at least once in the previous year.
The criteria for normal distribution adopted for the study were a skew between -3
and +3 (see Kline, 2009) and kurtosis less than 2.58, as recommended by Field (2009).
All demographic variables were appropriately distributed, with the exception of
participants’ asthma related visits to their family physician and ER related visits. That is,
these distributions peaked at 0, as 27 % of participants stated that they had not gone to
see their family doctor in the past year and 47 % stated they had not visited the ER.
These patterns of health care use statistics are similar to those reported by other
community- managed asthma patients (Horne & Weinman, 2002).
At the point at which they were recruited into the study, 46% of participants were
attending the asthma clinic at St. Joseph’s Hospital for the first time, with the remainder
(54%) attending for a follow-up visit. The majority (78.5%) had been prescribed a
combination medication inhaler as part of their asthma treatment regimen.
The demographic characteristics of those completing the follow-up questionnaires
and diaries by mail (44% of the sample) did not differ (as per independent samples t-tests

Table 4
Participant Characteristics
Observed
N (%)

Skew

Kurtosis

M (SD)
Range

Demographic Information
Age

135

45.39 (15.97)

19 - 82

.19

-1.02

Age at diagnosis

127

24.04 (18.71)

0 - 68

.59

-.72

Years of education

138

14.98 (3.31)

4 - 25

-.25

1.38

Household incomea

125

3.30 (1.74)

1-6

.15

-1.26

Employment statusb

138

6.13 (2.73)

-

-

-

Employed (Full time)

53 (37.9)

-

-

Working from Home

4 (2.9)

-

-

Employed (Part time)

25 (10.7)

-

-

Homemaker

4 (2.9)

-

-

Student

8 (5.7)

-

-
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Observed
N (%)

Skew

Kurtosis

.48

-1.42

2.50

10.87

M (SD)
Range

Retired

26 (18.6)

-

-

On Disability

15 (10.7)

-

-

Unemployed

6 (4.3)

-

-

7 (5)

-

-

Other
Health Care Use Variables
Attendance at Clinic

140

First Visit

64 (45.7)

-

-

Second Visit

13 (9.3)

-

-

Third Visit

20 (14.3)

-

-

Greater than 3 visits

43 (30.7)

-

-

140

2.89 (3.35)

0 - 24

Asthma related visits to family
physician (in past year)
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Observed
N (%)

Skew

Kurtosis

M (SD)
Range

Asthma related visits to ER
(in past year)

140

1.49 (2.06)

0 - 12

2.06

5.82

140

3.71 (1.22)

1-7

-.01

-.60

Combination Inhalers

110 (78.5)

-

-

Non-Combination Inhalers

20 (21.5)

-

-

Quality of Life Variables
AQLQ
Prescribed Medications

Note. Missing data may result in n’s not totaling 140.
a

1= Under $ 20,000, 2= $21,000–40,000; 3=$41,000–60,000 4= $61,000-$80,000, 5 = $81,000- 100,000, 6 = Over $100,000

b

9= Employed full time, 8 = Working from home, full time, 7= Employed part time, 6 = Homemaker, 5 = Student, 4 = Retired, 3 = On

Disability, 2 = Unemployed, 1 = Other
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with Bonferroni corrections) from those completing the measures on-line. Accordingly,
all subsequent analyses were collapsed across these two groups.
Descriptive Statistics on the Outcome Measures
Descriptive statistics for the adherence measures – MARS at Time 1 and 2 and the
diary measures - are presented in Table 5. Internal consistency for the MARS was good
(α = .86 at Time 1 and α = .87 at Time 2). The scale means of 4.21 and 4.37 respectively,
were close to the highest possible score of 5, indicating that participants reported high
levels of compliance. Consistent with the elevated reported compliance levels, both
MARS scores were negatively skewed. Transformations failed to produce normal
distributions.
Adherence was derived from the daily diaries as follows: The number of
prescribed medication doses was subtracted from the absolute value of the number of
doses participants reported taking. These scores were averaged across each week.
Accordingly, a score of 0 would indicate perfect adherence, whereas other values indicate
the degree to which patients deviated from their prescribed regimen. For ease of
interpretation, these scores were multiplied by -1 so that higher scores (the maximum
being 0) reflect better adherence. Notably, the distributions for diary scores at Time 1 and
Time 2 were highly peaked at 0, as 58.5 and 61.2 percent of patients reporting being
perfectly adherent at Time 1 and 2, respectively.
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Table 5
Descriptive Statistics for the MARS and Diary Recordings
Range

MARS-

n

M (SD)

α

Potential

Observed

Skew

Kurtosis

137

4.21

.86

1-5

1.89-5

-5.57

1.67

.87

1-5

1.78-5

-5.85

3.80

T1
MARS-

(.76)
113

T2

4.37
(.65)

Diary T1

121

.22 (.73)

-

-

0 to 3.57

2.39

7.19

Diary T2

105

.27 (.87)

-

-

0 to 4

1.98

4.90
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A repeated measures t-test of MARS-T1 versus MARS-T2 scores indicated that
reported adherence across the sample increased from baseline to one month postappointment, t(110) = 2.35, p < .05. This effect was driven by changes in those
attending the clinic for the first time at baseline (t(48) = 2.25, p < .05); those whose
baseline measure was taken at a follow-up visit did not have higher adherence scores onemonth post appointment, t(61) = 1.19, ns. A comparable analysis of participants’ diary
scores assessed at one and four weeks post appointment indicated no difference between
diary scores at one week and four weeks either in the entire sample, t(101) =. 53, ns, or in
the new or returning clinic attendees (t(45) = .69, ns, and t(55) = 1.38, ns, respectively).
Accordingly, diary scores were collapsed across the two time points.
Spearman correlations among the adherence measures are presented in Table 6.
Diary scores were significantly, albeit weakly, correlated with the MARS scores at T1 (rs
= .26) and modestly correlated with the MARS scores one month post-appointment (rs =
.35).
Belief Measures
Descriptive statistics.
The descriptive statistics for the illness belief (IPQ-R) and views about asthma
medications (BMQ) subscales are presented in Tables 7 and 8, respectively. All IPQ-R
subscales were reasonably internally consistent (all α’s higher than .60), except for the
immunity as cause subscale (α = .44). Of the remaining IPQ-R scales, the next lowest
internal consistency was for the treatment control scale (α = .63). This is not surprising,
given that the treatment control subscale does not differentiate between preventer versus
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Table 6
Spearman Correlations Amongst Adherence Measures

Scale

2

3

1. MARS T1

.52**

.26**

2. MARS T2

-

.35**

3. Diary Scores

**

p < .001.

-

Table 7
Descriptive Statistics for Beliefs about Asthma Measures
Range
a
Cronbach’s α Potential

IPQ-R Subscale

n

N of items

M (SD)

Observed

Skew

Kurtosis

Identity

76

14

4.80 (2.69)

n/a

0 – 14b

0 - 14

-.17

6.94

Timeline

139

5

4.05 (.88)

.89

1–5

1.6 - 5

-3.46

.50

Consequences

139

6

3.24 (.85)

.83

1–5

1.17 - 5

-.09

-.10

Personal Control

139

6

3.97 (.61)

.77

1–5

2.33 - 5

-1.43

-.56

Treatment Control

137

5

3.79 (.53)

.63

1–5

1.8 - 5

-2.87

4.02

Illness Coherence

137

5

3.55 (.82)

.88

1–5

2-5

-1.15

-1.47

Timeline Cyclical

137

4

3.35 (.73)

.68

1–5

1.25 - 5

-.14

.25

Emotion

137

6

2.72 (.85)

.85

1–5

1 – 4.67

.08

-1.38

Acute/Chronic
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Range
IPQ-R Subscale

n

N of items

M (SD)

a
Cronbach’s α Potential

Observed

Skew

Kurtosis

Causes

a

Psychological

137

6

2.59 (.85)

.87

1–5

1 – 4.33

-.99

-1.65

Risk Factors

137

6

2.71 (.77)

.70

1–5

1 – 4.5

.30

-.28

Immunity

137

3

3.16 (.76)

.44

1–5

1-5

-1.21

.96

Accident/Chance

137

1

2.16 (1.09)

n/a

1–5

1-5

3.40

-.68

Breathing Airways

137

2

3.46 (1.03)

.80

1–5

1-5

-3.32

.61

1 = Strongly Disagree, 2 = Disagree, 3 = Neither Agree nor Disagree, 4 = Agree, 5 = Strongly Agree. b0 = Experiencing no

symptoms to 14 = Experiencing all listed symptoms.
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Table 8
Descriptive Statistics for Beliefs about Asthma Medication Scales
Range
BMQ Subscale

n

N of items

M (SD)

135

6

135

Necessity Rescue
Concerns Rescue

Necessity

Skew

Kurtosis

Potential

Observed

3.86 (.74)

Cronbach’s
α
.87

-2.11

1.83

1-5

1-5

8

2.70 (.66)

.76

-2.09

.10

1–5

1.13 – 4.25

123

6

3.36 (.96)

.90

.38

-1.28

1–5

1–5

123

8

2.70 (.71)

.79

-.09

-1.02

1–5

1.13 – 4.25

Preventer
Concerns
Preventer
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relief medications. In contrast, the BMQ was administered twice, once with reference to
preventer and once with reference to rescue medications, and so each of the scales are
understandably more internally consistent because all questions pertain to the same (and
specific) class of medications. Accordingly, for the purposes of this study, the BMQ Necessity of Medication subscale was used to gauge perceived efficacy of treatment
rather than the IPQ Treatment control subscale.
With respect to distributional properties, the majority of the illness belief scales
(severity, consequences, coherence, cause, timeline and emotional toll) and views of
medicines scales were normally distributed. Exceptions were the IPQ-R Acute/Chronic
Timeline subscale and Airway Problem Causal subscale (both negatively skewed) and the
Accident/Injury Causal subscale (positively skewed). Consequently, correlations
involving these scales were conducted using both parametric (Pearson) and nonparametric (Spearman) approaches.
Intercorrelations among the belief measures.
Pearson and Spearman correlations yielded identical results and so only Pearson
correlations are presented in Table 9. Given the large number of correlations (120) and
the accompanying risk of Type I error inflation, only those correlations exceeding .40 are
considered indicative of meaningful associations.
Evident from the pattern of correlations, people with asthma clearly differentiate
between the therapeutic and adverse effects of their medications; for rescue medication,
the necessity and concern scales were only slightly correlated (r = .28, p < .05); these
scales were uncorrelated for preventer medications (r = .01, ns). However, those who

Table 9
Pearson Correlations among the Illness and Treatment Belief Subscales
Subscales

2

3

4

5

1. Timeline -

-.00

.28**

-.02

-

.31**

-

6

7

8

9

10

11

12

13

14

15

16

-.31** .21**

-.06

-.00

.10

.02

.11

.02

.42**

-.04

.23*

-.10

.07

.05

-.03

.28**

.33**

.24**

.19*

.12

.25*

.07

.25*

.27*

.31**

-.08

-.20*

-.13

.29**

.23**

.16

.26**

.24**

.58**

.40**

.37**

.47**

.38**

-

.51**

.20*

.07

.12

.11

-.08

.07

.20**

.23*

-.08

-.01

.01

-

.15

-.00

-.01

-.01

-.06

-.08

-.16

-.01

-.21*

.05

-.11

-

-.16

-.08

-.02

-.01

.05

.22*

.18*

-.25*

-.01

-.28**

-

.65**

.47**

.47**

.41**

.44**

.04

.32**

.19*

.28**

Acute/Chronic
2. Timeline Cyclical
3.Consequence
4. ControlPersonal
5. ControlTreatment
6. Coherence
7.Psychological
Causes
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Subscales

2

8. Risk Factors
9. Immunity
10. Accident
11. Airway

3

4

5

6

7

8

9

10

11

12

13

14

15

16

-

.52**

.57**

.37**

.21**

.05

.24**

.14

.23**

-

.44**

.51**

.10

.17

.21*

.16

.06

-

.27**

.05

.12

.28**

.21*

.18*

-

.21**

.13

.28**

.15

.12

-

.17*

.45**

.24*

.45**

-

.01

.47**

.03

-

.26**

.84**

-

.28*

Problem
12. Emotional
13. Necessity
Preventer
14. Concern
Preventer
15. Necessity
Rescue
16. Concern

-

Rescue
**

p < .001 , * p < .05
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had concerns about their preventer medications were also quite concerned about rescue
medications (r = .84, p < .001). Beliefs about the efficacy of these two classes of
medication appear less closely coupled (r = .47, p < .001). Interestingly, participants
believed more strongly about the need for their preventer than rescue medications (3.86
versus 3.36, repeated measures, t(119) = 6.45, p < .001), though were equally concerned
(2.70) about both, t(119) = .24, ns.
With respect to the association between medication belief and illness belief
subscales, necessity for preventer medication was correlated with the TimelineAcute/Chronic subscale (r = .42, p <.001), indicating that those who viewed their
condition as more chronic believed that their preventer was more necessary. Not
surprisingly, this association was weaker for beliefs about the need for rescue medication
(r = .23, p < .05). Moreover, the consequence scale (which can be taken as an index of
perceived severity) was significantly positively correlated with the perceived needs for
both preventer and rescue medications (r = .40, p < .001, r = .47, p < .001, respectively)
and, to a lesser degree, with concerns about taking them (r = .37, p < .001, r = .38, p <
.001, respectively).
Knowledge Data
As noted earlier, each of the items on the knowledge scale was scored as either 3
= “correct”, 2 = “unsure”, or 1 = “incorrect”. A total score as well as subscale scores
were calculated by adding up all the relevant items and dividing them by the number of
items in the scale. Accordingly, higher scores indicate more knowledge in given domain.
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Descriptive statistics for the knowledge questionnaire subscales are presented in
Table 10. The internal consistency scores for the various subscales (which, as reported
earlier, were classified as such based on expert ratings) are quite low, with none
exceeding an α of .51. This is not a concern because units of knowledge reasonably could
be expected to be discrete.
A repeated measures MANOVA with contrasts on the means demonstrated that,
as a group, participants were most knowledgeable about their symptoms and
environmental triggers and least knowledgeable about their medications, F(4,132) =
91.14, p < .001. Participants who were attending the asthma clinic for the first time when
recruited for the study were no less knowledgeable in any of the content areas than those
for whom it was a follow-up visit, F(5, 130) = 1.8, ns. Items, grouped by category, are
presented in the order of most to least correctly answered in Appendix L.
Whereas overall knowledge, knowledge of the pathophysiology and knowledge
about medication were normally distributed, the technique and environment subscales
were significantly negatively skewed and the symptom subscale was highly negatively
skewed and had a very peaked distribution. Notably, 66% of the sample responded
correctly to all symptom scale items (i.e., obtained a mean score of 3 on this scale).
Accordingly, Spearman correlations were conducted in subsequent analyses to meet
assumption criteria.
Pearson and Spearman correlations amongst the knowledge subscales are
presented in Table 11. The strongest correlation was between knowledge about the
pathophysiology of the disease and the medications necessary to treat it (r = .42, p <
.001).

Table 10
Descriptive Statistics for Knowledge about Asthma Subscales
N of Items

n

Ma

SD

Cronbach’s α

Skew

Kurtosis

Pathophysiology

9

137

2.72

.23

.42

-2.95

.47

Medication

12

137

2.44

.28

.51

-.57

-1.44

Technique

4

139

2.64

.32

.04

-3.34

.59

Symptom

4

139

2.86

.25

.13

12.37

20.65

Environment

6

139

2.84

.18

.40

-5.44

2.34

Total Scale

35

139

2.65

.16

.64

-2.47

1.27

Scale

a

1 = Incorrect, 2 = Unsure, 3 = Correct.
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Table 11
Intercorrelations Among Knowledge Subscales
Subscale
1. Pathophysiology

2. Medication

3. Technique

4. Environment

2

3

4

5

r = .42**

r = .05

r = .26**

r = .30**

rs = .40**

rs = .08

rs = .27**

rs = .30**

-

r = -.07

r = .28**

r = .19*

rs = -.06

rs = .31**

rs = .21*

-

r = .23**

r = .01

rs = .21**

rs = -.04

-

r = .27**
rs = .12

5. Symptoms
**

p < .01 , * p < .05

-
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Correlations between Knowledge and Belief Data
Given that this is the first study to explore the relative roles of asthma knowledge
and beliefs, exploratory Pearson correlations were conducted for the normally distributed
variables. Both Spearman and Pearson correlations were conducted for the non-normally
distributed variables, and yielded equivalent findings. Accordingly, only Pearson
correlation coefficients are reported (See Table 12). Again, given the large number of
correlations (96) only those exceeding .40 were deemed meaningful. Only two such
correlations met these criteria. Specifically, the belief that asthma is chronic (rather than
acute) was positively associated with overall knowledge about asthma (r = .41, p < .001)
and more specifically with knowledge about its pathophysiology (r = .48, p < .001).
Correlations between Predictor Variables and Adherence Measures
Correlations among the beliefs and knowledge subscales and the adherence
outcome measures are presented in Table 13. Given that MARS and diary scores were
significantly skewed, both Pearson and Spearman correlations were conducted. To
control for Type I error (given 44 associations were being examined), only correlations in
which either the Spearman or Pearson coefficient exceeded .25 were deemed to indicate
statistically meaningful associations. Only three such associations met this criterion.
Specifically, self-reported adherence at Time 2 (i.e., MARS-T2) was positively correlated
with the belief that asthma is a chronic condition (r = .26), the belief that preventer
medications are necessary (r = .36) and with knowledge about the pathophysiology of
asthma (r = .27). Notably, adherence as gauged by the diary method was not correlated
with any of the knowledge nor belief measures.

Table 12
Pearson Correlations between Belief and Knowledge Subscales
Knowledge Scales
Belief Scale

Knowledge

Pathophysiology

Medication

Technique

Environment

Symptoms

Total

Subscale

Subscale

Subscale

Subscale

Subscale

.41**

.48**

.24**

.18*

.19*

.13

Timeline - Cyclical

-.06

.02

-.14

-.01

.09

.16

Consequence

-.01

.10

-.10

.06

.05

.10

Control- Personal

.14

.16

.08

.05

.14

.10

Control- Treatment

.05

.01

.02

-.03

.11

.04

Coherence

.22**

.22**

.16

.04

.14

.04

Psychological

-.08

-.02

-.21*

.14

.09

.04

Timeline Acute/Chronic

Causes
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Belief Scale

Knowledge

Pathophysiology

Medication

Technique

Environment

Symptoms

Total

Subscale

Subscale

Subscale

Subscale

Subscale

Risk Factors

-.08

.01

-.14

.01

.06

-.01

Immunity

.10

.14

-.06

.12

.24**

.10

Accident

-.10

-.01

-.13

-.00

-.01

-.07

Airway

.15

.14

.07

.11

.17*

.04

Emotional

-.17*

-.12

-.18*

-.01

-.06

.04

Necessity

.10

.22**

-.03

.08

.12

.11

Concern Preventer

-.22*

-.25**

-.13

-.05

-.10

-.08

Necessity Rescue

-.13

-.13

-.15

-.08

-.01

.04

Concern Rescue

-.29**

-.29**

-.20*

-.01

-.04

-.07

Problem

Preventer

**

p < .001 , * p < .05
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Table 13
Correlations of Belief and Knowledge Scales with Adherence Measures
Subscale

MARST2

Diary Recordings

r

rs

r

rs

Identity

-.04

-.10

-.02

-.06

Acute/Chronic

.27**

.25**

.06

.01

Timeline- Cyclical

-.12

-.16

.06

.06

Consequences

.05

-.08

.06

.06

Personal Control

.15

.12

-.05

-.06

Treatment Control

-.01

.06

-.12

-.11

Coherence

.09

.05

.04

.06

Emotional

-.05

-.10

.14

.13

Psychological

-.18

-.21*

-.00

-.02

Risk Factors

-.11

-.17

.01

.04

Immunity

-.06

-.05

-.04

-.02

Airways

-.07

-.10

.11

.12

Accident

-.11

-.16

-.02

.05

Preventer

.36**

.33**

.11

.07

Preventer Concern

-.20*

-.21*

.00

.03

Rescue Necessity

.09

.07

.01

.04

Beliefs

Necessity
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Rescue Concern

-.06

-.14

-.04

-.04

Pathophysiology

.27**

.25**

.11

.12

Medication

.17

.23**

-.08

-.01

Technique

-.00

-.01

-.05

-.08

Environment

.14

.08

.01

.03

Symptoms

.08

.09

.07

.04

Knowledge

Note. r = Pearson correlation, rs = Spearman correlation.
*

p < .05, ** p < .001.
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Preference Data
Preference data were extracted though a series of steps. First, a given choice was
coded as either 0 (for the presumed undesirable option for each attribute) or 1 (for the
presumed positive option). See Table 14 for the coding scheme. To gauge the weight a
given participant placed on each of the seven attributes, total scores (ranging from 0 =
Never selected a scenario with a positive level of a given attribute to 8 = Always selected
the scenario with the more positive level of a given attribute) were then computed. This
calculation yielded 7 total scores for each participant. Higher scores indicated that
participants had selected scenarios wherein that attribute level had appeared more often.
Therefore, higher scores reflect a greater weighing of the attribute.
Latent class cluster analysis.
Total scores were analyzed using cluster analysis techniques. All analyses were
conducted using Latent Gold 4.5 latent cluster analysis (LCA). LCA segments
individuals into clusters based on estimated membership probabilities (Magidson &
Vermunt, 2005). How best to determine the number of appropriate classes is the subject
of some debate within the cluster analysis literature. However, many look to the Bayesian
Information Criterion (BIC) to determine model fit (Trivedi, Ayotte, Thorpe, Edelman, &
Bosworth, 2010). BIC scores aim to balance fit with model parsimony. Thus, lower BIC
scores represent models with better fit. Another valuable index of model fit is the
parametric likelihood ratio tests (LRT) with bootstrapped values, which compare
progressive iterations of models. Should the LRT be significant, the model with a greater
number of classes is deemed a better fit to the data (Trivedi et al., 2010).

Table 14
Coding of Attribute Levels
Attribute
Long Term Outcomes (10

Coded 0

Coded 1

Your airways will be worse in 10 years

Your airways will be the same in 10 years

Short Term Outcomes (6

You will have more asthma attacks over

You will have less asthma attacks over the next 6

Months)

the next 6 months

months

Immediate Effects

Your medication will relieve your

Your medication will relieve your symptoms within 5

symptoms within 30 minutes

minutes

Steroid Dose

High dose of steroids

Low dose of steroids

Number of Inhalers

Two

One

Dosing Only As Needed

Every day at set times and more when I

Only when I need it

Years)

need it
Side Effects

There is a risk of major/long term side

There is a risk of minor/short term side effects

effects
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To determine the presence of latent classes among preference choices, 1,2,3,4,
and 5 class models were tested. As per the fit indices presented in Table 15, the five
cluster model had the lowest BIC score and the LRT was significant and so would have
been chosen on solely empirical grounds. However, on the basis of interpretability (see
below), the four cluster model was deemed superior to the five cluster model.
The 4 and 5 cluster models are illustrated in Figures 2 and 3, respectively.
Patterns among the mean scores of the first two clusters (i.e., long term outcomes and
side effects) are virtually identical in the 4 and 5 cluster models (see Figures 4 and 5).
Cluster 1 (long term outcomes) accounts for 30% of the sample in both models and
Cluster 2 (side effects) accounts for approximately 20% of the sample in both models. As
is evident in Figure 6, both the 4 and 5 cluster models produce a group of participants
who weigh all the attributes more or less equally when making their decision (Cluster 3equal weighting). In the four cluster model, this group accounts for approximately 30%
of the sample. However, in the five cluster model, this group accounts for only 18% of
the sample. This is because in the 5 cluster model, this group, hovering around the middle
range of scores (i.e., between 3 – 5), is differentiated into 3 groups (refer back to Figure
3). However, given that the design was not perfectly balanced this distinction may simply
be a function of methodological error. In addition, the last cluster of the 4 cluster model
was no longer differentiated in the 5 cluster model. Given these issues, the 4 cluster
model was deemed a better fit.
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Table 15
Model Fit Indices
Model

LL

BIC (LL)

Npar

L2

BIC (L2)

df

pvalue

1 Cluster

-1449.41

3089.84

39

2046.43

1581.14

1.1e-

0.000

363
2 Cluster

-1349.75

2929.70

47

1847.11

1420.99

9.9e-

0.005

328
3 Cluster

-1309.20

2887.78

55

1766.00

1379.07

2.8e-

0.012

316
4 Cluster

-1287.41

2883.39

63

1722.43

1374.68

1.0e-

0.018

312
5 Cluster

-1242.64

2833.02

71

1632.88

1324.31

1.2e299

0.012
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Figure 2
Four Cluster Latent Class Model

Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER =
Steroid Dose, TIME = Time of day required to take medications, IN = Number of
inhalers, SE = Side effects.
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Figure 3
Five Cluster Latent Class Model

Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER =
Steroid Dose, TIME = Time of day required to take medications, IN = Number of
inhalers, SE = Side effects.
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Figure 4
Attribute Weights for Long Term Outcome Group in 4 and 5 Cluster Models

Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER =
Steroid Dose, TIME = Time of day required to take medications, IN = Number of
inhalers, SE = Side effects.
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Figure 5
Attribute Weights for Side Effect Group in 4 and 5 Cluster Models

Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER =
Steroid Dose, TIME = Time of day required to take medications, IN = Number of
inhalers, SE = Side effects.

94

Figure 6
Attribute Weights for Equal Weight Group in 4 and 5 Cluster Models

Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER =
Steroid Dose, TIME = Time of day required to take medications, IN = Number of
inhalers, SE = Side effects.
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Focusing then on the 4 cluster model, a numerical depiction of how the four
clusters identified by the model differentially weighed attributes is presented in Table 16.
The largest number of participants (n = 44; 33% of the sample) fell into Cluster 1 which
most valued the long term (i.e., 10 year) outcomes associated with their medications.
Individuals in this cluster almost always selected scenarios in which lung function would
remain the same (rather than worsen) over the next 10 years. Those in Cluster 2 (n = 28;
21% of the sample) appeared to value low side effects. That is, they almost always chose
scenarios describing minor and short term (rather than major and long term) side effects.
Cluster 3 (n = 36; 27% of the sample) respondents appeared to accord equal weight to all
seven attributes. And finally, those in Cluster 4 (n = 26; 19% of the sample) valued all
outcomes, be they immediate, intermediate or long-term. Participants in this cluster were
willing to trade off more side effects, a higher dose of steroids and a more complex
treatment regimen (more inhalers, fixed dosing plus as needed versus only as needed) for
better efficacy immediately, and in the short and long term treatment range.
A MANOVA revealed no significant differences in demographic characteristics
(gender, age, education, employment status, and clinic visits) between the clusters,
F(21,327) = .67, ns.
Differences in beliefs and knowledge among clusters.
Exploratory MANOVA analyses were conducted to determine whether
individuals in the clusters differed with respect to their beliefs and knowledge about
asthma. Box’s tests were all non-significant, indicating that the matrices were equivalent
despite the unequal sample sizes across groups. As such, all analyses met the assumption
of homogeneity of the covariance matrices.

96

Table 16
Means of Total Scores among Clusters
Cluster 1: Long

Cluster 2: Side

Cluster 3:

Cluster 4:

Term Outcome

Effects

Equal

Medication

(n = 44)

(n = 28)

Weighting

Efficacy

(n = 36)

(n = 26)

10 Year Effects

7.16

4.41

5.07

3.71

6 Months

5.48

4.81

5.48

3.89

4.40

3.67

4.93

4.04

Steroid Dose

2.78

3.07

4.80

2.08

Medications As

3.52

4.16

4.35

2.10

2.80

4.90

4.98

2.74

4.49

7.40

5.41

3.31

Effects
Immediate
Effects

Needed
Number of
Inhalers
Side Effects

Note. Column totals are not all equal because the design is orthogonal, but not perfectly
balanced.

97

As per Roy’s largest root, there was a significant effect of clusters on beliefs,
F(14,114) = 2.17, p < .05, partial ε2 = .21. Separate univariate ANOVAs (Table 17) on
the outcome variables revealed that the groups differed with respect to their beliefs about
problems with their airways being the cause of their condition. Follow-up contrasts with
LSD corrections indicated that participants who preferred long term outcomes were more
likely to believe that “airway problems” were the cause of their condition than both those
who weighed all treatment elements equally and those valuing treatment efficacy (Table
18).
A second MANOVA also was conducted to assess differences in asthma
knowledge across clusters. Again, as per Roy’s largest root, there was a significant
multivariate effect of clusters on knowledge, F(5,125) = 2.45, p < .05, partial ε2 = .09.
Separate univariate ANOVAs revealed that the groups differed with respect to knowledge
about asthma pathophysiology as well as asthma medications (see Table 19). Follow-up
contrasts (LSD correction; Table 20) for asthma pathophysiology indicated that those
weighing all attributes equally (Cluster 3) were less knowledgeable about asthma
pathophysiology and asthma medications than were those who privileged long term
outcomes (Cluster 1) and those who valued medication efficacy above the negative
elements of medications (Cluster 4). Moreover, those most concerned about side effects
(Cluster 2) were less knowledgeable about asthma pathophysiology than those who most
valued short, intermediate or long- term outcomes (Cluster 4).

Table 17
Summary of Univariate ANOVA Statistics of Beliefs by Cluster
Sum of
Squares

df

Mean Square

F

Partial eta2

Timeline- Acute/Chronic

.11

3

.04

.05

.00

Consequences

.15

3

.05

.07

.00

Personal Control

.29

3

.10

.17

.00

Treatment Control

.44

3

.15

.53

.01

Coherence

3.19

3

1.06

1.60

.04

Timeline- Cyclical

.50

3

.17

.31

.01

Emotional

.29

3

.10

.14

.00

Psychological Cause

5.23

3

1.75

2.55

.06

Risk Factors

.57

3

.19

.31

.01

Immunity

.95

3

.32

.54

.01

Problem with Airways

8.99

3

2.99

3.03*

.07
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Sum of
Squares

df

Mean Square

F

Partial eta2

Accident/Injury

3.92

3

1.31

1.09

.03

Necessity of Preventer

1.26

3

.42

.76

.02

Concern for Preventer

2.27

3

.76

1.8

.04

*

p < .05.
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Table 18
Estimated Marginal Means for Beliefs about Airway Problems as a Cause of Asthma by
Cluster Group
Cluster Group

M

SE

Long term effects (C1)

3.77

.17

Side Effects (C2)

3.39

.19

Equal Weighting (C3)

3.16

.15

Medication Efficacy (C4)

3.73

.20
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Table 19
Summary of Univariate ANOVA Statistics for Difference of Knowledge by Clusters
Sum of

Mean

Partial

Squares

df

Square

F

eta2

Pathophysiology

.40

3

.13

2.70*

.06

Medications

.61

3

.20

2.79*

.06

Technique

.20

3

.07

.65

.02

Symptoms

.20

3

.07

1.04

.02

Environmental Triggers

.15

3

.05

1.41

.03

*

p < .05.
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Table 20
Estimated Marginal Means for Knowledge of Pathophysiology and Medication by
Cluster
Pathophysiology

Medication

M

SE

M

SE

Long term effects (C1)

24.72

.31

29.95

.49

Side Effects (C2)

24.18

.38

28.68

.61

Equal Weighting (C3)

23.92

.33

28.17

.54

Medication Efficacy (C4)

25.29

.41

30.04

.66
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Testing Study Hypotheses
Hypothesis 1: Knowledge about the pathophysiology of asthma will predict treatment
adherence.
As per a linear regression analysis, knowledge of asthma pathophysiology predicted
MARS scores one month post-appointment, accounting for 6 percent of the explained
variance, R2 = .06, F(3,106) = 2.15, p < .05. This finding remained unchanged when the
demographic variables which correlated with pathophysiology knowledge (i.e., education
level and number of family doctor visits in the past year) were entered at step 1 (Table
21).
As expected, given the non-significant correlations between any of the knowledge
subscales and reported diary adherence, knowledge of the pathophysiology of asthma did
not predict diary reported medication use, R2 = .01, F(1, 120) = 1.47, ns.
Hypothesis 2: Beliefs about the chronicity of the disease, amount of control, severity
of symptoms, sense of coherence and necessity of preventer medications will predict
increased treatment adherence.
As noted earlier, of the illness belief variables, only the Acute/Chronic Timeline scale
was appreciably correlated with adherence scores. Because the hypotheses were related to
the unique contribution of each belief, rather than their contribution as a belief set, only
the Acute/Chronic Timeline variable was used as predictor in the regression analysis.
With respect to beliefs about medication, both beliefs about the need for and concern
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Table 21
Summary of Multiple Regression Analysis for Patient Knowledge as a Predictor of
Reported Adherence (MARS-T2) to Asthma Preventer Medication
Model
1β

2β

Level of Education

-.01

-.00

Visits to Family MD in

.07

-.04

Variable
Demographics

past year for breathing
symptom
.24*

Pathophysiology Knowledge
R2
∆R2
F
∆F
*

p < .05.

.01

.06

-

.05

.29

2.15

-

5.86*
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about preventer medications were correlated with adherence and were thus retained in
the regression analysis (Table 22), which indicated that the hypothesized beliefs predicted
MARS scores at one month post-appointment, accounting for approximately 20 % of the
explained variance, R2 = .21, F(7,96) = 3.63, p < .01. The amount of variance accounted
for was unchanged when the demographic variables which correlated with the belief
scales (i.e., participants’ education level, current job status, age, and number of ER and
clinic visits) were entered at step 1 (Table 22).
Surprisingly, when entered simultaneously, treatment beliefs (i.e., the belief in the
necessity of taking a preventer medication and less of a concern about the effects of the
medication) but not illness beliefs (about timeline) significantly predicted adherence. To
test the possibility that this arose because the predictive power of believing one has a
chronic illness is mediated by beliefs about the necessity of preventer medications (the
variables are correlated r = .42), a Sobel test (Preacher and Leonardelli, 2001) was
performed to test whether treatment necessity mediated the relationship between
chronicity beliefs and adherence (Baron and Kenny, 1986). The Sobel test indicated that
necessity did partially mediate (t = 2.70, p < .001) the relationship between chronicity
beliefs and adherence. And, parenthetically, the opposite did not hold; that is, chronicity
beliefs did not mediate the relationship between treatment necessity and adherence.
A regression including all the hypothesized beliefs measures explained virtually none
of the variance in diary-reported adherence, R2 = .01, F(3,116) = .51, ns.

Table 22
Summary of Multiple Regression Analysis for Patient Illness and Treatment Beliefs as Predictors of Reported Adherence (MARS-T2)
to Asthma Preventer Medication
Model
1β

2β

Age

.16

.16

Education

.10

.06

Visits to Family MD in past year for breathing symptoms

-.04

-.03

Visits to ER in past year for breathing symptoms

-.01

.02

Variables
Demographics

Beliefs
Acute/Chronic Timeline

.04

Preventer Necessity

.34***

Preventer Concern

-.23*

R2
∆R2
F
∆F

.04

.21

-

.17

1.01

3.63**

-

6.88***

*

p < .05. ** p < .01. *** p < .001.
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Hypothesis 3: Patient preferences will predict adherence. In particular, patients who
value long term outcomes will be more adherent than those who do not value long term
outcomes.
Participants were assigned to a cluster (1 - 4) based on their proximity to a cluster
pattern. Categorical membership was dummy coded for the purpose of the regression
analysis. The long term group was used as the constant comparator and was therefore
assigned all zeros. As such, univariate contrasts compared each group against the long
term group.
As per a regression analysis, preferences (as defined by cluster membership)
predicted MARS scores at one month post appointment, accounting for 13.4 percent of
the variance in adherence scores, R2 = .13, F(3,105) = 5.43, p < .01 (Table 23). Beta
values indicated a significant difference between participants who valued long term
outcomes and those who weighed all attributes equally such that those who valued long
term outcomes were more adherent to their preventer medication. Participants who
valued long term outcomes were not more adherent than those who consistently preferred
scenarios with minor medication side effects nor those who valued the efficacy of
treatment over side effects with respect to adherence.
A regression including group classification explained virtually none of the variance in
diary-reported adherence, R2 = .00, F(3, 116) = .12, ns.
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Table 23
Summary of Regression Analysis for Patient Preferences as a Predictor of Reported
Adherence (MARS-T2) to Asthma Preventer Medication
Variable
Equal Weighting – Long Term

β
-.40***

Side Effects – Long Term

-.04

Efficacy – Long Term

-.16

R2

.13

F

5.42**

***

p < .001. **p < .01.
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Hypothesis 4: Patients’ preferences for elements of their medication will predict
adherence above and beyond that predicted by knowledge of their disease and beliefs
about the disease and its treatment.
A hierarchical multiple linear regression revealed that preferences for long term
outcomes accounted for an additional 10% of the variance in adherence scores on the
MARS at one month follow-up, after demographic variables were included in step one
(i.e., age, income, and education), clinical factors included in step two (i.e., number of
family doctor and emergency room visits for respiratory related problems in the past year,
and number of asthma clinic visits), knowledge of pathophysiology in step 3, and beliefs
in step 4 (Table 24). The full model explained 39% of the variance in reported adherence.
Moreover, a reverse analysis in which preferences were entered in step 1 and beliefs and
knowledge in step 2 confirmed that preferences accounted for a unique portion of
explained variance (Appendix M).
An examination of the standardized beta coefficients revealed that, when the
knowledge and belief variables were entered simultaneously, only the belief that
medication is necessary predicted adherence (partial correlation = .42); knowledge of
asthma pathophysiology was no longer predictive. To determine whether the drop in the
predictive power of knowledge of pathophysiology was due to its being mediated by the
belief that preventers are necessary, a Sobel test was performed. It indicated that the
perceived necessity of preventer medication did, indeed, partially mediate, (t = 2.16, p <
.05) the relationship between pathophysiology and adherence.

110

Table 24
Summary of Hierarchical Regression Analyses for Patient Knowledge, Beliefs and
Preferences as Predictors of Reported Adherence (MARS-T2) to Asthma Preventer
Medication
Model
Variable

1β

2β

3β

4β

5β

Demographics
Income

.04

.06

.03

.07

.07

Education

.14

.12

.05

.05

.04

Age

.13

.09

.09

.07

.07

.00

-.02

.03

.00

.01

.04

.05

.09

.12

.13

.07

.11

.26*

.17

.24

Timeline- Acute/Chronic

-.01

-.05

Necessity of Medication

.42***

.37***

Concern of Medication

-.15

-.10

Clinical Factors
Visits to Family MD in
past year for breathing
symptom
Visits to ER in past year
for breathing symptoms
Visits to Asthma Clinic
Pathophysiology
Knowledge
Beliefs
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Model
Variable

1β

2β

3β

4β

5β

Preferences
-.30**

Equal Weighting -Long
Term
Side Effects – Long Term

.06

Efficacy – Long Term

-.18

R2
∆R2
F
∆F
*

.05

.06

.12

.30

.39

-

.01

.06

.18

.10

1.41

.86

1.51

3.25**

3.86***

-

.35

5.16*

6.55***

3.90**

p < .05. ** p < .01. *** p < .001.
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Supplementary Analyses
Although the following analyses do not address this study’s a priori hypotheses,
they were nonetheless pursued to explore the added value of the novel DCE methodology
and to examine the predictive power of psychosocial variables shown to predict
adherence in other domains.
Clustering versus rating scales.
To determine whether the discrete choice and rating tasks were measuring similar
phenomena, Pearson correlations were conducted between the rating items and their
corresponding discrete choice item total score (Table 25). Notably, only long term side
effects correlated with its matched DCE variable. Although significant, the correlation
was small (r = .28, p <.001). It appears, therefore, that people’s overt ratings of what is
important to them differ from what they are willing to give up in a trade-off situation.
A Principal Axis Factor Analysis (Oblimin rotation) of the 9 rating items
corresponding to the discrete choice options suggested three factors, which explained
70.58% of the total variance. Table 26 illustrates the factor pattern matrix. For an item to
be considered part of a factor, it had to load: (1) .50 or higher on the primary factor and,
(2) .40 or lower on all the remaining factors. The factors were labeled: (1) Complexity of
treatment (Eigen value = 3.13; percent variance = 34.78; items: number of inhalers,
taking an inhaler every day, taking an inhaler only when I need it; α = .74), (2) Efficacy
of treatment (Eigen value = 1.77; percent variance = 19.69; items: relieves symptoms in
minutes, keeps asthma from getting worse in 10 years, and reduces attacks over the next
6 months; α = .81), (3) Side effects (Eigen value = 1.45; percent variance = 16.11;
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Table 25
Correlations between Rating Item and Corresponding Discrete Choice Attribute
Rating Item

DCE Attribute

r

Long Term Outcome

.14

2. Number of inhalers

Number of Inhalers

-.04

3. Taking an inhaler every

Frequency of Dose

-.04

Frequency of Dose

.10

5. Short term side effects

Side Effects

.04

6. Long term side effects

Side Effects

.28**

7. Risk of Addiction

Steroid Dose

.15

Immediate Effects

-.06

Short Term Outcome

.06

1. Keeps asthma from
getting worse in 10 years

day
4. Taking an inhaler only
when I need it

8. Relieves Symptoms in
Minutes
9. A decrease in asthma
attacks over the next 6
months
**

p < .001.
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Table 26
Pattern Matrix of Rating Scale Items
Component
Item

1

2

3

Number of inhalers

.73

-.11

.06

Taking an inhaler every day

.87

.03

-.37

Taking an inhaler only when I need

.50

-.05

.30

Short term side effects

.29

.06

.60

Long term side effects

-.14

-.11

.82

Risk of addiction

.01

.03

.61

Relieves symptoms within minutes

-.05

-.53

.13

Keeps asthma from getting worse in

.20

-.92

.06

.11

-.86

-.11

it

10 years
Reduces attacks over next 6 months
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items: short term side effects, long term side effects, risk of addiction; α = .71). Notably,
long term outcome did not emerge as its own factor.
Only the efficacy of treatment factor (which includes the long term outcome item)
correlated with the MARS-T2 scores (r = .21, p< .05). However, when a linear regression
analysis was performed to examine whether the rating-based preference factor scores
predicted adherence on the MARS at one month follow-up, none of the factors
significantly predict asthma adherence scores, R2 = .06, F(3, 109) = 3.4, ns.
Cost, which was not assessed through the discrete choice scenarios (nor correlated
with any of the discrete choice attribute total scores), was not significantly correlated
with MARS scores.
Other psychological factors as predictors of adherence.
Previous studies have demonstrated that patients’ sense of enablement (Haugney,
Cotton, Rosen, Morrison, & Price, 2007) and satisfaction (Jackson et al., 2004) following
a clinical encounter influence adherence. In addition, given that asthma (or asthma
symptoms) has also been associated with increased prevalence of anxiety and panic-fear
(Jessop, Rutter, Sharma, & Albery, 2004), and that negative affect has been associated
with non-adherence (Lehrer, Feldman, Giardino, Song & Schmaling, 2002), exploratory
correlations were conducted to see if these factors, if included, would improve the
predictive power of the regression analysis. None of the factors were correlated with
MARS or Diary scores, and as such, it was deemed unnecessary to add them to the
regression analyses.
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Rescue medication use.
Although this study was designed to explore the effects of knowledge, beliefs and
preferences on preventer medication adherence, it is also interesting to note any
associations with rescue medication use. Rescue medication use was significantly
correlated only with the belief in the necessity of taking one’s rescue inhaler (r = .27, p
<.001, rs = .30, p < .001) and the number of asthma symptoms experienced (ridentity = .27,
p < .05, rs = .26). Individuals in different preference clusters did not differ with respect to
the frequency of rescue inhaler use, F(68,131) = 1.07, ns.
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Chapter V: Discussion
The main goal of this study was to explore the additive effects of knowledge,
beliefs and preferences on preventer medication adherence in a sample of patients with
asthma. Specifically, it was hypothesized that knowledge of asthma pathophysiology as
well as beliefs about the consequences, chronicity, and controllability of asthma and
necessity for preventer medications would be preconditions of adherence, but that
preferences for long term improvements would further predict reported adherence. These
predictions were borne out by the primary study findings, which are reviewed and
discussed in the following sections.
Main Findings Pertaining to MARS Reported Adherence
As expected, the study findings support the assertion that knowledge, beliefs and
values pertaining to the understanding and valuing of long term, rather than immediate
outcomes predicts preventer medication adherence. Specifically, when examined on their
own, knowledge of asthma pathophysiology (i.e., recognizing that asthma is a tonic
inflammatory condition of the lungs), perceiving the need for preventer medications (i.e.,
understanding that they stymie progression of the disease) and preferring long term
outcomes over short term symptom alleviation, each significantly positively predicted
reported adherence. When assessed together, preference for long-term improvement in
asthma accounted for 10% of the variance in adherence beyond that explained by
knowledge and beliefs alone. As a group, the three classes of variables accounted for
33% of the variance in adherence beyond that accounted for by demographic and clinical
factors. The implications of these findings are each discussed in detail below.
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Knowledge of asthma pathophysiology is important but not sufficient.
This was the first study to explore the extent to which specific domains of asthma
knowledge predict adherence. As hypothesized, knowledge about the pathophysiology of
and functional changes associated with asthma was the only knowledge domain to
correlate with reported adherence (r = .27). However, when entered along with treatment
beliefs in a regression predicting adherence, the predictive power of pathophysiology
knowledge was lost. This suggests that knowledge of pathophysiology is important only
in so far as it leads one to believe that preventer medication is necessary to treat the
condition. These findings are considered in greater detail below.
Knowledge of asthma pathophysiology is the only knowledge domain to predict
adherence.
That pathophysiology was the only knowledge domain to predict adherence
suggests that, in order to adhere, patients need more than simply to know what to do they must understand why they are being asked to do it. The National Asthma Education
Prevention Program (Bethesda, 1997) recommends that standard content areas, including
inhaler technique, environmental triggers, roles of medications and self-monitoring
approaches, all be included in all programs. Yet, as per these study findings, if one wants
to increase the likelihood of adherence to preventer medication, it may be most
efficient/cost-effective to ensure that patients understand the tonic pathophysiology of
asthma and how it is targeted by corticosteroids.
Research in other domains has similarly demonstrated that, when given a
rationale or explanation for a prescribed behaviour, people are more likely to comply. For
example, Taylor and Bower (2004) found that undergraduates were far more likely to
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wear protective gloves before applying a liquid plant fertilizer when given the following
instructions: “Gloves are recommended during application to prevent possible skin
irritation and/or skin staining” (65% compliance) than when simply told the following
“Gloves are recommended during application” (23% compliance).
Moreover, in a series of studies on decision making heuristics and errors, Tversky
and Kahneman (1983) demonstrated that the more specific a link could be made between
a cause and outcome, the more easily it could be elaborated upon and perceived as likely.
This may be especially important for health behaviours, wherein the consequences of
perceiving an outcome to be less likely than it is really prove dangerous. This danger is
compounded by people’s general tendency to be optimistically biased with regard to their
health (Hahn & Reiner, 1998; Renner, Knoll, & Schwarzer, 2000; Weinstein, 1980). So,
anything that can counter the forces that push people away from taking medication for
long-term conditions (i.e., helping them understand why the medication is important)
should be part of the clinical armamentarium.
To re-iterate, the results of this study suggest that ensuring patients understand
“why” asthma medications are necessary (i.e., the physiology of asthma and their
functional impact) will promote adherence. This finding has health policy implications in
that it suggests that interventions targeting adherence should focus on providing patients
with the information they need to understand the mechanisms of their condition. Thus, in
the interest of improving adherence, practitioners arguably should routinely include an
assessment of patients’ knowledge of asthma pathophysiology.
To date, however, there has been no clinical tool that adequately assesses patients’
knowledge of their asthma. That is, current measures of asthma knowledge tend to tap
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patients’ knowledge of medications (e.g., Kritikos, Krass, Chan, & Bosnic-Anticevich,
2005) or have focused on symptoms, the stigma associated with asthma and perceptions
of quality of life (e.g., Grant et al., 1999). Of those measures that assess pathophysiology,
the focus is on the physiology of asthma attacks (acute bronchoconstriction) rather than
the underlying chronic inflammation. For example, Allen and Jones (1998) asked
participants in an asthma intervention program whether statements such as “During an
asthma attack, more mucus is produced in the airtubes” (T) and “During an asthma
attack the airtubes collapse” (T) were true or false. These items, however, only tap
knowledge of the physiology of acute airway constriction that give rise to asthma
symptoms, but not knowledge of the underlying chronic inflammatory mechanisms
which are treated by preventer medication. Based on the current study’s findings, it could
be argued that items such as “People with asthma can have swollen and inflamed
airways even when they feel well” (T), “Asthma can be cured” (F), “When someone’s
asthma attack is over it means that the asthma has gone away” (F), “Asthma is a disease
that does not last for a long time”(F) and “It is possible for someone’s asthma to be
worse without them noticing a change in their breathing” (T) also should be included in
these measures.
Notably, Schaffer and Yarandi (2007) included two similar items (“People with
asthma have swollen and inflamed airways even when they feel normal” and “Asthma can
be completely cured) in their instrument. Similarly, in a survey designed for parents of
children with asthma, Ho et al. (2003) included “Asthma is due to inflammation in the
lungs”. However, one or two items are not enough to adequately assess patients’
knowledge in this domain. Our scale, which included nine items targeting participants’
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understanding of asthma pathophysiology, provided a more comprehensive measure of
patients’ knowledge in this domain.
Beliefs about the necessity of a medication mediate the effect of
pathophysiology on adherence.
Although knowledge of pathophysiology predicts adherence, it is erroneous to
assume that this knowledge, in and of itself, directly leads to adherence. A meditational
analysis revealed that knowledge of asthma pathophysiology leads to adherence, in part,
because it enables people to see why they should take their preventer medication;
individuals must know why they need their medications in order to believe in their
necessity. In fact, the variable most strongly associated with reported medication
adherence was the perceived need for medication (r = .36), which accounted for an
additional 18% of the variance in adherence reports beyond that accounted for by
participant demographics and asthma knowledge. The strength of the association between
treatment beliefs and adherence is similar to that observed by Horne and Weinman
(2002).
These findings are also consistent with those of others. For example, McHorney
and Gadkari (2010) found that, across various conditions, patients’ perceived lack of
medication need (as gauged by a self-report survey) was an important factor for
medication non-fulfillment rates, stronger than that of medication knowledge. Knowledge
also has been shown to indirectly affect adherence through behavioural skills (Amico,
Toro-Alfonso, & Fisher, 2005), personal motivation (Martin, Haskard-Zolnierek, &
Dimatteo, 2010) as well as health beliefs (McHorney, 2009).
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In the case of this study, one reason the effect of knowledge of pathophysiology
was partly accounted for by beliefs about the need for preventer medication may be
because the latter taps not only the why (because asthma is the result of a problem in the
airways), but also the how (medications keep the airways from getting worse).
Pathophysiology knowledge and perceived need for preventer medication were modestly
correlated (r = .22), suggesting that, although beliefs and knowledge are distinct, patients
must understand that asthma persists even when they are not experiencing symptoms if
they are to believe that the medications will help in this regard. It is thus not surprising
that beliefs about the necessity of medications and beliefs about the chronic nature of
asthma were moderately correlated (r = .42), and that pathophysiology knowledge also
moderately correlated with the belief that asthma is a chronic condition (r = .48).
Beliefs about an illness are not as strong a predictor as beliefs about its
treatments.
Contrary to prediction, the illness belief subscales did not predict reported
adherence when considered in conjunction with treatment beliefs. Among other health
populations, treatment beliefs also have proven to be stronger predictors of adherence
than illness beliefs (Leventhal et al., 2008; McHorney & Spain, 2011). For example, in a
sample of 180 stroke survivors, O’Carroll et al. (2011) observed that concerns about
medications and low perceived medication benefits were the two primary predictors of
poor medication adherence, whereas illness beliefs were not predictive. Similarly, in a
path analysis of the effect of beliefs on reported adherence, Horne and Weinman (2002)
found that necessity beliefs largely mediated the effect of illness perceptions (with the
exception of consequences beliefs) on reported preventer medication adherence. These
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findings were essentially replicated in this study by the finding that the association
between the belief that asthma is a chronic condition and adherence to preventer
medication was partly mediated by the belief that preventer medications are necessary.
Why, then, might treatment beliefs better predict adherence than illness beliefs?
McHorney (2009) recently proposed a proximal-distal continuum of drivers of
adherence. Adapted from Brenner’s proximal-distal continuum (Brenner, Curbow, &
Legro, 1995), she argues that the strength of the association between a belief and
adherence is a function of the beliefs’ proximity to patient decision making about
whether or not to take a medication. Proximity of a belief or construct is based on how
specific it is to the decision. Accordingly, McHorney hypothesized that treatment beliefs
would be most proximal to the decision to not purchase a newly prescribed medication
(medication non-fulfillment) or to discontinue medication use without consulting a health
care provider (medication non-persistence). On the basis of bivariate and multivariate
analyses of treatment beliefs, illness beliefs, and demographic factors, she found that
only the perceived need for and concern about medication (i.e., treatment beliefs)
differentiated adherers from non-fulfillers and non-persisters. Demographic and
psychosocial factors (the most distal in McHorney’s model), were only weakly associated
with non-adherence, a finding which has been supported by other research (i.e.,
Dimatteo, 2004).
This study fails to replicate Horne and Weinman’s (2002) finding that beliefs
about the consequences of asthma predicts adherence to preventer medication. It should
be noted, however, that the direction of their finding was counter-intuitively negative;
that is, the worse impact people believed asthma to have on their lives, the less (rather
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than more) likely they were to adhere. However, given that Horne and Weinman’s (2002)
study was cross-sectional, the finding might be explained by non-adherence leading to a
worsening of asthma and thereby augmenting its adverse impact. With reference to the
current study’s findings, one might propose that, rather than perceived consequence
exerting its effect on adherence directly, it acted through the perceived need for preventer
medication, as these variables were positively correlated (r =.40). However, because
beliefs about consequences were not significantly correlated with adherence (r = .05),
there was no effect to be tested for mediation.
Notably, the only illness belief subscale to correlate with adherence in this study
was the acute/chronic timeline scale (r = .27), and its effect was, indeed, partially
mediated by the perceived need for preventer medications. The acute/chronic timeline
subscale taps beliefs about the long-lasting nature of one’s condition, which, like
understanding asthma pathophysiology and believing in the necessity of preventer
treatment, entails an appreciation for long-term outcomes. Beliefs about the cyclical
nature of the symptoms were not correlated with participants’ beliefs about the chronicity
of asthma. This suggests that participants differentiated between the fluctuating (or not)
nature of asthma symptoms and the chronicity of its underlying pathophysiology.
Appreciating the long-lasting nature of asthma and not the variability in symptoms
predicted adherence. Along these lines, Schiaffino and Cea (1995) found that the ability
to separate beliefs about symptoms and those about a disease predicts outcome in chronic
pain. That is, they observed that when patients with chronic pain are able to make the
distinction between their symptoms and their underlying disease, they came to recognize
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that symptom improvement is not predicated on finding a cure for their disease and,
consequently, their symptoms seem more manageable.
Preferences predict adherence above and beyond knowledge and beliefs.
Previous research already has shown that people with asthma have strong
preferences regarding treatment. For example, McKenzie and colleagues (2001)
demonstrated that, as a group, patients see cough as the most important symptom to target
and reduce. Moreover, McTaggart-Cowen et al. (2008) as well as Haugney et al. (2007)
found that patients are willing to trade symptom free days for a less complex treatment
plan. This was the first study, however, to identify clusters of asthma patients based on
treatment preferences and to subsequently use the clusters to predict adherence
behaviour. Four groups, those privileging (1) long term benefits, (2) medication side
effects, (3) a trade-off between side effects and efficacy and (4) all attributes equally,
emerged. As predicted, a regression analysis indicated that preferences for long term
outcome predicted improved adherence scores, accounting for an additional 7% in
variance above that accounted for by knowledge and beliefs. Together, these three classes
of variables accounted for 39% of the variance in self-reported adherence, an increase of
almost 20% from previous studies (e.g., Horne and Weinman, 2002).
As noted earlier, long term considerations are what drove adherence to preventers.
Namely, those most likely to adhere (1) believed that asthma is a long lasting chronic
condition, (2) believed that preventer medications are necessary to reduce the progression
of the disease in the long term, (3) understood that asthma is a problem with the airways
that will worsen over time (pathophysiology) and (4) valued the extent to which a
treatment will produce long term effects above other elements of a medication (e.g.,
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immediate effects, side effects, and complexity of the regimen). In addition, those who
valued long term outcomes were more likely to acknowledge “airway problems” as a
cause for their condition and had better knowledge of asthma pathophysiology than those
who weighed all attributes equally.
Grouping participants into clusters, as was done here, has some advantages. Until
recently, preferences for treatments have been explored either at the aggregate (whole
group) level or at the micro level of individual participants (Singh et al., 1998). However,
overall group data over-generalizes participants’ views and individual differences are
lost. Therefore, it is not surprising that interventions based on this “one size fits all”
group level approach yields inconsistent results. In contrast, data at the individual level
may be oversensitive to individual variation making it impossible for policy makers to
systematize intervention. As such, an intermediary step of subgroup analyses is
particularly useful. Interventions can then target different patient groups who may use
different decision factors based on their distinct goals, needs, and motivations. For
example, in the current study, group membership predicted adherence such that those
who valued long term outcomes were more adherent than those who weighed all
medication attributes equally. Had we not been able to extract subgroups based on
preferences, this finding would have been obscured.
It was expected that those inclined to avoid side effects would be less adherent
than those focused on long-term outcomes. This prediction was not borne out. One
possible reason for this null finding may be decisional uncertainty. That is, the side effect
options contained the term “risk” (i.e., “There is a risk of major/long term side effects”
versus “There is a risk of minor/short term side effects”), whereas the long term options
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were phrased more definitively (“Your airways will be worse in 10 years” versus “Your
airways will be the same in 10 years”). Research in the area of psychology of decision
making has identified many biases that come into play when individuals judge the
likelihood of an event (Chapman & Elstein, 2000) and has demonstrated that probability
theory is often violated under conditions of uncertainty (Redelmeier, Koehler, Liberman,
& Tversky, 1995). Arguably, the term “risk of” evokes more uncertainty than the more
decisive wording of the long term outcome options. Accordingly, certain maintenance of
airway integrity over the long-term may have carried more weight (and hence “predictive
punch”) than the possibility of side effects.
Main Findings Pertaining to Diary-Reported Adherence
The two measures of adherence - the medication diary and the MARS scores at one
month follow-up- were significantly correlated in the expected direction, but the
magnitude of the association (rs= .35) is lower than observed between the MARS and
electronic monitoring indices of adherence (rs=.50) (Cohen et al., 2009). Moreover,
whereas the MARS scores correlated with many of the hypothesized predictors of
adherence, diary scores correlated with none.
One explanation for this pattern of findings is a lack of sufficient variation in the
diary scores, which were “0” (indicting ‘perfect’ compliance) roughly 60% of the time.
Another explanation is that the MARS scale used in this study and the diary recording
may actually measure different aspects of adherence.
Recent data suggests that adherence is not a uni-dimensional construct (Mora et al.,
2011; Clifford et al., 2008). For example, a recent factor analysis of the revised MARS-A
10 item scale revealed two types of intentional non-adherence: (1) stimulus or symptom
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driven non-adherence and (2) intentional reduction or avoidance of medications. In the
first type of non-adherence, patients use somatic signs as cues to take their medications.
In other words, patients’ bodies provide them with feedback about the effectiveness of
their medications. Items such as “I only use it when I feel breathless” and “I use my
inhaler only when my other one doesn’t work” illustrate this construct. The second type
of intentional non-adherence is more deliberative, whereby patients make decisions as to
whether or not to take their medication based on their internal working models. Items
such as “I alter the dose” or “I try to avoid using it” reflect this more deliberative process.
Unfortunately, Mora et al.’s (2011) version of the MARS (the MARS-A) was not
available at the time this study was designed and executed. One could predict that had it
been administered, the subscale tapping somatically-cued adherence would have
correlated more strongly with the diary measures than the more deliberative subscale, the
reasoning being that if patients use their fluctuating symptoms as cues to take their
medications, their diary reports, on which they recorded the times they chose to take
medications, would reflect this behaviour. To verify this hypothesis, however, future
research will need to monitor fluctuations in symptoms that occur in tandem with
medication- taking.
Moreover, Mora et al. (2011) found the two subtypes of non-adherence to be only
slightly inter-correlated. If the diary recordings more directly tap the somatically-cued
adherence behaviours, then we would anticipate only a weak correlation with the MARS
measures used in this study, as it mostly gauged the second type of intentional nonadherence. In addition, the adherence behaviours recorded in the diary likely do not
reflect the more deliberative, planned adherence decisions tapped by the second factor on
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the MARS-A, as it makes sense that this second factor is more influenced by knowledge,
beliefs and preferences. This may explain why MARS, and not the diary measures,
correlated with the predictors of interest. As is argued in more detail in the sections
below, while a macro decision to follow health care recommendations may initiate
adherence, it is enacted through the myriad of daily decisions, which may be better
reflected in the daily diaries. Perhaps the knowledge, beliefs, and preference variables
explored in this study drive the macro more so than the daily decisions, and as such, did
not correlate with the diary measures.
Other Notable Findings
Although not the main focus of the study, other findings worthy of comment
emerged.
Reported adherence on the MARS increased over time.
As a group, participants reported higher adherence on the MARS at one month follow
up than they did initially, just before being seen by their health care provider at the clinic
visit. Without a control group, we cannot really know whether this is due to the
Hawthorne effect or due to specific ‘interventions’ that took place between the two
administrations, namely the self-monitoring requirement of the daily diary, or meeting
with the clinic physician. Both are plausible mechanisms. With respect to self-monitoring
as a potential mechanism, in a non-controlled study, Straka et al. (1997) found that after
completing medication diaries, heart disease patients’ adherence rates (as gauged by
electronic monitors) increased by 9 percent.
However, that the effect was observed only for those visiting the clinic for the first
time and not amongst those coming for repeat visits strongly suggests that, rather than
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being due to self-monitoring, the meeting with the asthma centre clinician and/or simply
the novelty of initiating treatment at a specialty clinic (rather than primary care) provided
the new patients an added incentive to adhere. Accordingly, the more plausible
explanation, supported by findings reported by DiMatteo et al., (2003) for the increases in
MARS scores is that patients’ treatment efficacy attitudes were shaped/reinforced during
their first visit at the specialty clinic which, in turn, increased their tendency to adhere.
Discerning preferences.
Participants’ overt ratings of the importance of various attributes of their
treatment regimen did not correlate (all r’s less than .28) with the preferences revealed
through the DCE task. Moreover, had we relied solely on data from the rating scales,
subgroup differences would have been obscured. Factor analysis of the rating scales for
the entire sample yielded four factors, namely: (1) Efficacy of treatment, (2) Complexity
of treatment, (3) Side effects and, (4) Cost, but long term outcomes did not emerge as a
factor. Notably, preferences for long term outcomes, inferred from the DCE task,
emerged as the dominant predictor of adherence, and none of the explicit rating factors
predicted.
Rating scales (which require participants to rate their opinions or attitudes on a
numerical or semantic scale) and ranking tasks (which require respondents to give an
ordinal ranking of items such that the items that receive the highest ranking are
considered most important) are widely used in the health research domain (Ryan et al.,
2001; van Helvoort-Postulart, van der Weijden, Dellaert, de Kok, von Meyenfeldt, &
Dirksen, 2009). Based on an a systematic literature review of quantitative and qualitative
methods for eliciting public preferences for health care, Ryan et al. (2001) argued that
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although the ease of both administering and scoring ranking and rating scales makes them
attractive, they are limited in that they do not take context into consideration. Moreover,
ranking and ratings entail judgments, not choice, and rating one alternative higher than
another does not necessarily mean one will choose the former (Payne, Betteman, &
Johnson, 1992).
Unlike rating/ranking scales, DCEs, take context and strength of preference into
account. Moreover, they assess preferences in a more externally valid way. By comparing
options that vary along several attributes at once, respondents are impelled to consider
trade-offs. This has important implications for health care resource allocation. Rating or
ranking something very highly does not necessarily mean that a health consumer or
funder wants to allocate all resources (e.g., funds, efforts) to that consideration at the
expense of everything else. This recognition has resulted in the increased use of discrete
choice scenarios (which assess trade-offs) in health care research (Ryan, Bate, Eastmond,
& Ludbrook, 2001; Ryan & Farrar, 2000; van Til, Stiggelbout, & Ijzerman, 2009). Given
that health care provider time is a limited resource, using this methodology to elicit
patient preferences may optimize the time spent with health care providers.
As far back as two decades ago, there was a call for psychologists and economists to
work more closely together to better explain health choice behaviour and uptake of health
services (Phillips & Rosenblatt, 1992). Health economists, interested in exploring market
choices, have established useful methods (such as discrete choice experiments) to explore
real-world “trade-offs” of medication choices. Yet, classic economic theory cannot
account for when individuals make irrational choices that seem not to logically balance
costs against benefits and act/choose so as to maximize their personal advantage (Phillips
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et al., 2002). Behavioral economists and cognitive psychologists, however, have
identified systematic ‘non-rational’ yet perfectly understandable biases (e.g.,
representativeness and availability) shown to play out in medical decision making
(Dawson & Arkes, 1987). There are also biases (e.g., hindsight bias and confirmation
bias) that affect the judged probability of an adverse health event, as well as the judged
utility (value) of a given outcome (e.g., framing effects, preference reversals, sunk cost
bias, decision weights, omission bias, and regret) (Chapman & Elstein, 2000). Therefore,
the combination of economic methodology to identify what decisions people make,
psychological research identifying how people come to the decisions as well as how to
rectify problematic biases will prove extremely useful.
Clinical Implications
The value of a given theory is enhanced when it can serve a pragmatic function – in
this case, improve adherence. Leventhal and Cameron (1987) suggested that the Common
Sense Model of Illness (CSM) can be incorporated into three types of educational
interventions. First, in “communication style”- focused interventions, health care
providers use their relationship with patients to help them accept a message. In essence,
belief in both the message and the messenger are presumed to encourage behaviour.
Second, cognitive-focused interventions emphasize less the relationship between the
parties and more the cost-benefit analysis of beliefs (health threat versus behaviour) as
motivating factors. Finally, interventions that focus on self-regulation emphasize patients
as an active problem solvers and their ability to meet the health challenge. While
interventions guided by these models do tend to improve patients’ abilities to manage
their disorder, the relative importance of each component as the active ingredient remains
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unclear (van Dumalen et al., 2004). Moreover, others (Horne et al., 2007) have suggested
that it is simply beliefs, not education, that motivates behaviour change.
However, our findings suggest that beliefs and knowledge alone are not enough, and
that patients’ goals and preferences for treatment also drive adherence. Psychologists
have long advocated using patient-defined goals to guide treatment and recently, medical
experts have begun to acknowledge the importance of incorporating goals into treatment
(Charles, Gafni, & Whelen, 1999). For example, Wilson et al., (2010) randomized
patients with asthma to either a treatment regimen wherein clinicians and patients worked
together to accommodate patients’ goals and preferences or a clinical decision group in
which patients’ goals were not elicited. Both groups received asthma education and two
in-person and three phone encounters. At one year follow-up, those patients whose
preferences and goals were targeted were more adherent to their preventer medication
and used their rescue medication significantly less than the standard care group at two
year follow-up.
It may be clinically useful to conceptualize adherence to asthma medications as a
two-tier process, wherein patients make both macro (i.e., “Will I fill my prescription?) as
well as micro (i.e., “Shall I take my preventer medication this morning?”) level decisions.
Preferences for treatment as well as knowledge and beliefs likely target macro level
decisions. Once the macro decision has been made, behavioural factors, such as patients’
skill and ability to take the medications likely play a more important role. Targeting
patients’ behavioural abilities has been shown to be imperative for the prediction and
promotion of sexual and reproductive health behaviours (Bryan, Fisher, Fisher, &
Murray, 2000; Cornman, Schmiege, Bryan, Benziger, & Fisher, 2007; J. Fisher, Fisher,
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Bryan, & Misovich, 2002; W. Fisher, Williams, Fisher, & Malloy, 1999). For patients
with asthma, current treatment guidelines suggest using written asthma action plans as
well as providing education about the techniques associated with inhaler use. These
strategies have been shown to be moderately effective (Gibson & Powell, 2004), likely
because patients must first make a decision about whether or not they are going to adhere
at all; a decision based on their beliefs and preferences. Notably, the technique subscale
of the asthma knowledge scale used in this study was not correlated with adherence on
the MARS. Again, it appears that the MARS tap higher order (macro) decisions and not
daily medication decisions.
As such, Motivational Interviewing (MI) strategies, emergent from the psychological
literature, may be particularly useful for targeting patient health care preferences and
goals that need to be addressed before behavioural skills are taught. MI is a method for
enhancing change behaviours by exploring and resolving ambivalence (Miller &
Rollnick, 2002). Incorporating MI into interventions can double the effect size of an
intervention and improve retention and adherence (Burke, Arkowitz, & Menchola, 2003;
Hettema, Steele, & Miller, 2005). However, it should be noted that motivational
interviewing techniques tend to focus on ambivalence around changing behaviour to
achieve one given goal, in part, by helping people address the actual costs of the
behaviour change (i.e., Although I want to lose weight, and know that one of the ways I
can do so is exercise, I’ll sweat when I exercise, and I hate the sensation of sweating).
Horne et al. (2007) note, however, that patients often present with what appear to be
contradictory goals. For example, a patient might have as a goal to reduce symptoms of
the disease but might equally want to reduce the risk of side-effects. If a given medication
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equally promises/threatens both outcomes, then this patient understandably is in a bind.
However, individuals often are unaware of the sources of their ambivalence and the
present study presents a means – DCE- by which to elucidate (for patients, their
practitioners, and health system planners), the trade-offs individuals are willing to make.
Main Limitation: The Dependent Measure - Adherence.
Adherence is likely overestimated.
Measurement of adherence is both controversial and fraught with methodological
challenges. Self-report surveys, while the most widely-used in research, tend to
underestimate non-adherence by approximately 20 percent (Horne & Weinman, 1999),
probably because patients are loathe to admit (to themselves and others) that they do not
follow their health care providers’ prescriptions. Moreover, diary records have been
shown to overestimate medication use (as gauged by electronic monitoring) by more than
50% (WHO, 2003). There is, however, no ideal way to measure adherence (Clifford,
Barber, & Horne, 2008) and it is recommended that convenience, participant
acceptability, and cost be taken into consideration when deciding which measure to use
(Vitolins, Rand, Rapp, Ribisl, & Sevick, 2000). Given logistic constraints, we chose to
employ self-report measures of adherence, which reviews of the literature (Haynes et al.,
1980; Stephenson, Rowe, Haynes, Macharia, & Leon, 1993; Bende et al., 2003) have
shown compare well with more objective measures electronic records and pharmacy
reports.
Our primary outcome measure (MARS) was significantly negatively skewed people reported a high degree of adherence. But despite the high scores, 83% of
participants in our sample admitted to sometimes, always, or often engaging in at least
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one of the nine non-adherent behaviours. In fact, our sample more readily acknowledged
non-adherence than did that of Horne and Weinman (2002) who report that only 74% of
their sample admitted to these behaviours. And, even with this distributional challenge,
Horne and Weinman (2007) still observed statistically and conceptually meaningful
relationship between adherence and their predictors of interest, as did we. The emergence
of statistically significant associations despite the distributional properties of the
dependent variable suggests that the relationships are quite robust, and if anything, the
strength of the predictors is likely underestimated. Accordingly, it may be useful in the
future to use more objective measures of adherence (though they can be relatively
expensive monetarily and effort-wise) to explore these relationships further.
Failing to differentiate intentional and non-intentional non-adherence.
There are different types of non-adherence including erratic non-adherence (e.g., nonadherence due to forgetfulness or changing schedules), unwitting non-adherence (i.e.,
unintentional non-adherence stemming from a lack of patient understanding about how to
take their medications) and intelligent non-adherence (i.e., non-adherence stemming from
a reasoned choice not to take medication) (WHO, 2003). Clifford, Barber and Horne
(2008) argue that the hundreds of factors hypothesized to influence adherence can be
categorized into intentional or non-intentional factors. Non-intentional factors are
synonymous with unwitting and erratic non-adherence factors described above, in that
patients may inadvertently be non-adherent either because they have failed to understand
the skills necessary to take their medications or they cannot manage to take it. Intentional
non-adherence, on the other hand, is influenced by patients’ beliefs, knowledge and
motivation. Notably, intentional and nonintentional adherence factors may overlap. For
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example, patients who have fewer beliefs about the necessity of their medication may be
less motivated to take it and, as a result, forget to take it more often.
Clifford et al. (2008) demonstrated differences in treatment beliefs among intentional
and unintentional adherers. Compared to adherers, intentional (but not unintentional nonadherers) believed less in the necessity of and had more concerns about their prescribed
medications. A limitation of the current study is that the MARS contained only one item
tapping unintentional non-adherence (I forget to use it) which was significantly correlated
(r’s ranging from .30 to .60) with the other items on the scale (with the exception of “I
use it only as a reserve”), and so it was not possible to discern the differential predictors
of intentional and non-intentional adherence in this sample. If Clifford et al.’s (2008)
measure had been used in this study, one would hypothesize that knowledge, beliefs and
preferences would predict intentional but not non-intentional non-adherence.
Future Directions
The current study was novel in its integration of theory and methodology from a
number of disciplines which, when combined, suggest that, to the extent to which
individuals with asthma understand and believe in the long term nature of their disorder
and the need for medications and value long term outcomes, they will be likely to adhere
to their preventer medication. While these findings provide a first step to better
understanding patient decision making in the context of asthma medication adherence,
more work has to be done to extend the scope of inquiry. In particular, examining a
broader number of attributes and levels, expanding the focus to other aspects of self-care
regimens, increasing the length of the prospective sampling period and exploring the
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reciprocal relationships between the variables are all potential future research directions.
Each is considered below.
When developing a discrete choice experiment it is essential to ensure that the design
involves an appropriate range of levels which capture salient elements of the attributes.
The levels must be plausible and clinically relevant (Lancsar & Louviere, 2008). The
attributes chosen in this study were dictated by the study hypotheses and the attribute
levels were chosen so as to be able to generate cluster scores to subsequently be used to
predict adherence. Consequently, only binary attribute levels were employed. While the
binary attribute is the most common DCE design (Street & Bourgess, 2007), the study
might have benefited from the inclusion of more nuanced attribute levels. Therefore,
while the design in the current study met the necessary criteria (i.e., all attributes and
levels were salient, clinically plausible, and relevant), future research may improve our
understanding of the effect of preferences on adherence behaviours by incorporating a
greater range of preference options.
According to Osterberg and Blaschke (2005), patients with chronic conditions
demonstrate consistently low rates of adherence that drop dramatically after the first six
months of treatment. Adherence is of interest largely (if not only) because it should lead
to decreased morbidity. The limited length of the follow-up period (one month) precluded
our finding any association between knowledge, attitudes and preferences and changes in
asthma quality of life, as mediated by adherence. As a result, future research involving a
longer time frame would be useful for exploring this relationship.
Given the gravity of the problems associated with asthma medication non-adherence,
this study was focused specifically on adherence to preventer medication. But, lifestyle
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factors, including getting rid of pets, exercising to lose weight to improve lung
functioning, or quitting smoking are also clinically relevant “behavioural prescriptions”.
It is quite plausible that beliefs and preferences may play an even greater role in
explaining adherence to these recommendations as they involve more complex trade-offs
off people’s values (i.e., keeping my pet vs. maintaining my lung function). As such,
future research should focus not only on the predictors of medication adherence, but also
on what drives people’s lifestyle modification decisions.
Finally, this study examined the additive effects of patient preferences on adherence.
However, the reciprocal nature of the relationship between knowledge, beliefs and
preferences remains unclear. Future research would benefit from exploring interaction
effects between these three important constructs.
Overall Summary and Conclusion
Adherence is a complex and multifaceted phenomenon. The consequences of nonadherence are significant and include increases in health care costs and poor medical
outcomes. Hundreds of factors have been hypothesized to be associated with adherence
across a number of health conditions, treatments, and populations (Clifford et al., 2008)
and many health care providers and policy officials have attempted to incorporate the
associated factors into intervention programs. To date, however, costly and time
consuming intervention programs have been met with only modest success.
In an attempt to improve the understanding of patient non-adherence, this thesis
integrated the theory and methods of three disciplinary literatures, namely, nursing/public
health, psychology and economics, to explore the additive effects of knowledge, beliefs
and preferences on medication adherence in a sample of patients with asthma. It was

140

predicted that long term factors- understanding the chronic nature of the disorder, the
necessity for medications to stymie the progression of the disease and valuing long term
effectiveness of medications above immediate symptom alleviation, treatment complexity
and side effects- would improve adherence reports.
A notable finding is that participants who understood that their asthma was a chronic
pathophysiological condition which could deteriorate if preventers were not taken as
prescribed were more adherent to their medication than those who did not hold this
knowledge and belief. This strongly suggests that, to improve patient adherence to
asthma preventer medications, patients should be helped to understand why they require
these medications.
In a recent position paper, Horne et al. (2007) stated that “In the real world where
patients make choices that may reflect conflicting priorities, asthma still imposes a
considerable burden on healthcare systems” (p. 9). Identifying the sources of conflicting
priorities for each individual, however, is impractical for developing systematized
interventions. On the other hand, eliciting preferences of overall patient groups overgeneralizes and limits the clinical utility of findings. An intermediate step, subgroup
analysis, is much more practical. This study was among the first to assess preferences at
the intermediate step of subgroup levels and represents the first attempt to use latent
cluster analyses of data from discrete choice experiments to uncover previously
unidentified heterogeneity among a sample of patients with asthma.
Identifying what is important to patients and ultimately working collaboratively
towards valuing long term outcomes will improve adherence rates among patients with
asthma. In designing intervention programs, policy makers must understand that
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knowledge is only half of the story. Programs should focus on making sure patients
understand the physiology and functional limitations of asthma, why medications are
required, and help guide them to value long term asthma outcomes. After all, our findings
suggest that if the why is clear, patients are more likely to adhere.

142

References
Addelman, S. (1962). Orthogonal main-effect plans for asymmetrical factorial
experiments. Technometrics, 4, 21-46. doi: 10.2307/1266170
Ajzen, I., & Fishbeing, M. (1980). Understanding attitudes and predicting behavior.
Englewood Cliffs, NJ: Prentice Hall.
Amico, K.R., Toro-Alfonso, J., & Fisher, J.D. (2005). An empirical test of information,
motivation, and behavioral skills model of antiretroviral therapy adherence. AIDS
Care, 17, 661-673. doi: 10.1080/09540120500038058
Anis, A.S., Lynd, L.D., Wang, X.H., King, G., Spinelli, J.J., Fitzgerald, M., et al. (2001).
Double trouble: Inappropriate asthma medication use linked to increased use of
health care resources. Canadian Medical Association Journal, 164, 625-631.
Allen, R.M., & Jones, M.P. (1998). The validity and reliability of an asthma knowledge
questionnaire used in the evaluation of a group asthma education selfmanagement program for adults with asthma. Journal of Asthma, 35, 537-545.
doi: 10.3109/02770909809048956
Avishay, E., Lishner, M., & Melamed, S. (2011). Treatment beliefs and attending followup visits in a lipid clinic. British Journal of Health Psychology, 16, 61-71. doi:
10.1348/135910710X510232
Awad, A. (2004). Antipsychotic medication: Compliance and attitudes towards treatment.
Current Opinion Psychiatry, 17, 75-80. doi: 10.1097/00001504-20040300000002
Bailey, W.C., Kohler, C.L., Richards, J.M., Windsor, R.A., Brooks, C.M., Gerald, L.B. et
al. (1999). Asthma self-management: Do patient education programs always have

143

an impact? Archives of Internal Medicine, 159, 2422-2428. doi:
10.1001/archinte.159.20.2422
Baptist, A.P., Talreja, N., & Clark, N.M. (2011). Asthma education for older adults:
Results from the National Asthma Survey. Journal of Asthma, 48, 133-138.
doi:10.3109/02770903.2010.535880
Baron, R.M., & Kenny, D.A. (1986). The moderator-mediator variable distinction in
social psychological research: Conceptual, strategic, and statistical considerations.
Journal of Personality and Social Psychology, 51, 1173-1182. doi:
10.1037//0022-3514.51.6.1173
Bender, B., Milgrom, H., & Apter, A. (2003). Adherence intervention research: What
have we learned and what do we do next? Journal of Allergy and Clinical
Immunology, 112, 489-494. doi:10.1016/S0091-6749(03)01718-4
Bender, B., Milgrom, H., & Rand, C. (1997).Nonadherence in asthmatic patients: Is there
a solution to the problem? Annals of Allergy, Asthma, and Immunology, 79, 177185. doi: 10.1016/S1081-1206(10)63001-3
Berkanovic, E., Hurwicz, M.L., & Lachenbruch, P.A. (1995). Concordant and discrepant
views of patients’ physical functioning. Arthritis Care Research, 8, 95-101.
Bethesda, M.D. (1997b). National Asthma Education and Prevention Program (NAEPP)
expert panel report II: Guidelines for the diagnosis and management of asthma.
National Institutes of Health, National Heart, Lung and Blood Institute.
Borders, A., Earleywine, M., & Huey, S. (2004). Predicting problem behaviors with
multiple expectancies: Expanding expectancy-value theory. Adolescence, 39, 539550.

144

Bonner, S., Zimmerman, B.J., Evans, D., Irigoyen, M., Resnick, D., & Mellins, R.B.
(2002). An individualized intervention to improve asthma management among
urban Latino and African-American families. Journal of Asthma, 39, 493-500.
doi: 10.1081/JAS-120004913
Bosley, C.M., Fosbury, J.A., & Cochrane, G.M. (1995). The psychological factors
associated with poor compliance with treatment in asthma. European Respirology
Journal, 8, 889-904. doi: 10.1183/09031936.95.08060899
Brannon, L. & Feist, J. (2004). Health Psychology, 5th Edition. Belmont, CA: Thompson
Wadsworth.
Brenner, M., Curbow, B., & Legro, M. (1995). The proximal-distal continuum of
multiple health outcomes measures: The case of cataract surgery. Medical Care,
33, AS236-244.
Burke, B., Arkowitz, H., & Menchola, M. (2003). The efficacy of Motivational
Interviewing: A meta-analysis of controlled clinical trials. Journal of Consulting
and Clinical Psychology, 71, 843-61. doi: 10.1037/0022-006X.71.5.843
Buss, D.M., Abbott, M., Angleitner, A., Biaggio, A., Blanco-Villasenor, A.,
BruchonSchweitzer, M., et al. (1990). International preferences in selecting
mates: A study of 37 societies. Journal of Cross Cultural Psychology, 21, 5-47.
doi:10.1177/0022022190211001
Catz, S.L., Kelly, J.A., Bogart, L.M., Genosch, E.G., & McAuliffe, T.L. (2000). Patterns,
correlates, and barriers to medication adherence among persons prescribed new
treatments for HIV disease. Health Psychology, 19, 124-133. doi:
10.1037//0278133.19.2.124

145

Chang, K., Chan, K., Chang, S., Yang, M., & Chen, T.H. (2008). Decision analysis for
epidural labor analgesia with Multiattribute Utility (MAU) Model. Clinical
Journal of Pain, 24, 265-272. doi: 10.1097/AJP.0b013e31816111a5
Chapman, G.B., & Elstein, A.S. (2000). Cogntive process and biases in medical decision
making. In G.B. Chapman & F.A. Sonnenberg (Eds.), Decision Making in Health
Care: Theory, Psychology, and Applications (pp.183- 210). New York:
Cambridge University Press.
Chapman, G.B, & Sonnenberg, F.A. (2000). Introduction. In G.B. Chapman and F.A.
Sonnenberg (Eds.), Decision Making in Health Care: Theory, Psychology, and
Application (pp. 3-19). Cambridge: Cambridge University Press.
Charles, C., Gafni, A., & Whelen, T. (1999). Decision-making in the physician–patient
encounter: revisiting the shared treatment decision-making model. Social Science
and Medicine, 49, 651–661. doi: 10.1016/S0277-9536(99)00145-8
Chesney, A.P., Brown, K.A., Poe, C.W., & Gary, H.E. (1983). Physician-patient
agreement on symptoms as a predictor of retention in outpatient care. Hospital
and Community Psychiatry, 34, 737-739.
Ciechanowski, P.S., Katon, W.J., Russon, J.E., & Walker, E.A. (2001). The patientprovider relationship: Attachment theory and adherence to treatment for diabetes.
American Journal of Psychiatry, 158, 29-35. doi.org/10.1176/appi.ajp.158.1.29
Clark, A. M., Fredyberg, C. N., McAlister, F. A., Tsuyuki, R. T., Armstrong, P. W., &
Strain, L. A. (2009). Patient and informal caregivers’ knowledge of heart failure:
necessary but insufficient for effective self-care. European Journal of Heart
Failure, 11, 617-621. doi: 10.1093/eurjhf/hfp058

146

Claxton, A.J., Cramer, J., & Pierce, C. (2001). A systematic review of the associations
between dose regimens and medication compliance. Clinical Therapy, 23, 12961310. doi: 10.1016/S0149-2918(01)80109-0
Clifford, S., Barber, N., & Horne, R. (2008). Understanding different beliefs held by
adherers, unintentional nonadherers, and intentional nonadherers: Application of
the Necessity-Concerns Framework. Journal of Psychosomatic Research, 64, 4146. doi:10.1016/j.jpsychores.2007.05.004
Cohen, J.L., Mann, D.M., Wisnivesky, J.P., Horne, R., Leventhal, H., Musumeci-Szabo,
T.J., et al. (2009). Assessing the validity of self-reported medication adherence
among inner-city asthmatic adults: The Medication Adherence Report Scale for
Asthma. Annals of Asthma, Allergy and Immunology, 103, 325-331. doi:
10.1016/S1081-1206
Cooper, A., Lloyd, G.S., Weinman, J. & Jackson, G.(1999). Why patients do not attend
cardiac rehabilitation: Role of intentions and illness beliefs. Heart, 82, 234-236.
doi:10.1136/hrt.82.2.234
Cote, J., Cartier, A., Robichaud, P., Boutin, H., Malo, J.L., Rouleau, M., et al. (1997).
Influence on asthma morbidity of asthma education programs based on selfmanagement plans following treatment optimization. American Journal of
Respiratory Critical Care Medicine, 49, 1509-1514.
Couturaud, F., Proust, A., Frachon, I., Dewitt, J.D., Oger, E., Quiot, J.J., et al. (2002).
Education and self-management: a one-year randomized trial in stable adult
asthmatic patients. Journal of Asthma, 39, 493-500. doi: 10.1081/JAS-120004913

147

Crawford, M., Rutter, D., Manley, C., Weaver, T., Bhui, K., Fulop, N., et al., (2002).
Systematic review of involving patients in the planning and development of
health care. British Medical Journal, 325, 1263–1266. doi:
10.1136/bmj.325.7375.1263
Crzan, K. & Orme, B. (2000). An overview and comparison of design strategies for
choice-based conjoint analysis. Sawtoothe Software, Washington, Washington.
Dawson, N.V., & Arkes, H.R. (1987). Systematic errors in medical decision making:
Judgment limitation. Journal of General Internal Medicine, 2, 183-187.
Devine, E.C., & Reifschneider, E. (1995). A meta analysis of the effects of
psycheducational care in adults with hypertension. Nursing Research, 44, 237245. doi: 10.1097/00006199-199507000-00009
DiMatteo, M.R. (2004): Variations in patients' adherence to medical recommendations: a
quantitative review of 50 years of research. Medical Care, 42, 200-209.
doi:10.1186/1472-6963-7-55
Eagly, A., & Chaiken, S. (1996). Attitude structure and function. In The Handbook of
Social Psychology. D.Gilbert, S. Fiske, & G. Lindzey (Eds.). New York:
McGraw Hill.
Edwards, A., & Elwyn, G. (2009). Shared decision-making in health care: Achieving
evidence-based patient choice. Second Edition. London: Oxford University Press.
Elliott, R.A. (2006). Poor adherence to anti-inflammatory medication in asthma: Reasons,
challenges, and strategies for improved disease management. Practical Disease
Management, 14, 223-233. doi: 10.1097/MCP.0b013e3282f4070c

148

Farmer, A.J., Kinmonth, A.L., & Sutton, S. (2006). Measuring beliefs about taking
hypglycaemic medication among people with Type 2 diabetes. Diabetic Medicine,
23, 265-270. doi: 10.1111/j.1464-5491.2005.01778.x
Field, A. (2009). Discovering statistics using SPSS, 3rd Edition. London, UK; Sage.
Fortune, D.G., Richards, H.L., Main, C.J., & Griffiths, C.E.M. (2000). Pathological
worrying, illness perceptions and disease severity in patients with psoriasis.
British Journal of Health Psychology, 5, 71-82.
doi:10.1093/rheumatology/kem060
Fowler, C., & Baas, L.S. (2006). Illness representations in patients with chronic kidney
disease on maintenance and hemodialysis. Nephrology and Nursing Journal, 33,
173-186. doi: 10.1080/14768320701246535
French, D.P., Cooper, A., Weinman, J. (2006). Illness perceptions predict attendance at
cardiac rehabilitaion following acute myocardial infarction: A systematic review
with meta-analysis. Journal of Psychosomatic Research, 61, 757-767.
doi:10.1016/j.jpsychores.2006.07.029
Frostholm, L., Oernboel, E., Christensen, K.S., Toft, T., Olesen, F., Weinman, J., et al.
(2007). Do illness perceptions predict health outcomes in primary care patients? A
2-year follow up study. Journal of Psychosomatic Research, 62, 129-138.
doi:10.1016/j.jpsychores.2006.09.00
Garret, J., Fenwick, J.M., Taylor, G., Mitchell, E., Stewart, J., & Rea, H.(1994).
Prospective controlled evaluation of the effect of a community based asthma
education centre in a multiracial working class neighbourhood. Thorax, 49, 876983. doi: 10.1136/thx.49.10.976

149

Gellaitry, G., Cooper, V., Davis, C., Fisher, M., Date, H.L., & Horne, R. (2005). Patients’
perception of information about HAART: Impact on treatment decisions. AIDS
Care, 17, 367-376. doi: 10.1080/09540120512331314367
Gibson, P.G. & Boulet, L.P. (2001). Role of asthma education. In Fitzgerald, J.M, Ernst
P., Boulet, L.P., O’Bryne, P.M. (Eds.). Evidence-Based Asthma Management.
London: B.C. Decker Inc.
Gibson, P.G., & Powell, H. (2004). Written action plans for asthma: An evidence-based
review of the key components. Thorax, 59, 94-99.
doi:10.1136/thorax.2003.011858
Gibson, P.G., Ram, F.S., & Powell, H. (2003). Asthma education. Respiratory Medicine,
97, 1036-1044. doi:10.1016/S0954-6111(03)00134-3
Grant, E.N., Moy, J.N., Turner-Roan, K., Daugherty, S.R., & Weiss, K.B. (1999).
Asthma care practices, perceptions and beliefs of Chicago-area primary care
physicians. Chicago asthma surveillance initiative project team. Chest, 116, 145S154S. doi: 10.1378/chest.116.suppl_2.145S
Gravel, K., Legare, F., and Graham, I. (2006). Barriers and facilitators to implementing
shared decision-making in clinical practice: A systematic review of health
professionals’ perceptions. Implementation Science, 1, 16. doi:10.1186/17485908-1-16
Haggar, M.S., & Orbell, S. (2003). A meta-analytic review of the Common-Sense Model
of illness representations. Psychology and Health, 18, 141-184. doi:
10.1080/088704403100081321

150

Haggar, M.S., & Orbell, S. (2006). Illness representation and emotion in people with
abnormal screening results. Psychology and Health, 21, 183-209. doi:
10.1080/14768320500223339
Hahn, A., & Renner, B. (1998). Perceptions of health risk: How smoker status affects
defensive optimism. Anxiety, Stress, and Coping, 11, 93-112. doi:
10.1080/10615809808248307
Halimi, L., Pry, R., Pithon, G., Godard, P., Varrin, M., Chanez, P. (2010). Severe asthma
and adherence to peak flow monitoring: Longitudinal assessment of psychological
aspects. Journal of Psychosomatic Research, 69, 331-340.
doi:10.1016/j.jpsychores.2010.02.007
Halm, E.A., Mora, P., Leventhal, H. (2006). No symptoms, no asthma: The acute
episodic disease belief is associated with poor self-management among inner-city
adults with persistent asthma. Chest, 129, 573-580. doi: 10.1378/chest.129.3.573
Hampson, S.E., Glasgow, R.E., & Toobert, D.J. (1990). Personal models of diabetes and
their relations to self-care activities. Health Psychology, 9, 632-646. doi:
10.1037/0278-6133.9.5.632
Hancox, R.J., Le Souef, P.N., Anderson, G.P., Reddel, H.K., Chang, A.B., & Beasley, R.
(2010). Asthma: Time to confront some inconvenient truths. Respirology, 15,
194-201. doi: 10.1111/j.1440-1843.2009.01700.x
Hand, C.H., & Bradley, C. (1996). Health beliefs of adults with asthma: Toward an
understanding of the difference between symptomatic and preventative use of
inhaler treatment. Journal of Asthma, 33, 331-338. doi: 10.1037/0022006X.70.3.691

151

Haughney, J., Cotton, P., Rosen, J., Morrison, K., & Price, D. (2007). The use of a
modification of the Patient Enablement Instrument in asthma. Primary Care
Respiratory Journal, 16, 89-92. doi: http://dx.doi.org/10.3132/pcrj.2007.00014
Haynes, R.B., Ackloo, E., Sahota, N., McDonald, H.P., & Yao, X. (2008). Interventions
for enhancing medication adherence. Cochrane Database of Systematic Reviews,
2, 1-164. doi: 10.1097/HJH.0b013e32832d50ef
Haynes, R.B., Taylor, D.W., Sackett, D.L., Gibson, E.S., Bernholtz, C.D., & Mukherjee,
J. (1980). Can simple clinical measures detect patient non-compliance?
Hypertension, 2, 757-764.
Heijmans, M., & de Ridder, D. (1998). Assessing illness representations of chronic
illness: Explorations of their disease specific nature. Journal of Behavioral
Medicine, 21, 485- 503.
Heisler, M., Bourknight, R.R., Hayward, R.A., Smith, D.M., Kerr, E.A. (2002). The
relative importance of physician communication, participatory decision making,
and patient understanding in diabetes self-management. Journal of General
Internal Medicine, 17, 243-252. doi: 10.1046/j.1525-1497.2002.10905.x
Hettema, J., Steele, J., & Miller, W.R. (2005). Motivational interviewing. Annual Review
of Clinical Psychology, 1, 91-111. doi: 10.1146/annurev.clinpsy.1.102803.143833
Ho, J., Bender, B.G., Gavin, L.A., O’Conner, S.L., Wamboldt, M.Z., & Wambolt, F.S.
(2003). Relations among asthma knowledge, treatment adherence and outcome.
Journal of Allergy and Clinical Immunology, 111, 498-502.
doi:10.1067/mai.2003.160

152

Holgate, S.T., Price, D., & Valovirta, E. (2006). Asthma out of control? A structured
review of recent patient surveys. BMC Pulmonary Medicine, 6, S2. doi:
10.1186/1471-2466-6-S1-S2
Horne, R. (2006). Compliance, adherence, and concordance: Implications for asthma
treatment. Chest, 130, S65-S72. doi: 10.1378/chest.130.1_suppl.65S
Horne, R., Price, D., Cleland, J., Costa, R., Covey, D., Gruffydd-Jones, K., et al. (2007).
Can asthma control be improved by understanding the patient’s perspective? BMC
Pulmonary Medicine, 7, 8-18. doi:10.1186/1471-2466-7-8
Horne, R., & Weinman, J. (2002). Self-regulation and self-management in asthma:
Exploring the role of illness perceptions and treatment beliefs in explaining nonadherence to preventer medication. Psychology and Health, 17, 17-32. doi:
10.1080/08870440290001502
Horne, R., Weinman, J., & Hankins, M. (1999). The Beliefs about Medicines
Questionnaire (BMQ): The development and evaluation of a new method for
assessing the cognitive representation of medication. Psychology and Health, 14,
1-24. doi: 10.1080/08870449908407311
Insel, K.C., Meek, P.A., & Leventhal, H. (2005). Differences in illness representation
among pulmonary patients and their providers. Journal of Health Psychology, 10,
147-162. doi:10.1177/1359105305048561
Jackson, J., Kincey, J., Fiddler, M., Creed, F., & Tomenson, B. (2004). Differences
between out-patients with physical disease and those with medically unexplained
symptoms with respect to patient satisfaction, emotional distress and illness

153

perception. British Journal of Health Psychology, 9, 433-446. doi:
10.1348/1359107042304597
Janson, S., Hardie, G., Fahy, J., & Boushey, H. (2001). Use of biological markers of
airway inflammation to detect the efficacy of nurse-delivered asthma education.
Heart & Lung, 30, 39-46. doi: 10.1067/mhl.2001.110290
Janz, N.K., & Becker, M.H. (1984). The health belief model: A decade later. Health
Education Quarterly, 11, 1-47. doi: 10.1177/109019818401100101
Jessop, D.C., & Rutter, D.R. (2003). Adherence to asthma medication: The role of illness
representations. Psychology and Health, 18, 595-612. doi:
10.1080/0887044031000097009
Jessop, D.C., Rutter, D.R., Sharma, D., & Albery, P. (2004). Emotional and adherence to
treatment in people with asthma: An application of the emotional stroop
paradigm. British Journal of Psychology, 95, 127-147. doi:
10.1348/000712604773952386
Jinhee, P., Jackson, J., Skinner, E., Ranghell, K., Saiers, J., & Cherney, B. (2010). Impact
of an adherence intervention program on medication adherence barriers, asthma
control, and productivity/daily activities in patients with asthma. Journal of
Asthma, 47, 1072-1077. doi: 10.3109/02770903.2010.485660
Juniper E.F., Guyatt G.H., Cox F.M., Ferrie P.J., King D.R. (1999). Development and
validation of the Mini Asthma Quality of Life Questionnaire. European
Respirology Journal, 14, 32-38. doi: 10.1034/j.1399-3003.1999.14a08.x
Kellett, N., West, F., & Finlay, A.Y. (2006). Conjoint analysis: A novel, rigorous tool for
determining patient preferences for topical antibiotic treatment for acnes. A

154

randomized controlled trial. British Journal of Dermatology, 154, 524-532. doi:
10.1111/j.1365-2133.2005.07047.x
Kemp, S., Morley, S., & Anderson, E. (1999). Coping with epilepsy: Do illness
representations play a role? British Journal of Clinical Psychology, 38, 43-58.
doi: 10.1348/014466599162656
Khachani, I., Harmouche, H., Ammouri, W., Rhoufrani, R., Zerouali, L. Abouqual, R., et
al., (2011). Impact of psychoeducative intervention on adherence to HAART
among low-literacy patients in a resource-limited setting: The case of an Arab
country- Morocco. Journal of the international Association of Physicians in AIDS
care. doi: 10.1177/1545109710397891.
Kahneman, D.; Tversky, A. (1979). Prospect theory: An analysis of decisions under risk.
Econometrica, 47, 263–291. doi:10.2307/1914185
Kinnersley, P., Edwards, A., Hood, K., Cadbury, N., Ryan, R., Prout, H., et al., (2007).
Interventions before consultations for helping patients address their information
needs [review]. Cochrane Database of Systematic Reviews, 3, CD004565. doi:
10.1002/14651858.CD004565.pub2
Kline, R.B. (2009) Becoming a behavioral science researcher: A guide to producing
research that matters. New York, NY: Guilford University Press.
Kravitz, R.L., & Melnikow, J. (2004). Medical adherence research: Time for a change in
direction? Medical Care, 42, 197-199. doi: 10.1097/01.mlr.0000115957.44388.7c
Kripalani, S., Yao, X., & Haynes, R.B. (2007). Interventions to enhance medication
adherence in chronic medical conditions: A systematic review. Archives of
Internal Medicine, 26, 540-550. doi: 10.1001/archinte.167.6.540

155

Kritikos, V., Krass, I., Chan, H.S., & Bosnic-Anticevich, S.Z. (2005). The validity and
reliability of two asthma knowledge questionnaires. Journal of Asthma, 42, 795801. doi: 10.1080/02770900500308627
Kuhl, J. (2000). A functional-design approach to motivation and volition: The dynamics
of personality systems interactions. In M. Boekaerts, P.R. Pintrich, & M. Zeidner
(Eds.), Self-regulation: Directions and Challenges for Future Research (pp. 111169). New York: Academic Press.
Lacroix, J.M., Martin, B., Avendano, M., & Goldstein, R. (1991). Symptom schemata in
chronic respiratory patients. Health Psychology, 10, 268-273. doi: 10.1037/02786133.10.4.268
Lanscar, E.J., Hall, J.P., King, M., Kenny, P., Louviere, J.J., Fiebig, D.G., et al. (2007).
Using discrete choice experiments to investigate subject preferences for
preventative asthma medication. Respirology, 12, 127-136. doi: 10.1111/j.14401843.2006.01005.x
Lanscar, E. & Louviere, J. (2008). Conducting discrete choice experiments to inform
healthcare decision making: A user’s guide. Pharmacoeconomics, 26, 661-667.
Lau, R.R., Bernard, T.M., & Hartman, K.A. (1989). Further explorations of commonsense representations of common illness. Health Psychology, 8, 195-219. doi:
10.1037//0278-6133.8.2.195
Lau-Walker, M. (2006). Predicting self-efficacy using illness perception components: A
patient survey. British Journal of Health Psychology, 11, 643-661. doi:
10.1348/135910705X72802

156

Lehrer, P., Feldman, J., Giardino, N., Song, H.S., & Schmaling, K. (2002). Psychological
aspects of asthma. Journal of Consultation and Clinical Psychology, 70, 691-711.
doi: 10.1037//0022-006X.70.3.691
Lemiere, C., Bai, T., Balter, M., Bayliff, C., Becker, A., Boulet, L.P., et al. (2003). Adult
asthma consensus guidelines. Canadian Journal of Respirology, 11(Suppl A), 9A18A.
Leventhal, H., Brissette, I., & Leventhal, E.A. (2003). The common-sense model of selfregulation of health and illness. L. Cameron & H. Leventhal (Eds.), The selfregulation of health and illness behaviour (pp. 42-65). New York: Routledge.
Leventhal, H., Diefenbach, M., & Leventhal, E.A. (1992). Illness-cognition: Using
common-sense to understand treatment adherence and affect cognition
interactions. Cognitive Therapy and Research, 16, 143-163. doi:
10.1007/BF01173486
Leventhal, H., Meyers, D., & Nerenz, D.R. (1984). The common-sense representatikons
of illness danger. In Rachman (Ed.), Medical psychology: Volume 2 (pp. 7-30).
New York: Pergamon.
Leventhal, H., Nerenz, D.R., & Steele, D.J. (1984). Illness representations and coping
with health threats. In A. Baum, S. Taylor, & Singer (Eds.), Handbook of
psychology and health: Volume IV social psychological aspects of health (pp.
219-252). New Jersey: Lawrence Erlbaum Associates.
Leventhal, H., & Cameron, L. (1987). Behavioral theories and the problem of
compliance. Patient Education and Counseling, 10, 117-138. doi: 10.1016/07383991(87)90093-0

157

Leventhal, H., Weinman, J., Leventhal, E., & Phillips, A. (2008). Health psychology: The
search for pathways between behavior and health. Annual Review of Psychology,
59, 477-505. doi: 10.1146/annurev.psych.59.103006.093643
Levy, M.L., Robb, M., Allen, J., Doherty, C., Bland, J.M., & Winter, R.J. (2000). A
randomized controlled evaluation of specialist nurse education following accident
and emergency department attendance for acute asthma. Respiratory Medicine,
94, 900-908. doi: 10.1053/rmed.2000.0861
Ley, P. (1997). Compliance among patients. In A. Baum, S. Newman, J. Weinman,
R.West, & C. McManus (Eds.), Cambridge handbook of psychology, health and
medicine (pp. 281-284). Cambridge, UK: Cambridge University Press.
Littell, J. H., & Girvin, H. (2002). Stages of change: A critique. Behavior Modification,
26, 223–273. doi: 10.1177/0145445502026002006
Little, P., Everitt, H., Williamson, I., Warner, G., Moore, M., Gould, C., Ferrier, K., &
Payne, S. (2001). Observational study of effect of patient centredness and positive
approach on outcomes of general practice consultations. British Medical Journal,
323, 908-811. doi: 10.1136/bmj.323.7318.908
Lopez-Vina, A., & Castillo-Arevalo, F.D. (2000). Influence of peak expiratory flow
monitoring on an asthma self-management education program. Respiratory
Medicine, 94, 760-764. doi: 10.1053/rmed.2000.0815
Luoto, R., Kinnunen, T.I., Aittasaio, M., Kolu, P., Raitanen, J., Ojala, K., et al. (2011).
Primary prevention of gestational diabetes mellitus and large-for-gestational-age
newborns by lifestyle counseling: A cluster-randomized controlled trial. PLoS
Medicine, 8, e1001036. doi: 10.1371/journal.pmed.1001036

158

Martin, L., Haskard-Zolnierek, K., & Dimatteo, M. (2010). Health behavior change and
treatment adherence. New York, New York: Oxford University Press.
McHorney, C.A. (2009). The adherence estimator: A brief, proximal screener for patient
propensity to adhere to prescription medication for chronic diseases. Current
Medical Research and Opinion, 25, 215-238. doi: 10.1185/03007990802619425
McHorney, C.A., & Gadkari, A.S. (2010). Individual patients hold different beliefs to
prescription medications to which they persist vs nonpersist and persist vs
nonfulfill. Patient Preference and Adherence, 4, 187-195. doi:
10.2147/PPA.S10603
McHorney, C.A., & Spain, C.V. (2011). Frequency of and reasons for medication nonfulfillment and non-persistence among American adults with chronic disease in
2008. Health Expectancy, 14, 307-320. doi: 10.1111/j.1369-7625.2010.00619.x
McKenzie, L., Cairns, J., & Osman, L. (2001). Symptom-based outcome measures for
asthma: The use of discrete choice methods to assess patient preferences. Health
Policy, 57, 193-204. doi: 10.1016/S0168-8510(01)00128-2
McTaggart-Cowan, H.M., Shi, P., FitzGerald, J.M., Anis, A., H., Kopec, J.A., Bai, T.R.,
et al. (2008). An evaluation of patients' willingness to trade symptom-free days
for asthma-related treatment risks: A discrete choice experiment. Journal of
Asthma, 45, 630- 638. doi: 10.1080/02770900802126990
Mead, N., & Bower, P. (2002). Patient-centred consultations and outcomes in primary
care: A review of the literature. Patient Education and Counseling, 48, 51-61. doi:
10.1016/S0738-3991(02)00099-X

159

Michie, S., Miles, J., Weinman, J. (2003). Patient centredness in chronic illness: What is
it and does it matter? Patient Education and Counselling, 51, 197-206. doi:
10.1016/S0738-3991(02)00194-5
Miller, W., and Rollnick, S. (2002). Motivational interviewing: Preparing people for
change. New York: Guilford Press.
Morice, A.H., & Wrench, C. (2001). The role of the asthma nurse in treatment
compliance and self-management following hospital admission. Respiratory
Medicine, 95, 851-856. doi: 10.1053/rmed.2001.1166
Moss-Morris, R., Humphrey, K., Johnson, M.H., & Petrie, K.J. (2007). Patients’
perceptions of their pain condition across a multidisciplinary pain management
program: Do they change and if so does it matter? Clinical Journal of Pain, 23,
558-64. doi: 10.1097/AJP.0b013e318093fcab
Moss-Morris, R., Weinman, J., Petrie, K.J., Horne, R. Cameron, L.D., & Buick, D.
(2002). The revised illness perception questionnaire (IPQ-R). Psychology and
Health, 17, 1-16. doi: 10.1080/08870440290001494
Murphy, H., Dickens, C., Creed, F., & Bernstein, R. (1999). Depression, illness
perception and coping in rheumatoid arthritis. Journal of Psychosomatic
Research, 46, 155-164. doi: 10.1016/S0022-3999(98)00073-7
O’Byrne, P.M. (2010). Global guidelines for asthma management: Summary of the
current status and future challenges. Polish Archives of Internal Medicine, 120,
511-516.
O’Carroll, R., Whittaker, J., Hamilton, B., Johnston, M., Sudlow, C. & Dennis, M.
(2011). Predictors of adherence to secondary preventive medication in stroke

160

patients. Annals of Behavioral Medicine, 42, 383-390. doi: 10.1007/s12160-0109257-6
Ohm, R., & Aaronson, L.S. (2006). Symptom perception and adherence to asthma
controller medications. Journal of Nursing Scholarship, 38, 292-297. doi:
10.1111/j.1547-5069.2006.00116.x
Oldenmenger, W.H., Echteld, M.A., de Wit, R., Sillevis Smitt, P.A.E., Stronks, D.L.,
Stoter, G., et al. (2007). Analgesic adherence measurement in cancer patients:
Comparison between electronic monitoring and diary. Journal of Pain and
Symptom Management, 34, 639-647. doi: 10.1016/j.jpainsymman.2007.01.015
Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of
Medicine, 353, 487-497. doi: 10.1056/NEJMra050100
Payne, J.W., Betteman, J.R., & Johnson, E.J. (1992). Behavioral decision research: A
constructive process perspective. Annual Review of Psychology, 43, 87-131. doi:
10.1146/annurev.ps.43.020192.000511
Peterson, C., & Seligman, M.E.P. (2004). Character strengths and virtues: A handbook
and classification. Oxford: Oxford University Press.
Petrie, K.J., Cameron, L.D., Ellis, C.J., Buick, D., & Weinman, J. (2002). Changing
illness perceptions after myocardial infarction: An early intervention randomized
controlled trial. Psychosomatic Medicine, 64, 580-586.
Petrie, K.J., Jago, L.A., & Devcich, D.A., (2007). The role of illness perceptions in
patients with medical conditions. Current Opinion in Psychiatry, 20, 163-167.
doi: 10.1097/YCO.0b013e328014a871

161

Phillips, K.A., & Rosenblatt, A. (1992). Speaking in tongues: Integrating economics and
psychology into health and mental health services outcome research. Medical
Care Review, 49, 191- 231. doi: 10.1177/002570879204900204
Phillips, K.A., Johnson, F.R., & Maddala, T. (2002). Measuring what people value: A
comparison of “attitude” and “preference” surveys. Health Services Research, 37,
1659-1679. doi: 10.1111/1475-6773.01116
Phillips, L.A. (2009, April). Common-Sense model mastery: How physicians can obtain
better patient-adherence and coutocomes. In H. Leventhal (Chair), How does the
clinician’s recognition of patient’s mental models affect health outcomes?
Symposium conducted at the meeting of the Society of Behavioral Medicine,
Montreal, QC.
Preacher, K. J., & Leonardelli, G. J. (March, 2001). Calculation for the Sobel test: An
interactive calculation tool for mediation tests [online].
Prochaska, J.O., & DiClemente, C.C. (1983). Stages and processes of self-change of
smoking: Toward an integrative model of change. Journal of Consulting and
Clinical Psychology, 51, 390-395. doi: 10.1037//0022-006X.51.3.390
Prochaska, J. O., Redding, C. A., & Evers, K. E. (2002). The transtheoretical model and
stages of change. In K. Glanz, B. K. Rimer, & F. M. Lewis (Eds.), Health
behavior and health education: Theory, research, and practice ( pp. 60–84). San
Francisco: Jossey-Bass.
Rand, C.S., & Wise, R.A. (1994). Measuring adherence to asthma medications. American
Journal of Respiratory and Critical Care Medicine, 149, 69-76. doi:
10.1164/ajrccm/149.2_Pt_2.S69

162

Redelmeier, D.A., Koehler, D.J., Liberman, V., & Tversky, A. (1995). Probability
judgment in medicine: Discounting unspecified possibilities. Medical Decision
Making, 15, 227-230. doi: 10.1177/0272989X9501500305
Renner, B., Knoll, N., & Schwartzer, R. (2000). Age and body make difference in
optimistic health beliefs and nutritional behaviour. International Journal of
Behavioral Medicine, 7, 143-159. doi: 10.1207/S15327558IJBM0702_4
Ritz, T., Bobb, C., Edwards, M., Steptoe, A. (2001). The structure of symptom reports in
asthma: A reevaluation. Journal of Psychosomatic Research, 51, 639-645. doi:
10.1016/S0022-3999(01)00271-9
Roter, D.L., Hall, J.A., Merisca, R., Nordstrom, B., Cretin, D., & Svarstad, B. (1998).
Effectiveness of interventions to improve patient compliance: A meta-analysis.
Medical Care, 36, 1138-1161.
Ryan, M., Bate, A., Eastmond, C.J., & Ludbrook. (2001). Use of discrete choice
experiments to elicit preferences. Quality in Health Care, 10 (Suppl I), i55-i60.
doi: 10.1136/qhc.0100055
Ryan, M., & Farrar, S. (2000). Using conjoint analysis to elicit preferences for health
care. British Medical Journal, 320, 1530-1533. doi: 10.1136/bmj.320.7248.1530
Ryan, M., Scott, D.A., Reeves, C., Bate, A., van Teijlingen, E.R., Russell, E.M., et al.
(2001). Eliciting public preferences for healthcare: A systematic review of
techniques. Health Technology Assessment, 5, 1-186.
Rutter, C.L., & Rutter, D.R. (2007). Longitudinal analysis of the Illness Representation
Model in patients with irritable bowel syndrome (IBS). Journal of Health
Psychology, 12, 141-148. doi: 10.1177/1359105307071748

163

Schaffer , S.D., & Yarandi, H.N. (2007). Measuring asthma self-management knowledge
in adults. Journal of the American Academy off Nurse Practitioners, 19, 530-535.
doi: 10.1111/j.1745-7599.2007.00253.x
Schapira, M.M., Gilligan, M.A., McAuliffe, T.L., & Nattinger, A.B. (2004). Menopausal
hormone therapy decisions: Insights from a multi-attribute model. Patient
Education and Counseling, 52, 89-95. doi: 10.1016/S0738-3991(02)00266-5
Scharloo, M., Baatenburg de Jong, R.J., Langeveld, T. P. M., van Velzen-Verkaik, E.,
Doorn-op den Akker, M.M., Kaptein, A.A. (2005). Quality of life and illness
perceptions in patients with recently diagnosed head and neck cancer. Head and
Neck, 27, 857-863. doi: 10.1002/hed.20251
Scharloo, M., & Kaptein, A. (1997). Measurement of illness perceptions in patients with
chronic somatic illness: A review. Petrie & Weinman (Eds.), Perceptions of
Health and Illness (pp. 103-154). Amsterdam: Hardwood Academic Publishers.
Scharloo, M., Kaptein, A.A., Weinman, J., Hazes, J.M., Willems, L.N.A., Bergman, W.,
et al. (1998). Illness perceptions, coping and functioning in patients with
rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis. Journal
of Psychosomatic Research, 44, 573-585. doi: 10.1016/S0022-3999(97)00254-7
Schedlbauer, A., Schroeder, K, Peters, T.J., & Fahey, T. (2004). Interventions to improve
adherence to lipid lowering medication. Cochrane Database of Systematic
Reviews, 4, CD004371. doi: 10.1002/14651858.CD004371.pub2
Schiaffino, K.M., & Cea, C.D. (1995). Assessing chronic illness representations: The
implicit models of illness questionnaire. Journal of Behavioral Medicine, 18, 531549. doi: 10.1007/BF01857894

164

Schiaffino, K.M., Shawaryn, M.A., & Blum, D. (1998). Examining the impact of illness
representations on psychological adjustment to chronic illnesses. Health
Psychology, 17, 262-268. doi: 10.1037//0278-6133.17.3.262
Schroeder, K., Fahey, T., & Ebrahim, S. (2004). Interventions for improving adherence to
treatment in patients with high blood pressure in ambulatory settings. Cochrane
Database of Systematic Reviews, 2, CD004804. doi:
10.1002/14651858.CD004804
Schwartz, S. (1996). Valuing priorities and behavior: Applying a theory of integrated
value systems. In C. Seligman, J.M. Olson, M.P. Zanna (Eds.), The Psychology of
Values: The Ontario Symposium Volume 8. Hillsdale, New Jersey: Erlbaum.
Simone, M.J., Roberts, D.H., Irish, J.T., Neeman, N., Schultze, J.E., Lipsitz, L.A., Et al.,
(2011). An educational intervention for providers to promote bone health in high
risk older patients. Journal of the American Geriatrics Society, 59, 291-296. doi:
10.1111/j.1532-5415.2010.03240.x
Simpson RJ. (2006). Challenges for improving medication adherence. JAMA, 296, 26142616. doi: 10.1001/jama.296.21.jed60074
Singh, J., Cuttler, L., Shin, M., Silvers, J.B., & Neuhauser, D. (1998) Medical decision
making and the patient: Understanding preference patterns for growth hormone
therapy using conjoint analysis. Medical Care, 36, AS31-AS45.
Sodergren, S.C., & Hyland, M.E. (1999). Expectancy and asthma. In I. Kirsch (Ed.), How
expectancies shape experience (pp.197-212). Washington: American
Psychological Association.

165

Stephenson, B.J., Rowe, B.H., Haynes, R.B., Macharia, W.H., & Leon, G. (1993). Is this
patient taking the treatment as prescribed? Journal of the American Medical
Association, 269, 2779-2781. doi: 10.1001/jama.1993.03500210079036
Straka, R.J., Fish, J.T., Benson, J.R., & Sun, J.T. (1997). Patient self-reporting of
compliance does not correspond with electronic monitoring: An evaluation using
isosoride dinitrate as a model drug. Pharmacotherapy, 17, 126-132.
Street, D.J., & Burgess, L. (2007). The construction of optimal stated choice experiments:
Theory and methods. New Jersey: Wiley & Sons Inc.
Stuifbergen, A.K., Phillips, L., Voelmeck, W., & Browder, R. (2006). Illness perceptions
and related outcomes among women with fibromyalgia syndrome. Women’s
Health Issues, 16, 353-360. doi: 10.1016/j.whi.2006.05.003
Sud, A., Kline-Rogers, E.M., Eagle, K.A., Fang, J., Armstrong, D.F., Rangaragan, K., et
al. (2005). Adherence to medications by patients after acute coronary syndromes.
Annals of Pharmacotherapy, 39, 1792-1797. doi: 10.1345/aph.1G249
Sutton, S.R. (1982). Fear arousing communications: A critical examination of theory and
research. In J.R. Eiser (Ed.), Social psychology and behavioral medicine (pp. 303338). New York: Wiley.
Sweeney, K.G., Edwards, K., Stead, J., & Halpin, D. (2001). A comparison of
professionals’ and patients’ understanding of asthma: Evidence of emerging
dualities? Journal of Medical Ethics: Medical Humanities, 27, 20-25. doi:
10.1136/mh.27.1.20

166

Tanner, E.K.W., & Feldman, R.H.L. (1997). Strategies for enhancing appointment
keeping in low-income chronically ill clients. Nursing Research, 46, 342-344. doi:
10.1097/00006199-199711000-00008
Taylor, V.A., & Bower, A.B. (2004). Improving product instruction compliance: “If you
tell me why, I might comply”. Psychology and Marketing, 21, 229-245. doi:
10.1002/mar.20003
Tetlock, P.E. (1986). A value pluralism model of ideological reasoning. Journal of
Personality and Social Psychology, 50, 819-827. doi: 10.1037//00223514.50.4.819
Tetlock, P.E., Peterson, R.S., & Lerner, J.S. (1996). Revising the Value Pluralism Model:
Incorporating social content and context postulates. In C. Seligman, J.M. Olson,
M.P. Zanna (Eds.), The Psychology of Values: The Ontario Symposium Volume 8.
Hillsdale, New Jersey: Erlbaum.
Thier, S.L., Yu-Isenberg, K.S., Leas, B.F., Cantrell, C.R., DeBussey, S., Goldfarb, N.I.,
& Nash, D.B. (2008). In chronic disease, nationwide data show poor adherence by
patients to medication and by physicians to guidelines. Managed Care, 17, 48-52.
Trivedi, R.B., Ayotte, B.J., Thorpe, C.T., Edelman, D., & Bosworth, H.B. (2010). Is there
a nonadherent subtype of hypertensive patient? A latent class analysis approach.
Patient Preferences and Adherence, 21, 255-262. doi:
http://dx.doi.org/10.2147/PPA.S11335
Tversky, A., & Kahneman, D., (1983). Extensional versus intuitive reasoning: The
conjunction fallacy in probability judgment. Psychological Review, 90, 293-315.
doi: 10.1037/0033-295X.90.4.293

167

van Dumlen, S., Sluijs, E., van Dijk, L., de Ridder, D., Heerdink, R., & Bensing, J.
(2007). Patient adherence to medical treatment: a review of reviews. BMC Health
Services Research, 7, 55-68. doi: 10.1186/1472-6963-7-55
van Helvoort-Postulart, D., van der Weijden, T., Dellaert, B.G.C., de Kok, M., von
Meyenfeldt, M.F., & Dirksen, C.D. (2009). Investigating the complementary
value of discrete choice experiments for the evaluation of barriers and facilitators
in implementation research: A questionnaire survey. Implementation Science, 4,
1-12. doi:10.1186/1748-5908-4-10
Van Til, J.A., Stiggelbout, A.M., & Ijzerman, M.J. (2009). The effect of information on
preferences stated in choice-based conjoint-analysis. Patient Education and
Counselling, 74, 264-271. doi: 10.1016/j.pec.2008.08.025
Vermunt, J. K. & Magidson, J. (2005). Latent GOLD 4.0 User's Guide, Belmont
Massachussetts: Statistical Innovations Inc.
Vitolins, M., Rand, C., Rapp, S., Ribisl, P., & Sevick, M. (2000). Measuring adherence to
behavioral and medical interventions. Controlled Clinical Trials, 21(Suppl. 5),
188S-194S. doi: 10.1016/S0197-2456(00)00077-5
Watson, D., Clark, L.A., & Tellegan, A. (1988). Development and validation of a brief
measure of positive and negative affect: The PANAS scales. Journal of
Personality and Social Psychology, 54, 1063-1070. doi: 10.1037//00223514.54.6.1063
Wearden, A., & Peters, S. (2008). Therapeutic techniques for interventions based on
Leventhal’s common sense model. British Journal of Health Psychology, 13, 189193. doi: 10.1348/135910708X295613

168

Weinstein, N.D. (1980). Unrealistic optimism about future life events. Journal of
Personality and Social Psychology, 39, 806-820. doi: 10.1037/00223514.39.5.806
Wilson, G.T., & Schlam, T.R. (2004). The transtheoretical model and motivation
interviewing in the treatment of eating and weight disorders. Clinical Psychology
Review, 24, 361-378. doi:10.1016/j.cpr.2004.03.003
Wilson, S.R., Strub, P., Buist, A.S., Knowles, S.B., Lavori, P.W., Lapidus, J., et al.
(2010). Shared treatment decision making improves adherence and outcomes in
poorly controlled asthma. American Journal of Respiratory and Critical Care
Medicine, 181, 566-577. doi: 10.1164/rccm.200906-0907OC
World Health Organization (2003). Adherence to long-term therapies: Evidence for
action. Geneva, Switzerland: World Health Organization.

Appendix A
Results from Expert Panel and Additional Consultation
Domain
(Based on
Schaffer and
Yarandi)
Pathophysiology

Survey Question

Expert
Rating

1. People with
asthma can have
swollen and
inflamed airways
even when they
feel normal (T)

3.62

Pathophysiology

2. During an asthma
attack, the
muscles around
the airways
tighten and the
airways become
narrow (T)

3.90

Pathophysiology

3. Having swollen
airways does not
increase the risk
of having an
asthma attack (F)

3.43

Expert Comments

Suggested
Change

- Would include “to
a much lesser degree
b/c otherwise
implies lots of
inflammation
- Replace normal
with well

People with
asthma can have
swollen and
inflamed
airways even
when they feel
well (T)

- Reword to true
statement (4
comments)
-Suggest: “Having
swollen airways
increases the risk of
having an asthma
attack”

Having swollen
airways
increases the
risk of having
an asthma
attack (T)

Consultation
Comments

Final Question

People with
asthma can have
swollen and
inflamed
airways even
when they feel
well (T)
During an
asthma attack,
the muscles
around the
airways tighten
and the airways
become narrow
(T)
Having swollen
airways does not
increase the risk
of having an
asthma attack
(F)
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Domain
(Based on
Schaffer and
Yarandi)
Pathophysiology

Survey Question

4. Asthma is a
disease that comes
and goes (F)

Expert
Rating

3.43

Expert Comments

Suggested
Change

Consultation
Comments

Final Question

-“vary in level of
symptoms from none
to quite frequent, but
never go away
completely”
-“can be true”
-“not sure I am
interpreting this
correctly- I suspect
most people
associate the disease
with symptoms”
- Pam’s suggestion,
replace with :
Asthma is a chronic
condition

Asthma
symptoms come
and go but the
disease is
always there.
(T)

The comments
are correct BUT
we are not
asking a
scientific
audience and
don’t expect a
scientifically
correct answer.
So yes, asthma
can go into
remission but if
you are asking
the question to
someone with
current asthma
the correct lay
answer is that it
does not go
away, it is a
chronic
condition.
I like the
second
question.

Asthma is a
disease that does
not last for a
long time.

OR:
Asthma is a
disease that
does not last for
a long period of
time. (F)
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Domain
(Based on
Schaffer and
Yarandi)
Medications and
Their Effects

Medications and
Their Effects

Survey Question

5. The purpose of
steroid medication
inhalers is to stop
an asthma attack
when it happens
(F)

Expert
Rating

3.57

6. Controller inhalers 3.57
prevent asthma
attacks (T)

Expert Comments

Suggested
Change

Consultation
Comments

- Consider
simplifying (steroid
inhalers stop asthma
attacks when they
happen)
- “Depends on if the
attack is due to
bronchoconstriction,
exacerbation, or
inflammation”
- “ICS, in fact, may
diminish worsening
asthma symptoms (if
taken regularly) or if
combined with
LABA (ie symbicort
SMART). “

The purpose of
an inhaled
steroid
(controller) is to
stop an asthma
attack when it
starts (F)

An inhaled
steroid
(controller) will
quickly stop an
asthma attack
when it starts.
(F)

- Do people know
what a controller
medication is?
- Suggest replacing
prevent with reduce

Inhaled steroids
(controllers)
prevent asthma
attacks (T)

Final Question

The purpose of
steroid
medication
inhalers is to
stop an asthma
attack when it
happens. (F)

Inhaled steroids
(controllers)
prevent asthma
attacks. (T)
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Domain
(Based on
Schaffer and
Yarandi)
Medications and
Their Effects

Survey Question

7. People with
asthma do not
need to take their
daily steroid
medication if they
feel normal (F)

Expert
Rating

3.62

Medications and
Their Effects

8. Quick relief
3.86
medication should
be taken every day
(F)

Medications and
Their Effects

9. People with
asthma should
wait until their
symptoms are
really bad before
using a quick
relief medication
(F)

3.90

Expert Comments

- Specify inhaled
steroid
-“if their breathing
feels normal”
-Replace normal
with well or have no
symptoms

Suggested
Change

People with
asthma do not
need to take
their daily
inhaled steroids
(controller) if
they feel well
(F)
- Add: …should be
Quick relief
taken every day even medication
if you are feeling
should be taken
well
every day, even
-“This is true only if if people are
the steroid is needed feeling well (F)
to control the
eosinophilic
component”

Consultation
Comments

Final Question

People with
asthma do not
need to take
their daily
inhaled steroids
(controller) if
they feel well.
(F)
Quick relief
medications
should be taken
every day, even
if people are
feeling well. (F)

People with
asthma should
wait until their
symptoms are
really bad before
using quick
relief
medication. (F)
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Domain
(Based on
Schaffer and
Yarandi)
Medications and
Their Effects

Medications and
Their Effects

Survey Question

Expert
Rating

10. People may not
notice
improvements in
their breathing for
1-4 weeks after
they start using
inhaled steroids
(T)

3.52

11. It is okay to take
inhaled steroid
medication only
when people
notice themselves
wheezing (F)

3.57

Expert Comments

-“ With adequate
steroid treatment,
improvement occurs
rapidly- within days.
By a week it is near
maximal”
- “People may notice
improvements
within days”
-Suggest: “may not
notice improvements
in their symptoms
(cough, wheeze,
SOB…)”
- “What about
people with mild
intermittent asthma
who are told to start
inhaled ICS only if
increase in
symptoms”

Suggested
Change

Consultation
Comments

Final Question

Leave the same. People may not
notice
improvements in
their breathing
for 1-4 weeks
after they start
using inhaled
steroids. (T)

It is ok to take
inhaled steroids
(controllers)
only when
people notice
their symptoms
getting worse
(F)

Patients treated
on an interval
basis are the
minority.

It is okay to take
inhaled steroids
(controllers)
only when
people notice
their symptoms
getting worse.
(F)
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Domain
(Based on
Schaffer and
Yarandi)
Medications and
Their Effects

Technique

Technique

Survey Question

12. Steroid inhalers
will relieve an
asthma attack
within 20 minutes
(F)
13. People with
asthma should
breathe out
partially, but not
fully, just before
taking their
medication (F)
14. People with
asthma should
hold their breath
for 10 seconds
after each puff of
their inhaler (T)

Expert
Rating

Expert Comments

3.76

Suggested
Change

Inhaled steroids
will relieve an
asthma attack
within 20
minutes

3.57

3.71

- “No evidence that
holding breath for 10
seconds affects drug
distribution”
-Add: “should try
and hold”
-Pam suggests: 8-10
seconds to be
consistent with clinic

People with
asthma should
try to hold their
breath for 8-10
seconds after
each puff of
their inhaler

Consultation
Comments

Final Question

Inhaled steroids
will relieve an
asthma attack
within 20
minutes. (F)
People with
asthma should
breathe out
partially, but not
fully, just before
taking their
medication (F)
People with
asthma should
try to hold their
breath for 8-10
seconds after
each puff of
their inhaler. (T)
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Domain
(Based on
Schaffer and
Yarandi)
Technique

Survey Question

15. People with
asthma should
wait about one
minute between
puffs of their
quick relief
medication (T)

Expert
Rating

3.32

Symptoms

16. Frequent coughing 3.86
can be a symptom
of asthma (T)

Symptoms

17. Asthma may cause 4.00
wheezing during
exercise (T)

Expert Comments

Suggested
Change

Consultation
Comments

Final Question

- “Not just for quick
relief. Revise to: ‘…
between puffs of
their medication
when taking 2 or
more puffs from the
same inhaler’ “
- 30 seconds more
reasonable (esp. at
St. Joe’s clinic)
- What about when
with a Turbuhalerthis does not apply

People with
asthma should
rinse and gargle
after each use of
their inhaled
steroid (T)

The initial
question is too
problematic for
the reasons
cited.

1. People with
asthma should
wait about one
minute between
puffs of their
quick relief
medication (T)

- Cough at night is
more diagnostic

However,
(according to
the nurse) we
do try to
recommend at
the clinics,
therefore, I
would leave it
in.

2. People with
asthma should
rinse and gargle
after each use of
their inhaled
(controller)
steroid. (T)
Frequent
coughing can be
a symptom of
asthma. (T)
Asthma may
cause wheezing
during exercise.
(T)
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Domain
(Based on
Schaffer and
Yarandi)
Symptoms

Environmental
Triggers and
Controls

Survey Question

18. It is possible for
someone's asthma
to be worse
without noticing a
change in their
breathing (T)

Expert
Rating

Expert Comments

Suggested
Change

3.81

19. People with
3.86
asthma can
usually control
their symptoms by
taking medicine
and avoiding
things that make
their asthma worse
(T)

- Suggest adding
“appropriate
medication”
- Replace medicine
with “medication as
prescribed”
-Replace “things that
make asthma worse”
with triggers

Split:
1. People with
asthma can
usually control
their symptoms
by taking the
appropriate
medications
2. People can
usually control
their symptoms
by avoiding
things (triggers)
that make their
asthma worse

Consultation
Comments

Final Question

It is possible for
someone's
asthma to be
worse without
them noticing a
change in their
breathing. (T)
1. People with
asthma can
usually help
control their
symptoms by
avoiding things
(triggers) that
make their
asthma worse.
(T)
2. People with
asthma can
usually help
control their
symptoms by
taking the
appropriate
medications. (T)
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Domain
(Based on
Schaffer and
Yarandi)
Environmental
Triggers and
Controls

Survey Question

Expert
Rating

Expert Comments

Suggested
Change

20. Keeping bedroom
windows open at
night will help
prevent asthma
attacks (F)

3.86

Environmental
Triggers and
Controls

21. Bedrooms are the
most important
room to keep free
of dust and animal
fur or feathers (T)

3.71

- True if allergic to
those things
-Factually incorrect
-only if patient is
allergic to dust and
animal dander

Remove and
replace with:
Cold air can
make asthma
symptoms
worse (T)

Environmental
Triggers and
Controls

22. Carpets that smell
moldy can trigger
asthma (T)

3.48

-“smells don’t
trigger asthma”
-change can to might
-“molds are overrated”

Remove and
replace with
more generic:
Stress is never a
trigger for
worsening
asthma
symptoms (F)

Consultation
Comments

Taking steps to
reduce airborne
particles such
as dust and
animal dander
can improve
asthma
symptoms in
people allergic
to them. (T)
Molds can
trigger asthma
symptoms in
some people.
(T)

Final Question

Keeping
bedroom
windows open at
night will help
prevent asthma
attacks. (F)
Cold air can
make asthma
symptoms
worse. (T)

Molds can
trigger asthma
symptoms in
some people.
(T)
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Domain
(Based on
Schaffer and
Yarandi)
Environmental
Triggers and
Controls

Other Asthma
Facts
Other Asthma
Facts

Other Asthma
Facts

Survey Question

Expert
Rating

23. Covering pillows
3.33
and mattresses
with plastic covers
can improve
asthma (T)
24. Untreated asthma 3.81
can cause death
(T)
25. Asthma can be
3.67
completely cured
(F)

26. People with
asthma should
avoid exercise (F)

3.90

Expert Comments

- “We don’t
recommend this”
-“True only for dust
mite allergy”

-Drop completely
because tautological
-“This is true when it
is caused by
avoidable allergens
or occupational
sensitizers”
-What about postinfectious asthmaisn’t that cured after
the infection?
-“use other wording
to prevent ‘cured’
from being confused
with ‘controlled’”

Suggested
Change

Remove

Consultation
Comments

Final Question

We don’t
REMOVE
recommend this
at the clinic so
patients will not
know about it.
Untreated
asthma can
cause death. (T)
Asthma can be
cured. (F)

People with
asthma should
avoid exercise.
(F)
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Domain
(Based on
Schaffer and
Yarandi)
Other Asthma
Facts

Survey Question

27. It does not bother
a person's asthma
when others
smoke cigarettes
around them (F)

Expert
Rating

3.76

Other Asthma
Facts

28. Taking an
3.81
antibiotic such as
penicillin will help
most bad asthma
attacks (F)

Other Asthma
Facts

29. If asthma attacks
stop, it means that
the asthma has
gone away (F)

3.71

Other Asthma
Facts

30. If a person does
not have asthma
by the time they
are 40, they will
never get it (F)

3.62

Expert Comments

Suggested
Change

-Perhaps rephrase:
“second hand smoke
is irritating to a
person with asthma’s
airways even if it
does not worsen
symptoms”
- Drop “such as
penicillin”

Second hand
smoke can
make a person’s
asthma worse,
even if people
do not notice a
change in their
symptoms(T)

- Near duplicate of
25
- “Not sure if saying
asthma attacks stop
means asthma is
gone when patients
still experience
symptoms”
- Suggest: “By the
age of 40”

Consultation
Comments

When
someone’s
asthma attack is
over it means
that the asthma
has gone way.

If a person does
not have asthma
by age 40, they
will never get it
(F)

Final Question

Being around
others who
smoke does not
bother a
person’s asthma,
as long as they
don’t smoke
themselves. (F)
Taking an
antibiotic such
as penicillin will
help most bad
asthma attacks.
(F)
When
someone’s
asthma attack is
over it means
that the asthma
has gone way.
(F)
If a person does
not have asthma
by age 40, they
will never get it.
(F)
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Appendix B
Asthma Knowledge Questionnaire
Please place a mark in the box marked “TRUE” for statements you believe are correct,
“FALSE” for those statements that are not correct, and “UNSURE” if you do not know if
the statement is true or false.

1. People with asthma can have swollen and
inflamed airways even when they feel well
2. Asthma is a disease that does not last for a long
time
3. Quick relief medications should be taken every
day, even if people are feeling well

TRUE FALSE UNSURE















4. People with asthma should try to hold their breath
for 8-10 seconds after each puff of their inhaler







5. It is possible for someone's asthma to be worse
without them noticing a change in their breathing







6. Molds can trigger asthma symptoms in some
people
7. Asthma can be cured













8. Being around others who smoke does not bother a
person’s asthma, as long as they don’t smoke
themselves







9. Inhaled steroids (controllers) prevent asthma
attacks







10. People with asthma should wait until their
symptoms are really bad before using a quick
relief medication







11. During an asthma attack, the muscles around the
airways tighten and the airways become narrow







12. People with asthma should rinse and gargle after
each use of their inhaled (controller) steroid







13. A person with asthma can use a combination
inhaler for quick relief, even if they do not use it
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every day
14. Taking an antibiotic such as penicillin will help
most bad asthma attacks







15. People may not notice improvements in their
breathing for 1-4 weeks after they start using
inhaled steroids







16. Cold air can make asthma symptoms worse







17. Frequent coughing can be a symptom of asthma







18. A combination inhaler includes two types of
medication to control asthma







19. Having swollen airways does not increase the risk
of having an asthma attack







20. The purpose of steroid medication inhalers is to
stop an asthma attack when it happens







21. People with asthma can usually help control their
symptoms by taking the appropriate medications







22. People can usually help control their symptoms
by avoiding things (triggers) that make their
asthma worse







23. People with asthma should avoid exercise







24. When someone’s asthma attack is over it means
that the asthma has gone way







25. It is okay to take inhaled steroids (controllers)
only when people notice their symptoms getting
worse







26. Inhaled steroids will relieve an asthma attack
within 20 minutes







27. People with asthma should wait about one minute
between puffs of their quick relief medication







28. People with asthma do not need to take their daily
inhaled steroids (controller) if they feel well
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29. People with asthma should breathe out partially,
but not fully, just before taking their medication







30. Asthma may cause wheezing during exercise







31. Keeping bedroom windows open at night will
help prevent asthma attacks







32. Untreated asthma can cause death







33. If a person does not have asthma by age 40, they
will never get it







34. Chest tightness is a common symptom of asthma







35. People with asthma get relief from their
symptoms at night







36. Asthma attacks often come on suddenly without
any warning
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Appendix C
Rating Scale
There are different things people have to weigh when deciding whether or not to use an
inhaler. For example, while some people with asthma may worry about a medication’s
side effects, they feel that the benefits from the medication are worth the risk. Others are
not so sure.
We are interested in what kinds of things you consider when deciding whether or not to
use an inhaler. Trying to keep the list of things below in mind, please rate on a scale of
1-10, the importance of each of the following.

2

1

3

4

5

6

7

8

Least
Important

9

10
Most
Important

1. The number of different inhalers I need to take ______
2. Having to take an inhaler every day ______
3. Being able to take an inhaler only when I need it ______
4. Possible short-term side-effects of the inhaler ______
5. Possible long- term side-effects of the inhaler ______
6. Risk of addiction to the inhaler ______
7. The inhaler can take my symptoms away within minutes ______
8. The inhaler can help keep my asthma from getting worse over the next 10 years
___
9. The inhaler can reduce how often I get asthma attacks over the next six months
___
10. The cost of the inhaler ______
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Appendix D
Discrete Choice Experiment Scenarios

Your Preferences for Asthma Treatments (Card 1 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
Program A
The Same

Program B
Worse

Fewer asthma attacks

The same number of
asthma attacks
Symptom relief within 30
minutes
High

In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Every day at set times and
extra if you need it

Only when you need it

You will get…

2 Inhalers

1 Inhaler

Because of your
medication, you may
experience…

Major and/or long-term
side effects

Minor and/or short-term
side effects

Symptom relief within 5
minutes
Low

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.

A

B
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Your Preferences for Asthma Treatments (Card 2 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
Program A
The Same

Program B
Worse

The same number of
asthma attacks
Symptom relief within 30
minutes
High

Fewer asthma attacks

In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Every day at set times and
extra if you need it

Only when you need it

You will get…

2 Inhalers

1 Inhaler

Because of your
medication, you may
experience…

Minor and/or short-term
side effects

Major and/or long-term
side effects

Symptom relief within 5
minutes
Low

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.

A

B
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Your Preferences for Asthma Treatments (Card 3 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Program A
Worse

Program B
The Same

Same number of asthma
attacks
Symptom relief within 5
minutes
Low

Fewer asthma attacks
Symptoms relief within 30
minutes
High

Only when you need it

Every day at set times and
extra if you need it

You will get…

1 Inhaler

2 Inhalers

Because of your
medication, you may
experience…

Minor and/or short-term
side effects

Major and/or long-term
side effects

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.
A

B
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Your Preferences for Asthma Treatments (Card 4 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Program A
The Same

Program B
Worse

Fewer asthma attacks

The same number of
asthma attacks
Symptom relief within 30
minutes
Low

Symptom relief within 5
minutes
High
Only as needed

Every day at set times and
extra if you need it

You will get…

1 Inhaler

2 Inhalers

Because of your
medication, you may
experience…

Minor and/or short-term
side effects

Major and/or long-term
side effects

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.
A

B
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Your Preferences for Asthma Treatments (Card 5 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
Program A
Worse

Program B
The Same

Fewer asthma attacks

The same number of
asthma attacks
Symptom relief within 5
minutes
High

In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Every day at set times and
extra if you need it

Only when you need it

You will get…

1 Inhaler

2 Inhalers

Because of your
medication, you may
experience…

Minor and/or short-term
side effects

Major and/or long-term
side effects

Symptom relief within 30
minutes
Low

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.

A

B
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Your Preferences for Asthma Treatments (Card 6 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Program A
The Same

Program B
Worse

The same number of
asthma attacks
Symptom relief within 30
minutes
Low

Fewer asthma attacks
Symptom relief within 5
minutes
High

Only when you need it

Every day at set times and
extra if you need it

You will get…

1 Inhaler

2 Inhalers

Because of your
medication, you may
experience…

Major and/or long-term
side effects

Minor and/or short-term
side effects

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.
A

B
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Your Preferences for Asthma Treatments (Card 7 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
Program A
Worse

Program B
The Same

The same number of
asthma attacks
Symptom relief within 5
minutes
High

Fewer asthma attacks

In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Every day at set times and
extra if you need it

Only when you need it

You will get…

1 Inhaler

2 Inhalers

Because of your
medication, you may
experience…

Major and/or long-term
side effects

Minor and/or short-term
side effects

Symptom relief within 30
minutes
Low

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.
A

B
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Your Preferences for Asthma Treatments (Card 8 of 8)
When considering your asthma treatment program, if you were offered the choice
between program A or B, which would you most prefer?
In 10 years, your asthma
will be…
Over the next 6 months,
you will have…
Your treatment program
will provide you with…
The dose of steroids in
your medication will be…
You take your medication
…

Program A
Worse

Program B
The Same

The same number of
asthma attacks
Symptom relief within 30
minutes
High

Fewer asthma attacks
Symptom relief within 5
minutes
Low

Only when you need it

Every day at set times and
extra if you need it

You will get…

2 Inhalers

1 Inhaler

Because of your
medication, you may
experience…

Major and/or long-term
side effects

Minor and/or short-term
side effects

Please tick the box (√) below to indicate which treatment (A or B) you would choose.
Remember, you may have to select some features you do not like because, all
things considered, you prefer it over the other treatment.
A

B
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Appendix E
Pilot Study Ethics Approval
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Appendix F
Proportion of Sample that Responded Correctly, Incorrectly or was Unsure of
Responses to Knowledge Questionnaire Items
Category

Item

Pathophysiology 2. Asthma is a disease that does not

% Correct

% Incorrect

% Unsure

94.6

1.8

3.6

91.1

5.4

17.9

89.3

3.6

7.1

85.5

1.8

12.7

78.6

8.9

12.5

75

5.4

19.6

last for a long time (F)
24. When someone’s asthma attack
is over it means that the asthma has
gone away (F)
11. During an asthma attack, the
muscles around the airways tighten
and the airways become narrow (T)
33. If a person does not have
asthma by age 40, they will never
get it (F)
32. Untreated asthma can cause
death (T)
1. People with asthma can have
swollen and inflamed airways even
when they feel well (T)
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Category

Item

% Correct

% Incorrect

% Unsure

75

7.1

17.9

66.1

16.1

17.8

7. Asthma can be cured (F)

64.3

1.8

33.9

21. People with asthma can usually

98.2

1.8

0

92.9

1.8

5.4

91.1

7.1

1.8

19. Having swollen airways does
not increase the risk of having an
asthma attack (F)
5. It is possible for someone’s
asthma to be worse without them
noticing a change in their breathing
(T)

Medication

help control their symptoms by
taking the appropriate medications
(T)
10. People with asthma should wait
until their symptoms are really bad
before using a quick relief
medication (F)
28. People with asthma do not need
to take their daily inhaled steroids
if they feel well (F)
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Category

Item

% Correct

% Incorrect

% Unsure

18. A combination inhaler includes

67.9

10.7

21.4

66.1

16.1

17.9

64.3

5.4

30.4

58.9

26.8

14.3

50

32.1

17.9

44.6

35.7

19.6

two types of medication to control
asthma (T)
25. It is okay to take inhaled
steroids only when people notice
their symptoms getting worse (F)
14. Taking an antibiotic, such as
penicillin, will help most bad
asthma attacks (F)
3. Quick relief medications should
be taken every day, even if people
are feeling well (F)
20. The purpose of steroid
medication inhalers is to stop an
asthma attack when it occurs (F)
9. Inhaled steroids (controller)
prevent asthma attacks (T)
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Category

Item
15. People may not notice

% Correct

% Incorrect

% Unsure

37.5

26.8

35.7

37.5

32.1

30.4

12.5

62.5

25

94.6

1.8

3.6

93

5.4

1.8

67.9

19.6

12.5

improvements in their breathing for
1-4 weeks after they start using
inhaled steroids (T)
26. Inhaled steroids will relieve an
asthma attack within 20 minutes (F)
13. A person with asthma can use a
combination inhaler for quick
relief, even if they do not use it
everyday (F)
Technique

12. People with asthma should
rinse and gargle after each use of
their inhaled steroid (T)
4. People with asthma should try to
hold their breath for 8-10 seconds
after each puff of their inhaler (T)
29. People with asthma breathe out
partially, but not fully, just before
taking their medication (F)
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Category

Item

% Correct

% Incorrect

% Unsure

27. People with asthma should wait

60.7

32.1

7.1

98.2

1.8

0

96.4

0

3.6

94.6

1.8

3.6

94.5

1.8

3.6

92.9

5.4

1.8

about one minute between puffs of
their quick relief medication (T)
Environmental

22. People can usually help control

Triggers

their symptoms by taking avoiding
things that make their asthma worse
(T)
6. Molds can trigger asthma
symptoms in some people (T)
8. Being around others who smoke
does not bother a person’s asthma,
as long as they don’t smoke
themselves (F)
16. Cold air can make asthma
symptoms worse (T)
23. People with asthma should
avoid exercise (F)
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Category

Item
31. Keeping bedroom windows

% Correct

% Incorrect

% Unsure

64.3

8.9

12.5

94.6

1.8

3.6

93.3

3.3

3.4

90

3.3

6.7

82.1

1.8

16.1

13.3

80.0

6.7

open at night will help prevent
asthma attacks (F)
Symptoms

30. Asthma may cause wheezing
during exercise (T)
35. People with asthma get relief
from their symptoms at night (F)
34. Chest tightness is a common
symptom of asthma (T)
17. Frequent coughing can be a
symptom of asthma (T)
36. Asthma attacks often come on
suddenly without any warning
symptoms (F)
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Appendix G
Full Study Ethics Approval
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Appendix H
Letter of Information

LETTER OF INFORMATION
Project Title:

The additive and interactive effects of patients’ asthma knowledge,
beliefs and treatment preferences on medication choices

Investigators:

Dr. Leora Swartzman, Psychology, UWO
Ms. Naomi Gryfe, Psychology, UWO
Dr. Christopher Lisckai, St Joseph’s Health Centre

Purpose of the Study
As an individual attending the asthma clinic, you are being invited to voluntarily
participate in a research study looking at patients’ views about asthma and what you feel
is important for your treatment.
The purpose of this letter is to provide you with the information you require to make an
informed decision to participate in this research.
Procedures
Approximately 120 patients will be approached to take part in this study. If you decide to
participate you will be asked to sign the consent form and then complete:
1. Surveys while you wait to see your physician today. These surveys will take
approximately 15 minutes to complete and will ask you about your experiences
while having an asthma attack and some information about you.
2. Surveys after you see your physician today. These surveys will take
approximately 25-30 minutes to complete. In these questionnaires, you will be
asked about your thoughts about asthma, what you feel is important for your
treatment, and the way in which you are currently using your medications (if any
medications have been prescribed for you).
3. At home tonight, you will be asked to complete a 5 minute survey about your
satisfaction with your appointment. You may complete these surveys online or on
paper copies which will be provided to you. Should you choose to complete these

201

surveys on paper copies, you will also be provided with a postage paid envelope
and asked to mail the surveys back to the investigators.
4. For one week after your appointment, you will be asked to record your symptoms
and when you take your medications. Again, you will have the option of
completing these surveys online or by hand. You must return this package by mail
(postage will be paid) or e-mail.
5. Four weeks after your appointment, you will be contacted by phone or email
(your preference) and asked to again record your symptoms and medication s for
one week (online or on paper copies which will be mailed to you). You will also
be asked a few questions about how you take your medications and your quality
of life. You must return the package by mail (postage will be paid) or e-mail.
Reimbursement
You will be reimbursed $10.00 for completing the portion of the study at today’s visit.
You will also receive $20.00 for completing each of the week-long symptom diaries and
surveys. In total, you will be paid $50.00 to compensate you for your time. If you
withdraw from the study early, you will be reimbursed according to the portion of the
study that you complete.
Risks and Discomforts
We do not believe this study poses any risk to your health or safety.
Benefits
This research project may lead to the development of improved clinical care for patients
suffering from asthma. You may not benefit personally from participation in the study.
Withdrawal
Participation in this study is completely voluntary. You may refuse to participate, refuse
to answer questions, or withdraw from the study at any time with no effect on your future
care.
Confidentiality
Maintaining your confidentiality is of the upmost importance to us. Your physician will
not see any of your answers and if the results of this study are published, no one will
know you were a part of the study. Your names will be removed from all of your answer
booklets, and the unidentifiable information will be stored in a locked cabinet at the
University of Western Ontario.
Should you decide to complete your questionnaires online, all of your information will be
password protected on a secure network through the University of Western Ontario. All
of your personal information will be removed from your answers one they are received.
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We will only release your records should representatives of the University of Western
Ontario Health Sciences Research Ethics Board wish to contact you or require access to
your study-related records to monitor the conduct of the research.
Contact Person
If you have any questions about the study procedure or content, please feel free to contact
Ms. Naomi Gryfe.
If you have questions about your rights as a research participant or the conduct of the
study you may contact Dr. David Hill, Scientific Director, Lawson Health Research
Institute.
Legal Rights
You do not waive any of your legal rights by signing the consent form.
This letter is yours to keep.
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Appendix I
Informed Consent

Consent to participate in the study entitled:
The Additive and Interactive Effects of Patients’ Asthma Knowledge, Beliefs, and
Treatment Preferences on Medication Choices

I, ______________________________, have read the Letter of Information, had the
nature of the study explained to me, and I agree to participate.

All questions have been answered to my satisfaction.

______________________________

______________________________

DATE

SIGNATURE

______________________________________________
NAME OF PERSON OBTAINING CONSENT (please print)

_________________________________________
SIGNATURE OF PERSON OBTAINING CONSENT

Appendix J: Medication Diary

Please complete the chart below at the end of each day of the week:
MEDICATION

Example
Thursday,
March 2, 2010

I took my
preventer
medication
at:

Day 1
Date: _____
___________

Day 2
Day 3
Date: _____
Date:_____
___________ _________

Day 4
Date:_______
____________

Day 5
Day 6
Day 7
Date:_______ Date:_______ Date:_______
____________ ____________ ____________

9:00 am
3:00 pm

I took a total 2
of __ puffs of
my rescue
inhaler today
I used my
rescue
inhaler at
____

1:00 pm
4:00 pm

On day one, please record the number listed on your preventer inhaler. If you have more than one inhaler, please record the number on each inhaler:
Inhaler 1: __________ Inhaler 2:_____________ Inhaler 3:_____________ Inhaler 4:___________
At the end of the week, please record the number listed on your preventer inhaler. If you have more than one inhaler, please record the numbers on each of the
inhalers.
Inhaler 1: _______________ Inhaler 2: _________________ Inhaler 3: _______________ Inhaler 4:__________________
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Appendix K
Demographic Information

ABOUT YOUR ASTHMA
1. Have you been diagnosed with asthma (please circle yes or no)?
YES

NO

If YES:
1. At what age were you given an asthma diagnosis:
________
2. In what year were you given an asthma diagnosis:
________
2. Is this your first visit to this asthma clinic (please circle yes or no)?
YES

NO
If NO: Not including this visit, how many times have you been seen at
this asthma clinic (please circle)?
1 Time
2 Times 3 Times More
than 3
Times

3. In the past year, how many times have you had to:
i. Go to see your family doctor for breathing problems? ________
ii. Go to the emergency room (ER) for breathing problems? _______
4. Have you been prescribed any medications to help control your asthma (by your
family doctor, the ER, or a doctor at this clinic)? Please circle yes or no.
YES
If YES: Please list the names of the medications:

Are you currently taking these medications?

YES

NO

NO
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ABOUT YOU
Sex (please circle): Male Female
Date of Birth: _______________ (DD/MM/YYYY)
1. What is the highest grade of school that you have ever attended? Add one year
for each additional year beyond grade 13 (For example, two years of college would
be 15 years).
____________ Years
2. Which of the following best describes your current job status (please check one)?
Employed outside of the home (30
or more hours a week)
Retired
Homemaker
Working from home
Student

Employed outside the home, part time (less than 30
hours
a week)
Unemployed
On disability (Is this related to your asthma? Yes No)
Other, please specify: ______________

3. What certificates, diplomas or degrees have you obtained?
None
Secondary/ High School Certificate
Trade certificate or diploma
Community College

Bachelor Degree(s) (ex: B.A., B.Sc.)
Master Degree(s)
Professional Degree (Medicine, dentistry, law)
Doctorate Degree

4. Describe the range in which your annual household income falls (please check
one):
Under $20,000
$21,000- $40,000
$41,000-$60,000
$61,000-$80,000

$81,000-$100,000
Over $100,000
I would prefer not to say

5. Your current relationship status is:
Legally married (not separated)
Separated or divorced
Living common law

In a relationship, but not living together
Single
Widowed
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Appendix L
Percentage of Sample who Answered Knowledge Items Correctly and Incorrectly
Category

Item

Pathophysiology 19. Having swollen airways

Percent
Correct
71.9

Percent
Incorrect
6.5

Percent
Unsure
21.6

94.2

2.9

2.9

94.2

.7

5.1

91.4

2.2

6.5

80.6

1.4

18.0

78.4

1.4

20.1

71.9

6.5

21.6

68.8

12.3

18.8

61.4

11.4

26.4

does not increase the risk of
having an asthma attack
24. When someone’s asthma
attack is over it means that the
asthma has gone away
11. During an asthma attack,
the muscles around the airways
tighten and the airways become
narrow
2. Asthma is a disease that does
not last for a long time
33. If a person does not have
asthma by age 40, they will
never get it
32. Untreated asthma can cause
death
19. Having swollen airways
does not increase the risk of
having an asthma attack
1. People with asthma can have
swollen and inflamed airways
even when they feel well
5. It is possible for asthma to be
worse without noticing a
change in their breathing
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Category

Medication

Item

Percent

Percent

Percent

Correct

Incorrect

Unsure

7. Asthma can be cured

57.9

14.3

27.1

21. People with asthma can

95.0

1.4

3.6

89.9

5.1

5.0

86.3

7.9

5.8

79.9

2.9

17.3

71.9

18

10.1

71.2

17.3

11.2

65.2

18.1

16.7

56.8

35.3

7.9

usually help control their
symptoms by taking the
appropriate medications
28. People with asthma do not
need to take their daily inhaled
steroids if they feel well
10. People with asthma should
wait until their symptoms are
really bad before using a quick
relief medication
18. A combination inhaler
includes two types of
medication to control asthma
3. Quick relief medications
should be taken every day, even
if people are feeling well
25. It is okay to take inhaled
steroids only when people
notice their symptoms getting
worse
9. Inhaled steroids (controller)
prevent asthma attacks
14. Taking an antibiotic, such
as penicillin, will help most bad
asthma attacks
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Category

Item

20. The purpose of steroid

Percent

Percent

Percent

Correct

Incorrect

Unsure

51.8

35.3

12.9

38.8

28.8

32.4

33.3

33.3

33.3

13.7

56.8

29.5

97.8

.7

1.4

91.4

3.6

4.3

61.9

21.6

16.5

52.5

28.8

18.7

medication inhalers is to stop an
asthma attack when it occurs
15. People may not notice
improvements in their breathing
for 1-4 weeks after they start
using inhaled steroids
26. Inhaled steroids will relieve
an asthma attack within 20
minutes
13. A person with asthma can
use a combination inhaler for
quick relief, even if they do not
use it everyday
Technique

12. People with asthma should
rinse and gargle after each use
of their inhaled steroid
4. People with asthma should
try to hold their breath for 8-10
seconds after each puff of their
inhaler
27. People with asthma should
wait about one minute between
puffs of their quick relief
medication
29. People with asthma breathe
out partially, but not fully, just
before taking their medication
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Category

Item

Environmental

6. Molds can trigger asthma

Triggers

symptoms in some people
23. People with asthma should

Percent

Percent

Percent

Correct

Incorrect

Unsure

97.1

1.4

1.4

95.7

.7

3.6

94.2

2.2

3.6

93.5

5.0

1.4

91.4

3.6

5.0

56.1

10.8

33.1

94.2

1.4

4.3

90.6

2.2

7.2

85.6

3.6

10.8

84.2

4.3

11.5

avoid exercise
8. Being around others who
smoke does not bother a
person’s asthma, as long as they
don’t smoke themselves
22. People can usually help
control their symptoms by
taking avoiding things that
make their asthma worse
16. Cold air can make asthma
symptoms worse
31. Keeping bedroom windows
open at night will help prevent
asthma attacks.
Symptoms

30. Asthma may cause
wheezing during exercise
34. Chest tightness is a
common symptom of asthma
35. People with asthma get
relief from their symptoms at
night
17. Frequent coughing can be a
symptom of asthma
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Appendix M
Summary of Hierarchical Regression Analysis with Patient Preferences Entered at
Step One
Model
Variable

1β

2β

Long Term – Equal Group

-.40***

-.25**

Long Term – Side Effects

-.02

.74

Long Term to Efficacy

-.17

-.16

Preferences

Pathophysiology Knowledge

.07

Beliefs
Timeline- Acute/Chronic

.03

Necessity of Medication

3.34***

Concern of Medication

-.78

R2

.14

∆R2

∆F
**

.19
5.44**

F

p < .01. *** p < .001.

.33

4.00***
3.10
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